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Abstract 
Increasing evidence suggests that cell membranes play an important role in the 
pathophysiology of Alzheimer's disease (AD). Direct interaction of small molecules, such as 
cholesterol and melatonin, with cellular membrane can alter the physical structure of the 
membrane lipid bilayer, which can affect the interaction of membrane with amyloid-β (Aβ) 
peptides that are implicated as one of the main culprits of the disease. The hormone 
melatonin has been shown to decrease the toxic effects of Aβ peptides. Evidence suggests 
that melatonin may interact with lipid membranes non-specifically in exerting its protective 
effects. The goal of the project was to measure the non-specific membrane interaction of 
melatonin (and contrast it to cholesterol) and also to characterize how the membrane's action 
affects Aβ peptide's interaction with and accumulation on the membrane.  
First, Langmuir monolayers were used to study the effects of melatonin. The results show 
that melatonin acts on the monolayer membrane model in ways that reduce or counter the 
effects of cholesterol. Contrary to condensing and thickening effect of cholesterol, melatonin 
showed thinning and fluidizing effects. It was also discovered that melatonin's precursor 
molecules, which have also been shown to have protective effects in AD, also exert similar 
effects in the membrane as melatonin. 
The action on the membrane of melatonin and its effects on Aβ binding to the membrane 
were studied using atomic force microscopy and breakthrough force spectroscopy on 
supported bilayer membrane models. Protocols and methods for producing good quality 
supported bilayers, obtaining control breakthrough force spectroscopy data, and imaging of 
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Aβ binding to the membrane were successfully developed and performed. However, 
conclusively showing the effects melatonin's membrane action and on binding and 
accumulation of Aβ on the membrane using AFM will require further investigation. 
In conclusion, the work confirmed and characterized the membrane action of melatonin 
and its related molecules, however, it was not possible to show how it affected the Aβ 
peptide accumulation in the membrane. The results indicated that the direct membrane 
interaction of molecules may have significant effects on the biophysical properties of the 
membrane, but verifying the impact of the effects will require further work. The results of 
this work added new important discoveries in the field of membrane biophysics, and the 
techniques, methods, and protocols developed throughout the work further contributed to the 
field by fostering future work.  
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Chapter 1 
Introduction 
1.1 Alzheimer's Disease and Amyloid Hypothesis 
Alzheimer's disease (AD) is the most common age related neurodegenerative disease[1]. Also 
as the most prevalent form of dementia[1], the clinical symptoms of the disease include 
progressive memory loss[2], and aberrant night time behavior, which includes sleep disturbance 
and nightly mood swings[3]. It is one of the most serious diseases as currently there is no 
effective treatment or cure available that can stop the progression of the disease[4], [5]. 
Historically, Dr. Alois Alzheimer first discovered the disease back in 1907[5], [6]. During 
post-mortem examination he found and described three pathological alterations in the brain of a 
female patient who has succumbed to the disease[6]. The three hallmark features of the disease, 
as described by Alzheimer, included "peculiar substance" occurring as extracellular deposits in 
some brain regions, which are now known as "amyloid plaques"[6]. The second feature 
identified were neurofibrillary tangles (NFTs), which are intracellular legions of phosphorylated 
proteins. Third, he described the presence of "adipose inclusions" or "lipoid granules", hinting 
that abnormal lipid metabolism may be involved[6]. Since then, on-going research has revealed 
that there are many other structural and functional alterations that are present, such as signs of 
inflammatory responses and oxidative stress[5]. The combined result of all the pathological 
changes observed are believed to be responsible for the severe neuronal synaptic dysfunction and 
loss observed in the patients[5]. The disease's effects on the brain tissue can be quite dramatic, as 
the brain of an AD patient at the time of death may weight about one third less compared to an 
age-matched healthy individual[5]. 
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Of the aforementioned pathological hallmarks of AD, the most attention has been given to 
studying the amyloid plaque formations, as they are the distinguishing pathological feature in the 
diseased brain[7]. Although the jury is still out on the extent and significance of the different 
pathophysiological changes observed in the brain, current consensus is that amyloid 
pathophysiology plays a central role and that it is also involved as a co-factor in many of the 
other pathophysiological changes in AD[8]. Thus much focus was given in studying the amyloid 
plaques, and by the mid 1980s, researchers characterized them as containing a particular form of 
peptide, now named amyloid-β (Aβ) peptide. Culminating research has now established the 
hypothesis that overproduction and accumulation of Aβ peptide is likely a causal factor in 
AD[8].  
Although is widely agreed that the over accumulation of Aβ is fundamental to the disease[9], it 
is still not exactly clear why it occurs, and also how the presence of the peptide results in 
neuronal death[10],[11]. In order to better understand the disease processes, attention has been 
given to studying a portion of AD patients who suffers from a genetically linked form of AD 
called 'familiar AD'. Familiar AD is passed down through generations in an autosomal dominant 
fashion[8], however, the familial form of AD represented less than 1% of all cases; the vast 
majority suffer from what is classified as the "sporadic" form of AD with unknown exact 
causes[12]. Although not the majority, examining the genetic form of AD to study and 
understand Aβ related processes proved to be advantageous for several reasons. Symptom 
presentation in the genetic form of AD is high predictable, thus it was possible to develop 
various animal models of AD that can reliably reproduce the pathophysiological and clinical 
features of AD. The sporadic form has no traceable known cause[13], but the pathological 
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features are similar in both the genetic and sporadic forms of AD. In the genetic model of AD, 
various mutations are found in a genes that codes for amyloid related components, such as the 
amyloid precursor protein (APP), the presenilins[14], and secretases[15] that together produce 
Aβ. However, attempts at targeting these protein products in order to decrease the production of 
Aβ have yielded limited success[8]. Because decreasing the precursors of Aβ proved to be less 
than successful, instead the focus was then shifted toward trying to increase or accelerate the 
clearance of Aβ. Many different compounds and approaches (vaccination being a major one) 
have been tried and tested to inhibit the production of Aβ as well as increase or facilitate the 
clearance of Aβ (basically decrease the amount of Aβ in the brain). However, to date the 
interventions that utilize this strategy has all failed in Phase III clinical trials or earlier [8], [16]. 
Thus currently, any form of treatment for AD is limited to managing the symptoms by increasing 
the activities of cholinergic neurons through acetylcholinesterase inhibiters (Sp3 inhibitors), 
and/or by targeting glutamatergic neurons with NMDA antagonists such as Memantine[10]. 
However, treatment offers little to no effect on the long term progress of the disease[4]. 
There is one other strategy that is being tested. Apart from reducing the amount (production, 
accumulation) of Aβ in the brain or compensating for the neuronal deficit, targeting the cell 
damaging mechanism of Aβ may be a meaningful (capable of disease modification) therapeutic 
strategy. However, the cytotoxic mechanisms of Aβ are highly complex[17], [18]. Aβ, along 
with other amyloidogenic peptides, are known to cause a host of different diseases, which are 
grouped together as "amyloidosis". There are many different amyloid peptides with different 
primary sequences that are involved in the various different amyloid-related diseases[19], but it 
has been postulated that these peptides may employ a common cytotoxic mechanism. 
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Figure 1- Alzheimer's schematic. Aβ oligomers and plaques (shows as red dots) are involved in AD 
pathophysiology through inducing synaptic/ dendritic impairment, and plaque formation, modified 
from E. D. Roberson and L. Mucke, “100 years and counting: prospects for defeating Alzheimer’s 
disease” Science, vol. 314, no. 5800, pp. 781–4, Nov. 2006. Reprinted with written permission from 
AAAS [7]. 
All amyloid peptides are known to form various different self-aggregates that are toxic to cells. 
They are capable of spontaneously forming twisted strands of fibrillar aggregations that are rich 
in β- sheet formations, consisting of hundreds and thousands of individual peptides. They can 
also form smaller more amorphous aggregates consisting of a lower number of peptides than the 
fibirillar aggregates [20]. The smaller aggregates are called "oligomers", and they have been 
shown to be more toxic than the larger fibrillar aggregates. However, it is still unclear what exact 
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oligomeric aggregate is the most toxic form[21]. Characterizing the toxicity of oligomers is 
highly challenging due to their varying sizes and transient nature (spontaneously aggregates and 
changes over time). The structure specific toxicity of Aβ oligomers is unclear, and it is currently 
widely being investigated[22]. It should be noted that many receptor types and groups have been 
implicated as targets of these oligomers, including prion protein C (PrPC)[23], G-protein coupled 
receptors[24], as well as AMPA and NMDA receptors[25]. 
Increasing evidence suggests that rather than focusing on the exact species of oligomers, 
understanding the cellular condition that provokes and fosters the process of Aβ aggregation may 
be of greater importance[21]. The primary site of Aβ production, aggregation and toxic effects, is 
the cell plasma membrane. Therefore, the membrane environment is receiving increased 
attention as a potential target for AD therapeutic approaches[26]–[29]. Specifically, regions 
within a membrane that are rich in cholesterol have been implicated in the disease[6], [30], [31] 
Cholesterol containing membrane areas are know to have increased density of the Aβ precursor 
components, such as the APP (which is known to directly bind to cholesterol) and also the β and 
γ secretases[6], [30]. By increasing the interaction of the Aβ producing components, cholesterol 
in the lipid membrane has been shown to be associated with increased Aβ production[6], [32], 
aggregation, and toxic effects[30], [31], [33]. 
1.2 Cell Membrane Connection 
Aβ originates from the cell plasma membrane and is cleaved from the membrane-spanning 
amyloid precursor protein (APP)[34]. Also the harmful effects of Aβ are primarily linked with 
destabilizing the structure and function of the lipid membranes[6]. Furthermore, the amount of 
membrane bound Aβ directly correlates to AD symptoms in humans[35]. Therefore, 
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understanding the effects of Aβ on the lipid membrane is thought to be crucial in understanding 
the overall disease mechanism and pathophysiology. 
 
Figure 2- Aβ production mainly occurs in membrane lipid rafts. Amyloid precursor protein (APP) 
as well as the enzymes required for Aβ (depicted as purple section within APP, shown in green) 
production prefer to locate in lipid rafts, favoring amyloidogenic proteolytic processing of APP, 
adapted by written permission from Macmillan Publishers Ltd: Nat Rev Neurosci DOI: 
10.1038/nrn3012, copyright 2011 [6]. 
 
It is known that membrane raft domains, enriched in cholesterol and sphingolipids facilitate 
amyloid clustering, aggregation, as well as production[30]. It was found that cholesterol levels 
directly influence the enzymatic activity and local density of the Aβ producing constituents 
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(APP, Beta-site APP Cleavage Enzyme1 or BACE1, and ϒ-secretase)[6]. When these 
components are present in non-raft regions, the amount of interactions are relatively low and are 
qualitatively different such that Aβ becomes a minor product. However, the components are 
more frequently found in lipid raft regions where their interaction highly favors amyloidogenic 
processing of APP [32], [33]. Thus it is evident that lipid rafts play a major role in Aβ 
pathophysiology, and targeting them could become an effective treatment strategy[6]. 
 
Figure 3- Molecular illustration of three different membrane phase states. (Left) Normal cellular 
membrane bilayers are in a 'fluid' or Ld state where the lipid molecules are highly mobile. (Middle) 
Addition of cholesterol reduces the structural freedom of the membrane lipid molecules to form a 
'lipid raft' or liquid ordered (Lo) state. (Right) Gel phase membranes consist of lipids with 
saturated fatty acid chains that are inherently stable in terms of molecular motional and diffusional 
freedom. Blue arrows at the bottom show how adding cholesterol can change the membrane phases 
into the liquid ordered state. Adapted by written permission from Macmillan Publishers Ltd: Nat 
Rev Mol Cell Biol, DOI:10.1038/nrm2330, copyright 2008 [36]. 
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1.3 Membrane Biophysics 
Membrane lipids have traditionally been considered to be passive bystanders in cellular 
processes. However, as illustrated in the Aβ related processes in AD, they are now considered to 
be an important factor involved in many cellular processes including stabilizing membrane 
bound protein motifs and affecting protein channel gating/ conductance properties[37], [38]. The 
most widely known membrane lipid effect on proteins is called the 'hydrophobic mismatch', 
where there is a discrepancy between the thickness of the hydrophobic region of a protein and 
the surrounding hydrophobic bilayer environment[38]. This mismatch can affect protein function 
through influencing its structural conformation. Many pharmacologically active compounds 
(drugs including antibiotics and anesthetics) are believed to alter such protein-lipid boundary 
conditions, at least in part by non-specifically interacting with the membrane lipids and changing 
the biophysical properties of the membrane bilayer[39], [40]. Small biologically active 
compounds such as anesthetics[41], [42] and other drug/ pharmacological agents including non-
steroidal anti-inflammatory drugs[43] have been shown to exert part of their effects through 
altering the properties of the lipid bilayer[44].  
The potency of these pharmacological agents correlates well with the molecules' 
hydrophobicity, and hydrophobicity, in turn, corresponds with their ability to incorporate into 
lipid membranes[45]. The relationship between anesthetic potency of molecules and their 
measured water-oil partition coefficients display a positive correlation, which is dubbed as the 
Meyer-Overton rule. New evidence suggests that the potency correlation becomes even stronger 
and more reliable if the effects were measured in the bilayer instead of the water-oil phase[46]. 
However, some of the molecules do not follow this simple potency versus lipid-water (or 
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membrane) partition coefficient relationship. The effect of solutes on the bilayer properties that 
alter protein conformational equilibria may depend not only on their concentration in the 
membrane (as determined by their hydrophobicity), but also on the structure dependent 
interaction of the solute[45]. Thus, a more structure based understanding of the membrane 
interaction of small molecules is needed to further improve the understanding of the functional 
mechanisms of these biomolecules that involve non-specific interactions with lipid 
membranes[47]. 
 
Figure 4- Illustrations of how different molecules in the membrane bilayer (peptide toxin shown as 
red, or other small molecules, shown as yellow) can alter membrane channel protein (blue) 
structure configuration and function by affecting the protein-lipid boundary conditions. (Bottom 
right) Small molecules can affect membrane proteins by changing the physical property (elasticity) 
of the bilayer, adapted by written permission from Macmillan Publishers Ltd: Nature, DOI: 
10.1038/nature08147, copyright 2009 [38].
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1.4 Melatonin and Related Molecules 
Melatonin (N-[2-(5-methoxy-1H-indol-3-yl)ethyl] acetamide) is a hormone known to reduce 
the effects of Aβ toxicity[48]. It is a neuro-hormone secreted mainly in the pineal body in the 
brain, and it is best known for its involvement in the circadian rhythm[49]. Melatonin is also a 
hormone associated with aging, since its synthesis and rhythmical secretions decline with 
age[50]. In the pineal body, melatonin is converted from serotonin via two enzymes, serotonin-
N-acetyltransferase (SNAT) and hydroxyindole-O-methyl transferase (HIOMT). The circadian 
rhythm of SNAT is controlled by the hypothalamic suprachiasmatic nuclei (SCN), which in turn 
produces melatonin's rhythmic production[51]. Due to relatively short (~30min) half life of 
melatonin in systemic circulation[52], melatonin levels fluctuate closely to its production. 
Interestingly, melatonin has also been shown to play a protective role in age related diseases such 
as in Parkinson’s disease as well as in AD[53].  
Early links between melatonin and AD came from sleep studies where many AD patients 
reported having abnormal sleep/wake cycles. It was discovered that they also had impaired 
melatonin secretion at night[54]. Melatonin levels in the cerebrospinal fluid/ brain of AD patients 
were significantly lower compare to aged matched control[55], and AD patients with ApoE-ε4/4 
alleles (know AD genetic risk factor) showed even lower melatonin levels and more severe 
symptoms than the patients without the genetic risk factor[54]. A recent report showed that sleep 
disturbances correlated with increased Aβ levels in the brain, so optimization of sleep, perhaps 
through enhancing melatonin's function, may help to reduce the levels of Aβ in slowing the 
progression of AD[56]. 
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In vitro cell studies also confirmed that melatonin provided protection against most of the 
currently identified cytotoxic processes associated with Aβ, including intracellular calcium 
accumulation, reactive oxygen species production, inflammatory autoimmune responses, nitric 
oxide production, decreased membrane fluidity, and alteration of cytoskeleton [57]–[64]. 
Furthermore, melatonin was able to decrease the Aβ self-aggregation process[65]. This effect 
(decrease amyloid fibrillization and neurotoxicity) was even more prominent in the presence of 
APOE (apolipoprotein E), which is the gene product of an AD risk factor gene ApoE-ε4[66]. The 
result corresponds with another related report that showed patients with the ApoE-ε4/4 alleles 
had lower melatonin levels and more severe symptoms, compared to patients without the 
gene[54]. In transgenic mouse models of AD in vivo, melatonin reduced the amyloid load in the 
brain, and it also increased the longevity of the animals when treatment starting from an early 
age[67], [68]. Much of its positive effects have been attributed to its anti-oxidative effects, 
however, melatonin has been shown to be more potent than its related analogues (with very 
similar anti-oxidative properties) or compared to other well-known anti-oxidants such as 
vitamins C and E. This may indicate that there are other additional mechanisms involved in 
melatonin's protective effects[69]. 
Melatonin's protective mechanism may also involve direct interactions with the cell 
membrane. Many studies have shown evidence that melatonin is able to interact with lipid 
membranes, however, the exact manner of interaction and the effects it has on the membrane is 
not yet clarified[70], [71]. It may be worth pursuing, as in vitro experiments showed that 
melatonin is able to increase cell survival by maintaining cell membrane lipid fluidity and 
blocking increased membrane ion conductance induced by Aβ[57], [60], [72], [73]. Also, in 
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primary rat hippocampal co-cultures, melatonin prevented calcium permeation through the 
mitochondrial membranes[74]; mitochondrial/ cell membrane depolarization via calcium ion 
influx is one of the well-known aspects of Aβ toxicity.  
Interestingly, there may be a relationship between melatonin and cholesterol. Melatonin has 
been shown to reduce the Aβ induced membrane ion conductance (uncontrolled permeability), 
but the presence of cholesterol has been shown to increase it[31]. Melatonin has been shown to 
lower serum cholesterol level in humans and animals, and it may also be directly competing with 
cholesterol in binding to membrane lipids[75]. It is possible that melatonin may have opposing 
or competing effects compared to cholesterol on the physical properties of the membrane. 
However, this has not been directly investigated as yet. 
In summary, it is possible that melatonin may be involved in protecting the membrane by 
directly interfering with the Aβ induced membrane effects, and also by having counteractive 
effects to cholesterol in the membrane. The hypothesis of the project is that melatonin is able to 
produce protective effects against Aβ by influencing the physical structure of the membrane. 
Through such effects then, it may be able to reduce the binding and accumulation of Aβ on the 
membrane. Although it may be true that receptor activation is not needed to provide cell 
protection[76] the concentrations of melatonin required to provide cell protective effects against 
Aβ are sufficient high (>10 µm concentrations needed versus nM to pM affinity for melatonin 
receptors[77]) to involve and invoke receptor activation. Thus, it is reasonable to assume that 
non-specific membrane effects of melatonin also promote and coincide with receptor activation 
and that the two phenomena are not mutually exclusive.  
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In addition to activating its own membrane receptors, membrane actions of melatonin may also 
indirectly influence the function of many other membrane proteins by altering the lipid 
membrane properties. Considering that Aβ also binds to large number of different types of 
membrane receptors[24], it is possible that melatonin may be involved in slowing down or 
altering the activities of theses receptors through affecting the membrane environment. It is also 
possible that, in line with the hypothesis of this project, melatonin may be able to decrease the 
amount of Aβ available in the membrane that are able to bind and activate these receptors. 
Although the primary focus of this project is to study the membrane effects of melatonin and 
other relevant molecules, establishing the connection between membrane protein function and 
membrane actions of the molecules might be essential to fully understand their role in AD as 
well as in cell biology in general. 
1.5 Project Overview 
The overall objective of the project is to clarify the effects of melatonin on the biophysical 
properties of membranes that occur through receptor independent non-specific interactions. It is 
also to show that the effects are involved in and responsible for its protective effects against Aβ. 
The consequence of melatonin's effects on membranes will be determined by assessing Aβ 
accumulation on model membranes.  
There are several points to be considered in this project of studying melatonin’s membrane 
effects. In addition to its non-specific interactions, melatonin has two other receptor independent 
effects that are probably involved in its protective effects. One of the effects is its ability to 
reduce Aβ aggregation in solution through directly interacting with Aβ[65], [78]. Second is its 
ability to reduce oxidative stress induced by Aβ through its anti-oxidative properties[69], [70]. 
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The significance of these properties will need to be verified against its membrane effects, in 
order to clearly distinguish the extent and the significance of its non-specific membrane action in 
Aβ toxicity. For example, suppose melatonin is found to reduce the amount of Aβ aggregates 
present in the membrane. Knowing how much of its anti-aggregation properties contributed 
toward the results will be important in distinguishing the significance of the membrane effects. 
Another factor to be considered is that measuring the reduction of Aβ aggregates present on 
membranes surfaces due to melatonin may only infer a possible reduction of the toxic effects of 
Aβ. It is difficult to ascertain the exact correlation between Aβ membrane accumulation and Aβ 
toxicity, as the relationship between the amount of Aβ in the membrane and the toxic effects are 
not yet clearly understood[28]. It is probable that if reduction of Aβ is observed with melatonin, 
then additional studies may be required to verify that toxicity reduction also occurs under the 
same condition, in order to strongly suggests a correlation between membrane action and 
toxicity. 
There were two main techniques utilized for the project: Langmuir monolayer technique and 
Atomic Force Microscopy (AFM). In consideration of the capabilities of the techniques utilized, 
the overall objective of the project has been distilled down to two specific goals. First goal was 
to characterize and measure the membrane effects of the hormone melatonin (and other related 
molecules) on model lipid membrane assemblies' physical structure. Once the membrane actions 
of the molecules in altering the physical properties were assessed, the second goal was to 
determine to what extent the measured membrane actions of the molecules affect the membrane 
association of Aβ. Experiments have been designed and conducted accordingly, and the details 
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of the experiments as well as the results are presented in the main body of the thesis, which is 
divided into three chapters (chapters two, three and four).  
In chapter two, development and experimental results using the Langmuir-Blodgett monolayer 
technique are shown. In this chapter, steps involved in developing the technique in order to 
improve the precision of the measurements are explained, followed by the results of assessing 
the effects of small molecules, such as melatonin and other tryptophan derived molecules as well 
as cholesterol, on the lipid monolayer assembly. Finally, results from Aβ binding and 
incorporation studies using the technique are included. 
In the third chapter, results from AFM imaging and AFM force spectroscopy are presented. 
Detailed steps taken in developing the necessary protocols for producing supported bilayers, as 
well as measuring bilayer membrane properties through using breakthrough force measurements 
are also presented. Results from assessing Aβ binding and assimilation on model bilayer 
membrane is also presented in this chapter. 
In chapter four, collaborative work was conducted to obtain complementary data to support 
and verify the membrane experiments, and also to extend the scope and relevance of the project 
in higher order biological systems, such as cells and tissues. Works including characterizing Aβ 
deposits in the human retina, as well as testing melatonin's effects in cell cultures are presented. 
Other collaborative works featuring other techniques are also presented, and the featured 
techniques include molecular dynamics simulations, and dynamic light scattering. The 
collaborative studies were conducted and utilized to obtain supportive and complementary data 
for the results in the main part of the study presented in the previous two main chapters. 
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The last, fifth chapter contains a summary of all of the experiments. Concluding remarks with 
perspectives on merits and achievements of the project are also included in this chapter. 
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Chapter 2  
Langmuir-Blodgett Monolayer 
2.1 Introduction 
There are various techniques that study phospholipid assemblies as model systems for the 
plasma lipid bilayer membrane. One of the techniques, called the Langmuir-Blodgett (L-B) 
monolayer technique, is widely used to study compression isotherms of films at the air water 
interface and for deposition of films on solid supports[79]. The technique focuses on studying a 
single layer of phospholipid molecules (or any amphiphilic molecule) by studying them at the 
air-water interface. It utilizes the air-water interface as a surface on which amphipathic 
phospholipid molecules can be spread very thin (single molecule layer thick) spontaneously. 
Historically, an American statesman, Benjamin Franklin, has first reported this property to the 
British Royal Society back in 1774:  
"At length at Clapman where there is, on the common, a large pond, which I observed to be one day very 
rough with the wind, I fetched out a cruet of oil, and dropped a little of it on the water. I saw it spread 
itself with surprising swiftness upon the surface. The oil, though not more than a teaspoonful, 
produced an instant calm over a space several yards square, which spread amazingly and extended 
itself gradually until it reached the leeside, making all that quarter of the pond, perhaps half an acre, as 
smooth as a looking glass." [79]  
 
This observation makes the first reported demonstration of how amphiphilic molecules form a 
self-organized structure or film at the interface between water and air. It is now known that 
amphiphilic surfactant molecules undergo self-orientation at the water-air interface by having 
their hydrophobic portions face toward the air and the hydrophilic portions orient toward water, 
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in forming a single molecule thick film. Irving Langmuir first systematically studied the floating 
monolayer films in the late 1910's and early 20's[80].  
 
 
 
 
Figure 5- A photograph of a modern Langmuir monolayer trough with movable barriers used in 
the experiments. The movable barriers are highlighted with black lines, and the trough area where 
water is held is highlighted in blue. The paper pressure plate used to measure the monolayer film 
pressure is marked by a red box. Below the photograph is a set of illustrations showing how the 
monolayer sample becomes compressed using the barriers.  
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L-B monolayer studies have been extensively used for studying lung surfactants[81]. Lungs 
surfactants are in majority phospholipids[82], [83]. The surfactants are naturally arranged in a 
monolayer formation at the air exchange surfaces along the lining of the alveoli, which are the 
air sacs in the lungs. They help to facilitate the expansion and contraction of the alveoli by 
reducing the surface tension at the liquid-air interface to near zero[83]. Langmuir monolayer 
simply reconstitutes the components of the lung surfactant onto a bath of water that is enclosed 
with movable walls or barriers. By bringing the barriers closer to or further from each other, one 
can replicate the expansion and contraction of the surfactant material and study its physical 
properties. Some of the measurable physical properties using the technique include area per 
molecule, lateral pressure per given area, compressibility, and surface tension. Also by 
incorporating various other molecules into the monolayer, thermodynamics of molecular 
interactions can be determined, such as binding kinetics and molecular mixing[84], [85].  
Moving beyond studying lung surfactants, lipid monolayers can be used to mimic and study 
the two-dimensional behavior that would occur in a membrane bilayer[86]. It is not technically 
possible as yet to measure directly the parameters in a bilayer, such as its lateral expansion and 
contraction as well as lateral pressure profiles[87]. A half of a bilayer (monolayer) spread at the 
air-water interface can be used to estimate such effects using the bilayer correspondence 
theory[40]. Further usefulness of the monolayer technique is that when studying incorporation of 
small molecules into the membrane lipid assembly, the effects such as the area per lipid and time 
of incorporation can be readily measured. 
In this work, the technique will be used to study monolayer isotherms, the most common and 
simple structural measure for floating monolayers. In an "isotherm", the surface pressure change 
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upon compressing the monolayer is measured against the area occupied by the film. The 
temperature is held constant during an isotherm, hence the name. During an isotherm 
experiment, the area of the trough (the monolayer film area) is reduced by moving the barriers 
closer to each other, and the surface pressure exerted by the film will increase as the result. 
Surface pressure (Π) is defined as a difference in the surface tension of water (γ) and water with 
the surfactant present (γ0) [80].  
Π = γ - γ0                        (1) 
Changes in the surface pressure are measured using the Wilhelmy plate method. A thin plate 
made from a choice of materials (very thin plate of platinum, quartz, mica, glass or filter paper) 
is suspended at the water surface partially immersed. The forces acting on the plate include 
gravity and surface tension pulling the plate down towards the water, and buoyancy pushing up 
on the plate from displacement of water. For a rectangular Wilhelmy plate with dimensions lp, wp 
and tp, of material ρp, immersed to a depth hl into the subphase containing liquid with a density 
of ρl, the equation for the net downward force is given by the following equation: 
F = ρp  x g x lp x wp x tp + 2γ(tp x wp)( cosθ ) - ρl x g x tl x wl x hl                        (2)  
 
Figure 6- Depicting a Wilhelmy plate suspended at the air-water interface. Figure redrawn with 
written permission [79]. 
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 F = ρp x g x lp x wp x tp + 2γ(tp x wp)( cosθ ) - ρl x g x tl x wl x hl                  (2)  
The first term of the equation (2), represents contributions from gravity (g) acting on the plate. 
The last term of equation (2) represents the upward force due to buoyancy. When measuring the 
change in surface tension or Π, only the 𝛾 is assumed to be changing and contributions from 
either the gravity or buoyancy are ignored, as they do not change. The middle part of the 
equation represents contribution from surface tension related to the contact angle of the plate 
(cosθ) in respect to the surface of the water. Assuming that the plate is completely wetted, this 
angle should be 0°, thus the cosθ = cos0 =1. Also the plate thickness is minimized to increase 
sensitivity, whrere tp<<<Wp. Then, for ∆𝛾, the equation becomes 
    ΔF = (gravity contribution ignored) + 2Δγ(tp x wp)( 1 ) - (buoyancy contribution ignored)   (3)                                                
ΔF = 2Δγ(tp x wp), but tp <<< wp                                                                                                 (4) 
    ΔF = 2Δγ(wp)                                (5) 
    Δγ = ΔF/(2wp)                 (6) 
Since Π (surface pressure) is the difference between the initial and final surface tension, 
Π= -Δγ = -ΔF/(2wp)                  (7) 
The change in force in equation (7) is measured by measuring the changes in mass of the 
Wilhelmy plate. Thus the plate is directly attached to a sensitive electrobalance to continuously 
and accurately measures the force, which is then used to calculate the surface pressure 
change[80]. 
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Measuring the surface pressure change as a function of the area occupied by the molecules is 
an important indicator of monolayer properties. This pressure (Π) vs area (cm2 or Å2/molecule) 
measure, or the isotherm, contains several features that are unique to the amphiphilic material 
being tested. There are several discontinuities present in the isotherm and these regions are called 
phases[88]. At the beginning of an isotherm, the area is large and the monolayer molecules are 
far apart to have minimum intermolecular interaction. This phase is denoted as a gaseous state 
(G). As the area is compressed constantly during the isotherm, the molecules in the gaseous 
phase are compressed further and reach a liquid expanded (LE) phase. With continuing decrease 
in the area, some of the molecules in the LE phase undergo a shift in their molecular orientation 
to a more compact form. This is called liquid condensed arrangement or LC phase. The 
molecules in the LE/LC phases can co-exist (shown as a plateau area in the isotherm) and the 
decrease in area is being compensated by shifting the molecular orientation and packing rather 
than by increasing the pressure. Decreasing the area further converts all of the molecules into the 
LC configuration. Further compression of the LC phase molecules will reach their minimum 
possible molecular area until the 2-dimensional monolayer can no longer be sustained. This final 
phase of the isotherm is dubbed as the solid (S) phase. Similar to crumpling a flat sheet of paper, 
compression beyond the solid phase will induce buckling of the monolayer (monolayer collapse 
into 3 dimensionally folded structure) due to the area being too small to sustain a 2-dimentaional 
monolayer film[89].  
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Figure 7- Schematic of a monolayer isotherm, displaying the various different phases during a 
monolayer compression. 
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The Langmuir monolayer technique often serves as a platform for characterizing and 
comparing the mode of molecular interaction of the group of biologically relevant molecules to 
the membrane lipids. The advantages of this technique, which utilizes a simple membrane model 
to obtain a pressure versus area isotherm, are that it is possible to quantitatively analyze the 
mechanochemical and thermodynamic properties of the solutes[90]. The data can also be related 
to the bilayer using the lipid monolayer-bilayer correspondence theory[86], [91], [92]. In the 
past, the technique has been mostly utilized to study the mixing behavior of lipids and other 
hydrophobic compounds[84], [93] as well as to study the incorporation of proteins in lipids[85]. 
For such reasons, it was decided to use this technique to accomplish two different purposes. The 
first was to study the incorporation of melatonin into the membrane lipid monolayer assembly. 
The second purpose was to characterize Aβ incorporation into the monolayer.  
For the first part of the study, Langmuir monolayer isotherms (area versus pressure 
measurement) were utilized. Monolayer isotherm measurements are used to study molecular 
ordering in two dimensions. The water surface serves as a flat substrate on which amphiphilic 
phospholipid molecules can be arranged and manipulated mechanically to form various 
differently arranged configurations (different phases). Such direct mechanical control of surface 
pressure using the movable barriers is unique to this method. The advantage of this lateral 
pressure manipulation is that it can be used to estimate the 3-dimensional compression that 
occurs in a biological bilayer membrane, considering that a bilayer may be thought of simply as 
two coupled monolayers on top of each other. The 3-dimensional compression or expansion of a 
bilayer can be analogously analyzed through examining the 2-dimensional pressure of a 
monolayer at constant temperature, and this measure is called the 'pressure versus area isotherm'. 
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The isotherm measure is especially useful since lateral pressure components in a bilayer are 
extremely difficult to measure experimentally[86], [87].  
The most frequently used phospholipid in monolayers as a membrane model has traditionally 
been DPPC. DPPC has many advantages as a staple compound used for monolayer experiments. 
It has saturated acyl chains (palmitate, 16:0), which are stable in air from degradation by reacting 
with oxygen in the atmosphere. Phospholipids with unsaturated acyl chains, or tails, can undergo 
oxidative damage within minutes when exposed to oxygen while being spread across the water-
air interface such as in a Langmuir trough environment[94]. Monolayer studies designed to 
utilize unsaturated lipids require extra care, such as having a gas-tight enclosure, to ensure the 
damage is minimized. A further advantage of using DPPC is the abundance of published data, 
which makes it possible to directly compare and verify the findings with respect to the 
previously published studies. Newly establishing a standard with a less commonly utilized 
phospholipid molecule would have been time consuming and unnecessary.  
Monolayer isotherms, especially DPPC monolayer isotherms can be used to study mixing 
behavior of multiple component monolayers. Studying how cholesterol and its closely related 
analogues behave in DPPC monolayers has been the most numerously published in the field. 
DPPC is also suitable in that the phosphocholine headgroup (PC) is the most abundant 
phospholipid headgroup type found in biological membranes[36]. PC molecules  amount to 
nearly 50% of all membrane lipids. Particularly, it makes up a very high proportion of the outer 
leaflet of the plasma membrane[36]. It is also the principal phospholipid in lung surfactant as 
well as in the blood plasma. It is also an integral component of lipoproteins, which are 
cholesterol binding and carrying molecules. Accordingly, studies examining cholesterol and 
  26 
membrane lipid interaction often use DPPC as the model PC. It is also the top choice for studies 
investigating lipid rafts, which are determined as membrane fractions that are not dissolved by 
detergent extraction[95]. Lipid rafts are hypothesized as cholesterol rich domains (domain refers 
to a specific area or patch within a membrane). The lipid rafts, or the cholesterol condensed 
domain (liquid ordered) regions are resistant to detergent extraction (figure 3). This is due to the 
fact that the high cholesterol raft fractions are highly enriched in saturated acyl chains relative to 
the average for whole cell phospholipids. This finding converged with studies of cholesterol 
interactions with saturated chain PCs, particularly DPPC, to suggest that the lipids of rafts, as 
defined by detergent insolubility, were in a liquid-ordered (Lo) phase. This phase was first 
defined in theoretical work based on five different experimentally determined phase diagrams for 
DPPC and cholesterol[95]. Since then, the DPPC and cholesterol system have been most widely 
used for both experimental and theoretical work, especially in Langmuir monolayer and 
molecular dynamics studies. Cholesterol has mainly a laterally condensing effect on both the 
monolayer and the bilayer, and this type of behavior can be best measured using the monolayer 
technique and/or in silico, and it is very difficult to measure directly in a bilayer.  
It is also possible to study how different molecules interact with lipid monolayers from the 
water subphase using the technique. Many compounds including water soluble drugs as well as a 
variety of different peptides have been studied with the technique[96]–[103]. Such studies 
involve monolayer isotherms as well as binding assays. Monolayer binding assays involve 
compressing a monolayer to a set pressure and then set it to hold the pressure, add the molecule 
of interest into the subphase, and observe any changes in the molecular area. Any increase in the 
area per molecule indicates that the added compound is capable of inserting into the monolayer. 
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The kinetics of the incorporation can be determined also by monitoring the time of interaction 
until no more changes are observed (reaches equilibrium).  
2.2 Method Development 
In order to characterize changes brought on by molecules in the monolayer, precise 
measurement of control monolayers needed to be made. However, protocols for the method vary 
widely among many groups, and there is no rigorously established technical standard in 
Langmuir monolayer studies, even though DPPC monolayers have been extensively studied and 
work on them has been published in the literature. The protocols used in the literature were 
examined thoroughly to determine optimal practice to maximize the precision of monolayer 
measurements. The following list generally describes the steps used in the method development. 
Step 1.  Gather preliminary data 
Step 2. Compare the results with literature 
Step 3. Assess areas of improvement 
Step 4. Test and improve each criterion 
Step 5. Establish the best possible protocol for obtaining control measures 
Step 6. Proceed to conduct experiments with the molecules of interest  
First, control isotherms of DPPC were collected. Having control values that agree with 
previously published data is essential for validating our data. The first initial isotherm data from 
the experiments are shown in figure 8. Previously published data is also shown in the same 
figure. The vast majority of monolayer papers only feature isotherms from a single trial of 
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compression without any error bars. Most of the papers only mention in the methods section that 
the data shown in the paper are representative sample of multiple trials[72], [93], [103]–[109]. 
The published experimental isotherms shown as green lines in the figure are highly varied. Some 
contributing factors in creating the variability seen in the published isotherms may include 
differences in compression rate, geometry of experimental apparatus, experimental artifacts 
(leakage, impurities, etc.), as well as experimental parameters (pH, ionic strength of subphase 
and spreading solvent)[103]. However, they vary within a range. The consensus in the published 
isotherms is that the area spans from about 110 Å2/molecule to no less than 40 Å2/molecule for 
all of them (the pressure ranges from 0 mN/m to 55 mN/m). It is reasonable to assume that the 
true reference value for DPPC lies somewhere within this range since the range encompasses the 
molecular areas measured or calculated for DPPC using other techniques[110], [111].  
The preliminary isotherms collected by myself and a colleague (red and blue lines) did not fall 
within the published range, aside from one of the later isotherms (purple line, figure 8). The 
collected isotherms show a much lower area per molecule than expected. A dark black line is 
drawn at the 40 Å2/molecule mark to indicate the lowest area reached by the published 
isotherms, and our experimental isotherms clearly are shifted further to the left of this line. The 
line at 40 Å2/molecule is also drawn in figures 9, 10, and 11 for the purpose of indicating where 
the published isotherms usually end. However, researchers need to be aware that the published 
isotherm data varies widely. 
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Figure 8- DPPC monolayer isotherms from literature compared to our own preliminary data from 
the lab. Green lines denote previously published monolayer isotherms, blue, red and purple lines 
denote our own data. The purple line represents an isotherm that agrees with the literature, which 
starts at about 100 Å2 per molecule and ends at about 40 Å2 per molecule. The black line at 40 
Å2/molecule is included for clarity (Figure credit Dr. Attwood, modified and presented with written 
permission).
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Precision of the isotherms was measured by repeating the trials. The variability (standard 
deviation) of the data is shown in figure 9. Overall, each of the three groups of ten isotherms 
varied in area by >10 Å2/molecule. The changes produced by adding melatonin in the subphase 
were evident (figures 10, 11), and at 11.5 mN/m, the difference between control and either of the 
two melatonin samples were significant (p<0.05). However the difference between the two 
melatonin groups was not significant. The observed precision (degree of variability as shown by 
the standard deviation) suggests that a representative (average) isotherm should be accompanied 
by error bars. Although melatonin's effects were discernable compared to control, the range of 
the isotherms (compared to the literature values) was still not initially within the previously 
reported values (figure 9). The shift in the isotherms away from the literature values is lower in 
figures 10 and 11, due to making various protocol adjustments as explained in this section below. 
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Figure 9- Raw initial DPPC monolayer isotherms. Each line represents an independent trial. Black 
line at area per molecule 40 Å2 is included to clearly indicate the shift toward area values lower 
than that found in the literature observed in the data. DPPC was used at room temperature, 
spreading solvent was chloroform, micropipette was used, and lipid solution concentration was 
1mg/ml with deposition volume of 10.0 µl. The starting points of all the isotherms are consistent due 
to the machine area capacity being at the maximum area possible. Varying amounts of lipids were 
deposited onto the trough at the beginning of the experiment due to variability in the procedures, 
and having different amounts of lipids resulted in the vertical shifts of the starting points, due 
primarily to having excess amount of lipids.
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Figure 10- Raw DPPC isotherms. Control DPPC (black), DPPC with 1.0 mM melatonin (orange), 
and DPPC with 2.0 mM melatonin (purple) in the subphase are shown. DPPC was used with 
melatonin in the subphase (water) at room temperature, spreading solvent was chloroform, 
micropipette was used, and lipid solution concentration was 1mg/ml with deposition volume of 10.0 
µl. The starting points of the isotherms are higher compared to figure 9, but they are in agreement 
with figure 8, purple line. A different maximum area was used in these trials than in figure 9, 
causing higher values at the start of the isotherms.   
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Figure 11- Data from figure 10 is converted to show averaged isotherms with standard error of the 
mean (SEM).  Averaged control DPPC is shown in black, averaged isotherm with 1.0 mM 
melatonin is shown in red, and 2.0 mM melatonin is shown in green.  Black line at area 40Å2 
denotes the minimum area most often observed for published isotherms in the literature (figure 8). 
The curves are tested with Student's t-test at critical points to confirm differences. The number of 
curves averaged for control (black curve) was 11, for melatonin 1.0 mM (red), n=7 and for 2.0mM 
melatonin (green), n=11 (Figure credit Dr. Attwood, modified and presented with written 
permission).
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In an attempt to further improve the precision of our isotherms, a detailed comparison of 
experimental parameters was performed to screen anomalies in the protocol used for the initial 
data. Factors such as the pH of subphase, experimental temperature, compression rate, source 
and purity of the compounds, concentration, experimental apparatus, spreading solvent, 
subphase, evaporation time after deposition, as well as solution volume were considered. Other 
than the apparatus used (all groups used different machines), the approaches used for the initial 
data were overall in agreement with the parameters used by other groups.  
Testing the apparatus involved comparing two different Langmuir monolayer troughs using an 
identical protocol. WATLab, University of Waterloo, provided access to a second monolayer 
trough. Isotherms as well as pressure hold measures were conducted using the two machines. 
The results are shown in figure 12. For the isotherms, our machine showed lower molecular area 
measures (isotherms were shifted to the left of the ideal range), whereas the WATLab machine 
had isotherms shifted to higher area per molecule values. The results were consistent even after 
multiple rounds of checking calibrations for both of the machines. The pressure hold experiments 
reveled that over time, both machines showed decreased area while keeping a constant 
compression pressure. The result indicates that DPPC molecules kept inside the trough between 
the barriers is decreasing and are being lost during compression, either through barrier leakage or 
through solubilization into the subphase. Even though both machines showed inadequacies in the 
isotherms as well as in pressure hold experiments, it was decided to improve our own existing 
trough by replacing its barriers.
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Figure 12- Isotherms gathered from the lab machine (dotted lines) and also from another machine 
at WATLab (solid lines) with increasing pressure. The shift of curves with pressure is similar for 
the two machines but those shifts are not a consistent function of pressure. However the WATLab 
machine (solid lines) showed an irreconcilable software bug that incorrectly skewed the results 
toward higher areas. The lab machine (dotted lines) has an opposite problem where the isotherms 
were shifted left or drawn out and skewed toward lower areas (Figure credit Dr. Attwood, modified 
and presented with written permission).
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To test for leakage, pressure hold experiments were conducted on both of the two machines. 
Pressure hold experiment involved compressing the isotherm to a set pressure, and setting the 
trough machines to hold that pressure for an extended amount of time. A full range of pressures 
was manually selected for testing to determine the pressure dependency on leakage rate. The 
selected pressures were 10, 20, 30, 40, and 50 mN/m. The data is represented in an area versus 
time graph. An ideal case for a pressure hold experiment should yield a flat horizontal line in the 
area versus time graph starting from the point at which the target area is reached (the area value 
is determined by the corresponding compression pressure, which is manually selected for the 
trial. The higher the pressure values are, the lower the area is). At all five pressures tested, both 
machines showed evidence of leakage. The area values decreased at various rates over time, 
rather than remaining constant. The area decrease indicates that in order to maintain the set 
lateral pressures, the barriers had to continuously move in and shrink the compressible area, 
implying that the material was constantly being lost through leakage.
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Figure 13- Area versus time data for the two troughs. Own machine data is represented in dotted 
lines, WATLab data is shown in solid lines. The initial downward slope represents the initial 
compression to the set pressure point, and then the area should remain unchanged in an ideal case. 
However, some trials show a decreasing trend (negative slopes) in the area over time. The decrease 
was immediate from the beginning of the pressure hold, and the pressure decrease is a problem for 
conducting pressure-hold experiments with Aβ, which may require up to 300 minutes of sustained 
monolayer pressure (Figure credit Dr. Attwood, modified and presented with written permission).
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Strategies to mitigate the problem involved purchasing new barriers. The new barriers were 
made of Delrin, which is a hydrophilic plastic specifically chosen for the monolayer application. 
Traditionally, monolayer trough machines utilized barriers made of Teflon, which is a 
hydrophobic polymer. Delrin barriers were chosen as the leakage of the material during a 
pressure hold experiment should be much lower compared to Teflon barriers[112]. 
Unfortunately, even with two sets of Delrin barriers, the trough leakage persisted, with the new 
second set of barriers providing a slight improvement over the old pair. One of the issues 
discovered was that the manufacturer recommended cleaning procedures for the barriers were 
obsolete and incorrect. The Delrin barriers were being cleaned using chloroform, which is only 
recommended for cleaning Teflon barriers due to their hydrophobicity. It was since corrected to 
only use ethanol and water for cleaning. A comparison of the leakage rates for the old and the 
new sets of barriers are shown in figure 14. There was a measurable decrease in leakage with the 
new barriers but the difference was not remarkable.  
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Figure 14- Comparing the differences in the loss rate (leakage) of two different sets of Delrin 
barriers at given pressures. The old barriers (blue) have been cleaned using chloroform, and new 
barriers were cleaned using ethanol only. A light reduction in the loss rate is observed with the new 
barriers (Figure credit Dr. Attwood, modified and presented with written permission).
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A second strategy was to increase the compression speed while collecting isotherms.  Since 
leakage occurs over time, it was reasonable to assume that minimizing the compression time in 
completing the isotherm may reduce or minimize the overall amount of leakage. The strategy 
worked to improve the compression isotherms by bringing the values closer toward the expected 
published values and also resulted in increased precision (repeatability). However, the speed at 
which the results showed most improvement surpassed the valued used in all other previously 
published reports. This is potentially a concern if speed is a factor in changing the shape of the 
isotherms. Fortunately, it has been reported that speed should not be a major factor in 
determining the characteristics of monolayer isotherms[103]. The single best speed value that 
gave the most consistent results was chosen and the same setting was kept for all subsequent 
isotherms for consistency. 
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Figure 15- Increasing the speed of compression for isotherms shifted them toward previously 
published values (grey arrow), presumably by decreasing the compression time, which meant that 
there was less time overall for phospholipid leakage to occur. Increased speed also resulted in closer 
grouping of the isotherms as the variability in the isotherms was reduced. DPPC was deposited at 
room temperature using a micropipette and chloroform was used as the spreading solvent.
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 Following the aforementioned steps in improving the control isotherms, obtaining 
reproducible (precise) and consistent (with the literature values) isotherms for DPPC at a given 
pressure was possible (figure 16). There were numerous other procedural changes that were 
made also that contributed to the overall improvement of the isotherms. First, the trough area, 
barriers, and the paper Wilhelmy plates were thoroughly cleaned after each trial. The spreading 
solvent, chloroform, was also changed to include a fraction of methanol (chloroform: methanol, 
4:1 ratio) to reduce evaporation, which results in increased solute concentration. Chloroform 
evaporates very quickly at room temperature, thus glass vials with the smallest openings (2 ml 
volume) were utilized. The vials were also always kept cold at -20°C and the solution was used 
right out of the freezer with minimum waiting time spent at room temperature (temperature 
equilibration occurred during evaporation time). Various evaporation times, after deposition, 
were also tested (as low as 1 minute up to an hour), and it was determined that 5 minutes was 
optimal. Deposition time is also not a major factor in changing the isotherms. Use of plastic 
pipette tips to measure the 10.0 µl of the depositing solution was also abandoned. The piston 
micropipettes available in the lab require buffer gas to be consistently present in the chamber in 
order to accurately pipette the correct amount of the volatile solution. Also, the pipettes require a 
specific calibration in order to correctly compensate for the density difference between the 
volatile spreading solvents and water. The majority of published papers as well as trough 
manufacturers recommend using glass syringes for depositing volatile solutions. Some 
considerations for using glass syringes are as follows. Since they are not disposable, they must 
be cleaned for use but also stored correctly according to the manufacturer instructions. Using the 
syringes with the vials can be tricky as there will be a constant presence of air within the needle 
space when the solution is drawn up in to the syringe without inverting the syringe. Inverting the 
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syringe to push the air bubble out of the chamber cannot be performed without causing extra 
solution to be left on the surface of the needle, which will increase the number of molecules 
being deposited on the surface of the trough. Consistently drawing the exact amount of solution 
every time without the aid of special syringe attachments (syringe reproducibility adaptor) will 
take a great amount of effort and practice. With care, it was possible to achieve highly consistent 
results manually without using the adaptor. 
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Figure 16- Averaged DPPC control isotherm with the standard error of the mean (SEM) calculated 
from three independent trials after procedure adjustments and improvements were made. The 
quality of the isotherm well matches and/or surpasses that of DPPC isotherms that were previously 
reported in the literature. DPPC was compressed at room temperature using chloroform:methanol 
4:1 as the spreading solvent and glass syringe was used to deposit the monolayer onto the trough. 
Compression speed was 82 cm2/min.
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The results of the steps taken to improve the isotherms produced highly precise control DPPC 
isotherms that had low variability with values that agreed with the previous publications (figure 
16). However, there are still variations in control isotherms that stem from technical limitations. 
From one set of experiments to another, the averaged control isotherms show a variation (figure 
17). This is due to several reasons. 
In order to eliminate as much of the variability seen in the isotherms as possible, the aliquots 
must be precisely prepared to achieve the final concentration of 1mg/ml DPPC in the spreading 
solvent (chloroform:methanol, 4:1). Making the solution requires using micropipettes with 
plastic tips to measure the volatile solutions. Also a very precise amount of DPPC in powder 
form (as received from the manufacturer) must be measured, yet DPPC as a phospholipid may be 
hygroscopic and increase in weight while being measured in a scale with the chamber full of 
ambient air. Despite best efforts, each batch of aliquots will contain slightly different 
concentrations of DPPC. Once the solution aliquots are made, solvent evaporation occurs from 
accessing the solution (opening and closing the bottle to use the solution) and the concentration 
of the solution changes over time. Also it is important to note that clean glassware has a capacity 
to decrease the solution concentration as the solutes may end up coating the inside wall of the 
vials. It was technically impossible to precisely produce the exact same concentration of 
solutions in different aliquots. 
The isotherms produced from two different aliquots are shown in figure 17. The differences 
observed are minimal, as the difference between the isotherms fell within one standard deviation 
of each other (figure 17 B). This small difference is also evident when the data is derived from 
them to produce compressibility modulus plot (figure 17 C). For experiments, each aliquot was 
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treated as a separate batch, and only data produced from a single aliquot on the same day (one 
batch) was used when directly comparing the effects of different molecules on the isotherms. 
The probable sources of experimental uncertainty and variability included inconsistencies in 
solution aliquoting, monolayer deposition, and environmental conditions. Aliquoting steps 
involved unavoidable lipid loss to the glass vial walls during liquid transfer while making 
dilutions of the stock solutions. Pipetting error and uncontrolled evaporative loss of the volatile 
solvent (chloroform and methanol) also occurred during the process. During monolayer 
deposition, having different amounts of extra lipids left on the syringe needle surface from being 
dipped in the solution may also have contributed to the uncertainty. In addition, variations in the 
distance between the needle tip and the trough water surface during deposition and the speed at 
which the lipid solution was being dispensed could not be precisely controlled. Lastly, variable 
environmental conditions included vibrations, room temperature, ambient atmospheric pressure 
and chamber area saturation. 
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Figure 17- Variability in the control isotherms from differing aliquots. Two averaged control 
isotherms obtained from separate experiments on different days are presented (A) with standard 
error of the mean, (B) standard deviation (SD), and (C) the compressibility modulus. The 
differences in the averaged controls from different trials indicate existence of uncertainty, even 
after the procedures were optimized for the technique. This causes a larger % uncertainty in the 
compressibility results. However, results from the second aliquot are within 1 SD of the first.
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Once the methods of collecting control data had been optimized, mixed monolayer isotherms 
were collected for the purpose of comparing cholesterol effects on the monolayer. DPPC and 
cholesterol isotherms have been extensively studied and published by many groups before, as it 
served as a model system for the lipid rafts[95], which are highly relevant to many biological and 
disease processes. Studying melatonin effects on DPPC as well as DPPC and cholesterol mixed 
monolayers was part of this project's plan as well, so it was important that we obtain 
DPPC/cholesterol monolayer data that matches or agrees with the published norm.  
Initial averaged isotherms with cholesterol are shown in figure 18. It is usual to include various 
different concentrations of cholesterol (in our case 5%, 20% and 33%, by weight) when studying 
the mixed monolayers. The initial results were anomalous compared to the previously published 
data[108], [113] using ratios of molecules. Cholesterol and DPPC mixed monolayers typically 
show a trend in decreasing area at all pressures with increasing fractions of cholesterol, and in 
theory, cholesterol is also expected to decrease the area with increasing amounts proportional to 
the DPPC. Cholesterol has been found to strongly remain in the monolayer and not readily 
solubilize into the subphase (water solubility of cholesterol is 2.6×10-8 g/ml[114]). However, in 
our data, the lowest fraction of cholesterol (5%) showed the highest decrease in the area per 
molecule. Secondly, the 20% and the 33% cholesterol isotherms did not show a decrease in area 
when compared to control at pressure above 15 mN/m. Overlapping or crossing isotherms as a 
function of cholesterol concentrations are not a feature of published isotherms[115]. 
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Figure 18- DPPC and DPPC/Cholesterol mixed isotherms. Black line is the averaged control DPPC 
isotherm, pink is 5% cholesterol, green is 20% cholesterol and red is 33% cholesterol. The blue 
arrow indicates an anomalous crossover of the 5% cholesterol/DPPC monolayer isotherm resulting 
in a decreased area per molecule value. The overall decrease in the area per molecule is as expected, 
however, it is unexpected to have a lower fraction cholesterol (5%, pink line) show a greater 
decrease in the area per molecule compared to isotherms that contain higher fractions of 
cholesterol (green and red lines corresponding to 20% and 30% cholesterol, respectively). Figure 
credit Dr. Attwood, modified and presented with written permission.
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Initially, we were using a weight % of cholesterol, as many lung surfactant papers appeared to 
[83] but later decided to switch to using molar ratio to precisely control the ratio between the 
number of DPPC and cholesterol molecules. As a simple illustration, having 10 molecules of 
DPPC with 2 molecules of cholesterol in a monolayer (20% molecular ratio) will yield a 
different result, compared to having a 0.20 fraction of cholesterol to DPPC monolayer (in this 
case, there are 10 total number molecules, 2 of which is cholesterol). The final DPPC/cholesterol 
isotherms showed minimal overlapping or crossover between the different concentration (molar 
fraction) isotherms, and also the values for the isotherms closely matched those in the literature 
using pure DPPC systems with cholesterol[84], [107], [116], [117].      
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Figure 19- DPPC/Cholesterol isotherms. Increasing the molar fraction of cholesterol leads to 
decreasing area per molecule (indicated by the red arrow). DPPC and cholesterol was dissolved in 
chloroform and spread using a micropipette. Compression speed was 82 cm2/min (From [118], 
modified and presented with written permission).
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2.3 Melatonin Directly Interacts with Cholesterol and Alleviates Cholesterol 
Effects in Dipalmitoylphosphatidylcholine Monolayers 
2.3.1 Introduction 
The first experiment involved assessing the effects of the hormone melatonin on DPPC 
monolayers, and also on DPPC/cholesterol mixed monolayers. Cholesterol has received a lot of 
attention as a molecule of interest in many diseases such as cardiovascular disease, cancers, as 
well as Alzheimer's disease[119]. Melatonin has also received attention as showing protective 
effects in these cholesterol-implicated diseases[120], [121]. There may be a countering 
relationship between cholesterol and melatonin in that melatonin may be able to decrease the 
overall amount of cholesterol in the body. Melatonin has been shown to negatively correlate with 
serum total cholesterol and LDL cholesterol levels in pre and post-menopausal women[121]. 
Several in vitro studies of atherosclerosis development, in relation to cardiovascular diseases, 
have reported that melatonin reduced plasma levels of total cholesterol, very low-density 
lipoprotein (VLDL)-cholesterol and low-density lipoprotein (LDL) cholesterol in hyper-
cholesterolemic rats[120]. The exact mechanism of how melatonin is linked to the reduction of 
cholesterol levels is not known, however it is hypothesized that melatonin may be able to 
augment the existing endogenous cholesterol clearance pathways[120].    
Cholesterol is used and stored in the body mostly in lipid membranes in general as a 
ubiquitous constituent. Its function in the membranes is still being studied, however, its 
involvement in the formation of lipid raft regions is considered to be of utmost significance[6]. 
Membrane lipid raft regions are considered as the site for many important cellular processes, 
including the pathophysiology of many cholesterol related diseases, particularly in Alzheimer's 
disease. The possible involvement of cholesterol rich membranes as the site of Aβ production 
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and toxicity is of particular interest[30]. One of the hypotheses of this project is that the 
membrane cholesterol may be key in establishing a connection between cholesterol and the 
protective role of melatonin. The idea is that the seemingly counteractive and contrasting effects 
of cholesterol and melatonin seen in these diseases could be partly due to their competition in the 
membrane. Melatonin's protective effects seen in various diseases may be due to its ability to 
directly interact and change the physical properties of the membrane. In addition, its effects in 
reducing the effects of cholesterol in the membrane may also be indirectly contributing to its 
protective effects.   
Melatonin has been shown to have protective effects against cholesterol related diseases[120], 
[121], and also it has been shown to interact with the membrane and affect its properties[71]. 
Further, melatonin has been shown to compete with cholesterol in binding to phospholipids in 
lecithin reverse micelles [74]. Bongiorno et al.,[75] further suggested that when present in high 
concentrations, melatonin should be able to displace some cholesterol from the membrane. 
However, there was no evidence of direct interaction and displacement of cholesterol by 
melatonin. 
It was decided that melatonin and cholesterol interaction should be measured and investigated 
using the monolayer technique. The goal of the experiment was two fold. First, melatonin's effect 
on the DPPC monolayer was to be assessed to confirm and characterize its standalone effect in 
the phospholipid assembly. Melatonin's effects in both lipid monolayer and bilayers have been 
reported before, however, monolayer isotherm measurements have never been previously 
reported. Cholesterol effects on DPPC monolayers have been widely available before. The 
second goal was to assess how melatonin interacts with cholesterol in the monolayer and to 
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characterize the competing interactions. Cholesterol is capable of forming a monolayer on its 
own, but melatonin is not and only stays dissolved in the aqueous subphase. Thus the effects of 
two different concentrations of melatonin in the subphase were assessed on pure cholesterol 
monolayers as well as for mixtures of cholesterol and DPPC monolayers.  
2.3.2 Materials and Methods      
Standard monolayer isotherm methods, as developed in the previous method development 
section (section 2.2) have been utilized. Melatonin, cholesterol, and DPPC were all purchased 
from Sigma-Aldrich in powder form and were used without further purification. Melatonin was 
directly dissolved in Millipore water (resistivity > 18.2 MΩ⋅cm) by gentle agitation to yield the 
final solutions used in the monolayer subphase[122]. 
Lyophilized, powdered DPPC was dissolved in chloroform (1.0 mg/ml). 10 ml of the DPPC 
solution was deposited using a micropipette on to a Langmuir–Blodgett micro-trough (NIMA, 
UK) with a subphase volume of approximately 50 ml. Melatonin solutions in water were used as 
the subphase at 0.2 mM, and 1.0 mM concentrations, to allow melatonin partitioning from water 
subphase into the lipid monolayer. Such high pharmacological concentrations of melatonin have 
been used in previous melatonin and membrane studies [122]–[124]. Such concentrations were 
chosen in order to observe its effects most clearly. Cholesterol enriched monolayer samples were 
prepared by dissolving cholesterol and DPPC in chloroform and spreading the chloroform 
solution onto the trough. Cholesterol to lipid percentages were: 5%, 20%, 33% and 100% by 
mol%. 10 µl of the sample solution was deposited for each isotherm experiment. The 
compression rate for the isotherms was 80 cm2/min or 9.8 A2/(molecule×min). The subphase 
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was kept at room temperature at 24°C. The isotherms were repeated in at least triplicate in order 
to obtain an accurate average for each concentration and averaged isotherms are shown in the 
results. Each pressure versus area isotherm represents an average of three separate experiments, 
with the error bars calculated as standard error of the mean. 
The elastic compressibility was calculated from the pressure versus area isotherm using 
equation (1). Cs-1 is the compression modulus, A is the area in the trough, and π is the pressure. 
Cs-1 = A(dπ/dA)      (1)  
In general, a lower Cs-1 value means an increase in the monolayer compressibility[125].
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2.3.3 Results 
DPPC monolayer compression isotherms with 0.2 mM and 1.0 mM melatonin are shown in 
figure 20. 
  
Figure 20- Melatonin in DPPC monolayers. The blue arrow depicts shifts in the isotherm with 
melatonin. Statistical testing at pressure 11.5 mN/m revealed that there is no significant difference 
between control and 0.2 mM melatonin, but with 1.0 mM melatonin, the area per molecules was 
increased significantly over that of control (n=3, both groups), with p=0.02, paired Student's t-test. 
The curves are shown as the average of three trials with standard error of the mean as the error 
bars. The data was obtained using materials and methods described in detail on pages 54-55 (DPPC 
was used with melatonin in subphase (water) at room temperature, spreading solvent was 
chloroform, using a micropipette, deposition volume 10.0 µl, lipid solution concentration 1mg/ml) 
(From [118], modified and presented with written permission). 
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1.0 mM melatonin significantly increased the pressure per given area at low compression 
pressures between 0 mN/m and 11.5 mN/m (figure 20), which is equivalent to increased area per 
molecule compared to control. Above the pressure of 20 mN/m, there is no significant difference 
between the three curves (at pressure = 45 mN/m, 1.0 mM melatonin and control were not 
significantly different, p=0.17, paired Student's t-test[126]). Repeated experiments (Figure 30E) 
that tested the same concentration of melatonin also revealed that there is no significant 
difference at the higher pressure ranges compared to control (figure 30E). The increase in 
pressure of the monolayer with melatonin at low pressure (high area) is much more reliable. 
Simply put, the molecules are pushing outward away from each other and spreading themselves 
out more when melatonin is present compared to when they are not. The results suggest that 
melatonin might be able to incorporate in between the DPPC molecules and somehow induce 
repulsion. Not all molecules that incorporate into the monolayer lead to spreading effects, as 
cholesterol, for example, has been shown to decrease molecular area of lipids through monolayer 
incorporation[93]. Melatonin also seems to lose its effects and may be excluded from the 
monolayer as the pressure increases. The diminishing effects may be indicative of a solubilizing 
effect on the lipid molecules into the subphase[127], [128], but also may be due to increased 
molecular order and tightened molecular packing by increasing head group hydration[43]. It is 
most likely that melatonin is simply losing its effects through being squeezed out of the 
monolayer, being unable to withstand the increased compression pressure brought on by the 
decreasing area of the trough. The squeeze out effect is associated with molecules that interact 
with phospholipids mainly through hydrophobic interactions[129]. The lack of strong 
electrostatic interaction with the lipids may be responsible for the diminishing effects at high 
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compression pressures. Our group's molecular dynamics simulation data, included in the 
published manuscript, also supports that melatonin utilizes hydrophobic interactions as the main 
driver in interacting with the lipids[71]. 
It is important to discuss bilayer equivalencies that can be inferred from the data, as values at 
these points may have biological relevance. The bilayer correspondent theory[91], [92] suggests 
that at certain parameters, monolayers may exhibit or closely match the physical properties found 
in bilayer membranes. Extensive theoretical discussion on this theory has led to some consensus 
on the precise parameters at which the monolayer may be considered bilayer equivalent. 
However, the matter is still being debated[130]. The most frequently cited bilayer equivalent 
point is the bilayer equivalent pressure, which is accepted to be at around Π = 30 mN/m[131]. 
Estimating the bilayer equivalent pressure is purely theoretical because bilayer lateral pressure is 
not experimentally measurable. Another frequently cited point is the bilayer equivalent 
molecular area, which for DPPC bilayers has been shown to be ~64 Å2[132]–[134].  
Data on melatonin measured in the DPPC monolayer seems to suggest that all effects are lost 
at the bilayer equivalent pressure of 30 mN/m. Considering that there are previous publications 
that studied and showed melatonin's ability to interact and alter membrane properties using 
bilayer systems, this result was surprising. It was decided that the bilayer equivalent area (~64 
Å2) should be used to estimate the bilayer equivalent effects of the data. The isotherms reached 
about 11- 12 mN/m pressure at the 64 Å2 mark, and thus 11.5 mN/m was chosen as the standard 
point at which to characterize and compare the isotherms. The data at the bilayer equivalent area 
shows that 1.0mM melatonin significantly increases the lateral pressure at this area per molecule, 
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which suggests a spreading effect (figure 21 inset A, also see figure 30). The spreading effect is 
in good agreement with the previous literature[70], [71]. 
Cholesterol isotherms showed the opposite effect compared to melatonin (figure 21). Inclusion 
of cholesterol in the DPPC monolayer resulted in decreased area per molecule at the given 
pressure (11.5 mN/m), and the smallest area per molecule at a given pressure was observed for 
the pure cholesterol monolayer. The results are in good agreement with the literature[135]. Also 
note that in addition to the decrease in the area, although effects were only significant starting at 
20% cholesterol and greater, the shape of the isotherms also changes with increasing cholesterol 
content. Higher cholesterol content makes the isotherm more smooth and curved without having 
distinctive discontinuities or phase-separated regions. This effect is especially evident with the 
LE/LC phase plateau (the characteristic kink in the DPPC isotherm just below 10 mN/m) slowly 
diminishing as the fraction of cholesterol is increased. This effect is due to cholesterol inducing 
condensation of the monolayer, whereby the DPPC molecules are drawn closer to each other by 
cholesterol to form condensed phases, which is essentially eliminating the LE phase. Lipid 
condensing effects of cholesterol is well documented in the literature[71].   
The elastic compressibility modulus was calculated from the isotherms (Figure 21B). 
Compressibility modulus is an inverse measure of the elastic compressibility. Comparing the 
compressibility moduli at the chosen standard 11.5 mN/m pressure reveals that the elastic 
compressibility modulus is inversely correlated to the pressure changes observed in the isotherms 
(figure 21). 33% and 100% cholesterol isotherms decreased the pressure at a given area per 
molecule, however, the results translated into increased elastic compressibility modulus 
(compared to control, p<0.05). In other words, condensing the monolayer by cholesterol resulted 
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in a stiffer less compressible film. It was found that the two concentrations of melatonin and the 
two lowest concentrations of cholesterol showed compressibility moduli that were not different 
from control (figure 21B). However, significant (p<0.05, paired Student's t-test) changes in 
compressibility modulus with melatonin were observed at a later repeated experiment at 
pressures 11.5 mN/m and 15 mN/m at the same 1.0 mM concentration (figure 31).
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Figure 21- (A) DPPC isotherms with melatonin present in the subphase and differing molar 
fractions of cholesterol presented with standard error of the mean. The blue and red arrows show a 
trend in the shift of the isotherms for melatonin and cholesterol, respectively. Inset shows relative 
change in the area per molecule at pressure 11.5 mN/m, error bars indicate standard error of the 
mean. (B) Relative comparison of the compressibility modulus calculated from the isotherms, also 
measured at 11.5 mN/m. Error bars indicate standard error of the mean. In the insets, *’s indicate 
concentrations which give values which are significantly (p<0.05 using paired Student's t-test) 
different from control. For figure A inset, the relative changes from control for the two melatonin 
concentrations were also significantly different with p<0.05. Note that even though the isotherm 
with 1.0 mM melatonin in the subphase had showed a noticeable increase in the molecular area 
compared to the 0.2 mM melatonin (A, inset, p<0.05), the relative change in compressibility 
modulus (compared to the control) for the two concentrations of melatonin and 5% and 20% 
cholesterol did not differ significantly (B) (From [118], modified and presented with written 
permission).
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Next, effects of having both melatonin and cholesterol in the monolayers were measured. The 
mixture permutations included four different cholesterol monolayer concentrations and two 
concentrations of melatonin. DPPC monolayers containing cholesterol (5, 20, and 33 mol%), and 
a pure cholesterol monolayer (100%), were compressed with the subphase containing melatonin 
at 0.2 mM and 1.0 mM concentrations. The corresponding pressure vs area isotherms are shown 
in figure 22. Figure 22 A–D show isotherms for DPPC monolayer with progressively increasing 
concentrations of cholesterol from 5 to 20, 33 and 100 mol% of cholesterol.  
At the beginning of the isotherms (area 98 Å2), all isotherms show a normalization and 
recovery toward the DPPC only isotherms (p<0.05 Student's t-test), in terms of lipid area per 
molecule but only when the high concentration melatonin is present (the increase is indicated 
with blue arrows in figure 22). The LE to LE/LE LC phase transitions in the mixed monolayers 
can be seen to diminish with increasing cholesterol. The complete lack of clear LE to LE/LC 
phase transition in the isotherms (figure 22 C and D) with higher amounts of cholesterol (33 and 
100% respectively), even with the highest concentration of melatonin present, indicates that 
cholesterol effects on the phase transition of the monolayers persisted and could not be countered 
completely by melatonin. Even though the influence of cholesterol on the shape of the isotherms 
was persistent, highest concentration of melatonin was able to increase the area per molecule at 
11.5 mM/m for 20, 30 and 100% cholesterol isotherms (p<0.05, figure 22B, C, and D, also 23A). 
Figure 22D contains pure cholesterol isotherms with melatonin in the subphase. Without any 
phospholipids present, the highest concentration of melatonin increased the area per molecule 
significantly (p<0.05), demonstrating that it is capable of partitioning into the pure cholesterol 
monolayers and directly modifying the molecular arrangement of cholesterol molecules without 
the need for the presence of any phospholipids. 
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The relative molecular area and compressibility changes are shown in figure 23. The change in 
the area per molecule relative to pure DPPC at pressure 11.5 mN/m is shown for all cholesterol 
samples and at all melatonin concentrations. Data confirms that melatonin at 1.0 mM 
concentration significantly increases the area per molecule in control, and in cholesterol mixed/ 
pure cholesterol isotherms, when cholesterol is at 20% or higher concentrations. Figure 23B 
shows relative change in compressibility modulus, compared to pure DPPC at Π = 11.5 mN/m, 
for all cholesterol containing samples and at all melatonin concentrations. The data shows that 
melatonin significantly decreased the compressibility modulus for all cholesterol containing 
samples at the highest concentration, and for the 33% samples, the decrease was concentration 
dependent.  
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Figure 22- Compression isotherms for lipid/ cholesterol mixtures with melatonin in water subphase 
(0.2 mM and 1.0 mM melatonin, in water subphase). (A) DPPC with 5% cholesterol. (B) DPPC with 
20% cholesterol. (C) DPPC with 33% cholesterol. (D) Pure cholesterol monolayer isotherms. Blue 
arrow indicates a significant shift in the area at Π = 11.5 mN/m on the addition of 1.0 mM 
melatonin. In figures A and B, the LE/LC phase (flat plateau) exists but in figure C the LE/LC 
transition is no longer visible (D is pure cholesterol). Molar fraction was used in determining the 
percentages of cholesterol, and subphase (water) contained melatonin, compression speed 80 
cm2/min (From [118], modified and presented with written permission).
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Figure 23- (A) Relative change in the area per molecule versus increased concentrations of 
melatonin in the subphase. Numbers were measured from the isotherms (in figure 22) at pressure 
π= 11.5 mN/m. Increasing melatonin in the subphase of cholesterol and or cholesterol/DPPC 
monolayers increased the area per molecule in all concentrations of cholesterol. (B) Relative change 
in the compressibility modulus in monolayers with cholesterol. The error bars denote standard 
error of the mean. *'s indicate p<0.05 compared to control, and **'s indicate p<0.05 compared to 
the lower concentration, determined using Student's t-test (From [118], modified and presented 
with written permission). 
 
2.3.4 Discussion 
Overall, the resulting changes in the lipid biophysical properties due to melatonin were an 
increased area per molecule and a decreased compressibility modulus in the cholesterol mixed 
monolayers. The results suggest that melatonin has both a spreading effect on the 
DPPC/cholesterol molecules, and also a softening effect on cholesterol containing monolayers. 
The findings are in agreement with previous reports that showed increased molecular area and 
decreased thickness in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) monolayer 
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with melatonin, and also with another report that showed similar results in both 1,2-dioleoyl-sn- 
glycero-3-phosphocholine (DOPC) and DPPC bilayers.[71] 
Melatonin’s influence in decreasing the elastic compressibility modulus in cholesterol 
containing monolayers, as well as the increase in the area per molecule may involve increased 
water interaction with the head groups, for several reasons. It has been reported by other groups 
that melatonin can augment hydration of the head groups[136]. The increase in the hydration of 
the lipid head groups may reduce the prevalence of highly dense liquid condensed areas within 
the monolayer, since it increases the area per lipid that promotes the acyl chain dynamic 
motional freedom (i.e. fluidity) due to entropy[137]. Increased lipid molecular area and acyl 
chain fluidity due to hydration would naturally lead to lowering the thickness of the 
bilayer[138]–[140], which was also reported for melatonin[70], [71]. Simply put, increasing the 
spacing of the DPPC molecules may induce increased interaction with water molecules. 
An especially notable result of this study is that there is evidence for direct interaction between 
cholesterol and melatonin (shown in figure 23). The pure cholesterol monolayer showed an 
increase in the area per molecule and a decrease in compressibility modulus, when the high 
concentration of melatonin was present in the subphase and partitioned into the monolayer. This 
suggests that melatonin is able to incorporate between both the phospholipids and also in 
between cholesterol molecules. Previously, it was known that melatonin prevented membrane 
fluidity decrease due to lipid peroxidation, for which only its anti-oxidative properties have been 
attributed to have been responsible[123], [124], [141], [142]. Our results show that melatonin 
interacts directly with the lipids and the cholesterol molecules, increases membrane fluidity and 
alleviates cholesterol’s condensing effect in the membrane. 
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A summarizing schematic of the results is shown in figure 24. It is hypothesized that melatonin 
and cholesterol, when mixed in the lipid monolayer, will counteract each other’s effects, 
resulting in a monolayer similar to the original DPPC monolayer with the characteristic 
molecular area for DPPC. The resulting hybrid L–B isotherms, when both melatonin and 
cholesterol were present in the monolayer, did show moderate recovery toward control but did 
not fully recover to match the normal DPPC control isotherm (figures 24B and C). Thus, 
attributes of cholesterol in the isotherms remained in conjunction with the increased molecular 
area due to melatonin. Figure 24D contains a depiction of melatonin’s influence on the 
monolayer as not disturbing the cholesterol rich condensed domains. However, it is likely that 
both the cholesterol rich domains as well as the lipids are affected as melatonin had effects that 
increased the pressure per given area in the pure cholesterol monolayer as well as in the pure 
lipid monolayer.  
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Figure 24- Schematics illustrating packing of DPPC molecules in a monolayer containing melatonin 
and/or cholesterol. (A) Pure DPPC monolayer showing even spacing of the phosphatidylcholine 
molecules spread over the air/water interface; (B) monolayer enriched with cholesterol causes the 
lipids to condense and form closely packed domains, decreasing overall area per lipid headgroup; 
(C) monolayer with melatonin, which likely locates between the headgroups increasing overall area 
per lipid headgroup. (D) When cholesterol and melatonin are both present, densely packed domains 
created by cholesterol may co-exist with widely spaced areas created by the presence of melatonin, 
leading to an overall area per lipid headgroup similar to the control. Side view: ball and stick 
schematic represents single DPPC molecules, orange and red molecules represent cholesterol and 
melatonin respectively; top view: circles represent space occupied by lipid groups alone (black), 
enriched with cholesterol (orange) and enriched with melatonin (red) From [118] presented with 
written permission. 
  69 
2.3.5 Conclusion 
Melatonin had a noticeable influence on the compressibility of DPPC monolayers in an 
opposing manner to that of cholesterol (Figure 23B). With melatonin present, both increase in 
the area per molecule as well as decrease in the compressibility modulus were observed in most 
of the cholesterol containing monolayers tested (5% cholesterol did not increase significantly in 
the molecular area, but significantly decreased in compressibility modulus). Significantly, pure 
cholesterol monolayers without any phospholipids also showed increased area per molecule and 
decreased elastic compressibility modulus with melatonin. The results indicate that both 
cholesterol and melatonin can co-exist in the monolayer. The possibility of competitive 
exclusion being part of the interaction cannot be dismissed, however, the evidence is weak 
compared to the co-existing and mutual influence from both of the molecules.  
Our results suggest that melatonin has a direct fluidizing effect in the membrane and 
counteracts the condensing effect of cholesterol. The results suggest that melatonin may be 
actively involved in counteracting cholesterol-induced changes of membrane structure and 
properties. High cholesterol induced membrane changes have been associated with various 
diseases such as cardiovascular diseases[120], cancer[143], and Alzheimer’s disease[69]. The 
results of our study demonstrate that melatonin’s ability to provide protection against such 
diseases might involve, at least in part, its nonspecific receptor independent interaction with the 
cell membrane. 
The countering effects of melatonin on cholesterol were in support of the hypothesis that 
melatonin's ability to alter the membrane properties may be involved in reduction of Aβ activity 
in the membrane. Membrane cholesterol has been shown to increase Aβ binding to the 
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membrane and also to enhance toxicity of Aβ[30]. It is possible that the membrane effect of 
melatonin is involved in both directly and indirectly reducing such effects. Melatonin may 
directly reduce Aβ effects by having membrane effects that are opposing to cholesterol, which is 
Aβ enhancing. Secondly, melatonin interacts with cholesterol and reduces its effect, which may 
indirectly reduce the associated Aβ effect. The significance of the biophysical effects of the 
molecules in affecting the effects of Aβ in membrane remains to be clarified.
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2.4 Testing Aβ Binding in Langmuir Monolayers 
 Characterizing melatonin and cholesterol effects in the monolayer was a step toward the next 
phase of the project, which was to determine the consequence of such effects on Aβ interaction 
with the membrane. By directly measuring how Aβ interacts with the monolayers, with and 
without melatonin and cholesterol, it is possible to ascertain the extent to which the biophysical 
effects of the molecules on the monolayer may play a role in the toxic effects of Aβ. 
For the experiments, peptide-binding assays were utilized. The assay involved injecting the 
peptide underneath a compressed monolayer. The monolayer was held at a constant pressure or 
area, usually at the bilayer equivalent pressure or bilayer equivalent area. Then, using an 
injection port or a bent needle syringe, the peptides are added below the monolayer and allowed 
to interact with the monolayer. As the peptides interact with the monolayer from the water 
subphase, the monolayer lateral pressure or the film area become altered, and by monitoring the 
changes over time, the thermodynamics of the interaction can be extracted from the observed 
changes. Such experiments are called 'pressure hold' or 'area hold' experiments, where either the 
pressure setting or the molecular area setting for the monolayer is set and held at a constant 
value, and changes to the other parameter induced by the introduction of the peptide molecules is 
monitored. The resulting data from the experiments are presented in graphs as change in area 
versus time or as change in pressure versus time. 
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Figure 25- Schematic of a pressure hold experiment, where the change in area is measured due to 
addition of peptide molecules (grey) interacting with the monolayer. The black arrow depicts the 
direction of force inducing expansion of the trough area upon addition of peptides (Modified from 
[144] presented with written permission). 
 
In an ideal case, a pressure hold experiment would yield a result where the monolayer is 
compressed to a pressure that corresponds to the bilayer equivalent molecular area (64Å2) and is 
held constant at that setting. Upon adding the peptide, the monolayer would undergo an increase 
in the area per molecule in a steady, repeatable, and predictable manner. Analyzing the increase 
in the molecular area over time can then be used to assess the thermodynamics of the peptide 
interaction. Further, adding other molecules such as melatonin or cholesterol (or both) and 
repeating the experiment would potentially alter the binding characteristics, and effects of the 
molecules on binding can thus be ascertained. Figure 26 depicts an ideal case in which the 
binding assay shows a flat constant control versus the experimental group showing an increase in 
the area compared to the control.
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Figure 26- Illustration showing an ideal area versus time data for a pressure hold experiment. The 
solid line depicts a control experiment where the area is kept constant over time. The dotted line 
depicts a case where the amyloid peptide is incorporated into the monolayer resulting in increased 
area per molecule over time. Analyzing the slope of increase can be used to determine the kinetics 
of the interaction.
  74 
2.4.1 Materials and methods 
Standard monolayer isotherms methods, as developed in the previous method development 
section (section 2.2) have been utilized. DPPC was purchased from Sigma-Aldrich in powder 
form and was used without further purification. Millipore water (resistivity > 18.2 MΩ⋅cm) was 
used to make HEPES buffered saline (10 mM HEPES, 140 mM NaCl, pH 7.4) that was used in 
the subphase. 
Lyophilized, powdered DPPC was dissolved in chloroform:methanol 4:1 solution (1.0 mg/ml). 
10 µl of the DPPC solution was deposited using a Hamilton syringe on to a Langmuir–Blodgett 
microtrough (NIMA, UK) with a subphase volume of approximately 50 ml. The compression 
rate for the isotherms was 80 cm2/min or 9.8 Å2/molecule × min. The subphase was kept at room 
temperature at 24°C. Aβ peptide (1-42, NaOH) was purchased from rPrptide (GA, USA) as 
lyophilized powder. The peptides were dissolved in 0.01M NaOH and sonicated for 30 seconds 
in a bath type sonicator (Branson, CT, USA) and flash frozen in dry ice at 0.5 mg/ml. The 
peptides aliquots were kept at -20°C and thawed at room temperature just prior to injection into 
the monolayer subphase. A 50 µl glass syringe (model 705 LT) with an 18 gauge, Kel-F Hub 
NDL, 2.65 in, point style 3 bent needle (model 90432), was used for injection (Hamilton 
Company, NV, USA). 
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2.4.2 Results and Discussion 
Figure 27 shows experimental results from 5 different independent trials. The results show that 
unlike the ideal control case depicted in figure 26, where the control remains constant over time, 
the experimental data (figure 27) shows the area decreasing over time. The negative slope of the 
graph indicates material loss or leakage in the trough. Also, the slope varies between trials and 
each trial has a rate of decline that is not constant (the downward slope varies and changes 
slightly over time).  
The results are problematic for several reasons. First, any potential increase in the area elicited 
by the addition of peptides will be masked by the area loss occurring in the system. It is still 
possible to have a control where the area declines over time, as long as the rate of decline is 
consistent and repeatable. An averaged value of the decline could serve as an adequate control to 
compare the effects of peptide binding and the resulting increased area, even though the overall 
final value would still be a net decrease compared to the initial. Nonetheless, the decline in the 
area over time is highly variable in between trials and within a trial over time. One is unlikely to 
be able to calculate a reliable averaged control baseline with such data. 
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Figure 27- Results of pressure hold experiment with control DPPC monolayers. Five independent 
trials resulted in negative decline of the area over time. DPPC was spread using a glass syringe and 
chloroform:methanol 4:1 was used as the spreading solvent.
  77 
Another issue with this experiment was that the rate of leakage was much too fast. Previous 
publications that studied Aβ binding in monolayers through conducting pressure hold 
experiments showed that peptide incorporation time (from injection of peptide to end of changes 
observed in the molecular area) would need to last for around 300 minutes. Due to the constant 
decrease in the area, the collected preliminary data shown in figure 28 indicates that the 
maximum sustainable pressure hold time was only around 27 minutes (1600 seconds). In 
addition to the poor precision, the overall length of time may be too short to fully determine the 
binding interaction of the peptide used in the experiment.   
There was a remote possibility that addition of the peptide would yield such a drastic increase 
in the molecular area over time, so much so that it would overcome the variability in the control 
trials. Thus, experiments with vehicle controls as well as with Aβ were conducted and the results 
are shown in figure 28. The vehicle controls included injection of the solution that normally 
contains Aβ, but without it, administered using a bent-needle syringe into the subphase. The 
experimental trial involved the injection including the peptide. It is evident that both the vehicle 
controls and the experimental fell within the variability of the control trials. Any differences 
produced by the peptide cannot be ascertained due to poor precision in controls. 
There are several other miscellaneous considerations that may have contributed to the 
unfavorable results of the experiments, including not having an enclosure that controls 
temperature and humidity, or an anti-vibration table that may be required for such extended time 
dependent trials. Peptide injection ports with bath temperature controllers and subphase stirring 
mechanisms to ensure uniform distribution of the injected material are all widely utilized in such 
experiments. However, it is unclear that accounting for these factors would have helped to 
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overcome the leakage issues that were present due to the design and the low barrier quality of the 
trough.  
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Figure 28- (A) Pressure-hold experiments with five different control DPPC monolayers and two 
different vehicle controls (pink lines). (B) Red line depicts a trial where Aβ is added. The value fell 
within the variability of the control trials. Vehicle control (pink lines) involved injecting the 
amyloid incubation solution (NaOH(aq)) in to the buffer subphase (HEPES 10 mM, NaCl 150 mM 
pH 7.4) using a bent needle glass syringe.  
 
2.4.3 Conclusion 
The monolayer pressure-hold experiments to study Aβ binding to the membrane model were 
unsuccessful due to technical difficulties. The use of bent needle syringe in depositing the 
sodium hydroxide solution (vehicle for Aβ) in the subphase was a success, although it showed 
leakage. Technical recommendations from the trough manufacturer included the use of 
differently designed machines with enclosed ribbon barriers, but that was not practically 
possible. It was decided that other techniques, such as AFM, should be utilized to investigate the 
binding of Aβ instead.
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2.5 Determining the Effects of Molecules that are Precursors to Melatonin in 
DPPC Monolayers 
2.5.1 Introduction 
  Despite the results on the monolayer pressure hold experiments, the monolayer isotherm data 
gathered using the technique have been proven to be reliable, and of quality that well matches or 
surpasses the standards admissible for publications. Using the isotherm measure, it was decided 
to measure and compare the effects of tryptophan, serotonin, N-acetylserotonin, and melatonin 
on DPPC monolayers. It was a good opportunity to study and publish data on melatonin and its 
related molecules. Melatonin analogues may have potentially positive effects in AD, and recent 
publications showed that melatonin's precursor molecules have protective effects against AD and 
Aβ toxicity[145]–[147]. 
Melatonin is produced in the body from converting the amino acid tryptophan into serotonin, 
then to N-acetylserotonin (NAS), then into melatonin[51]. It may be valuable to compare the 
effects of these molecules, especially their ability to interact with the monolayer nonspecifically 
and compare the differences. Although very similar in structure, each of the molecules may 
employ different mechanisms in reducing AD associated effects. For instance, NAS has been 
shown to have anti-oxidative properties but not prevent Aβ aggregation[65], unlike melatonin, 
which is capable of both effects[69]. If NAS and melatonin affect the membrane in a similar way 
and they both are able to decrease Aβ accumulation in the membrane, it would become clear that 
inhibiting Aβ aggregation does not play a significant role in the membrane Aβ accumulation. If 
melatonin shows an advantage over NAS in terms of decreasing the Aβ membrane accumulation, 
then the difference would be attributable to melatonin's ability to decrease Aβ aggregation 
(assuming they have similar membrane effects). By characterizing the differences in the 
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membrane biophysical effects between the closely related molecules, it may be possible to 
estimate the significance of those effects in affecting the Aβ accumulation in the membrane.  
There are other advantages to studying these molecules, in terms of their broader biological 
relevance. Understanding the structure specific effects of small molecules that affect the 
biophysical properties of the membrane lipid assemblies is an active area of research, as many 
biological molecules have been shown to directly interact with the membrane lipids with 
implications to their mechanism of action. Even certain neurotransmitters are proposed to have 
anesthetic properties that are suspected to result from membrane effects[44], [47], and 
experimental evidence of the membrane interaction of several neurotransmitters has been 
reported recently[148]–[152]. One of the works, by Peters and co-workers, investigated 
serotonin, the tryptophan derived neurotransmitter[148]. Using equilibrium dialysis 
measurements and also molecular dynamics (MD) simulations, they showed that serotonin 
strongly interacts with phosphocholine (PC) bilayer membranes. The measured high membrane 
partition and interaction for serotonin showed a strong influence of the electrostatically driven 
salt bridge formation between its positive amine group and the phosphate group of the lipid as 
the major driver in the lipid-serotonin interaction[148]. Wood and co-workers further showed 
through MD simulations that both tryptophan and serotonin had limited access to the 
hydrophobic bilayer core but instead interacted with the PC head groups through electrostatic 
interactions[151]. 
As a precursor to serotonin and many other biologically active compounds, L-tryptophan is 
also a molecule of interest for its interaction with lipids. Tryptophan is an essential amino acid 
that is present in significantly higher quantities in membrane proteins versus in soluble 
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proteins[153]. Earlier work on tryptophan in the bilayer focused on the location of the tryptophan 
residues in various membrane spanning proteins, as tryptophan is the most abundant amino acid 
residue that occurs at the bilayer water interface in stabilizing the trans-membrane regions of the 
proteins[153]–[155]. The location and abundance of tryptophan residues at the membrane 
interface have been known to act as "floats" within the bilayer, acting to stabilize the structure 
and function of proteins in the bilayer environment[155], [156]. Jain et al.,[157] using 
florescence spectroscopy reported that tryptophan, tryptophan derivatives, and tryptophan 
containing peptides were able to decrease the temperature transition of DMPC (dimyristoyl 
phosphocholine), which implies that they had a fluidizing effect. Also a previous monolayer 
study on tryptophan using vibrational spectroscopy has revealed that it increased the DPPC 
headgroup angle and changed the 2-dimentaional-lattice structure by interacting with the PC 
groups through electrostatic interactions[158]. 
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Figure 29- Molecular structures of tryptophan, serotonin, N-Acetylserotonin (NAS) and melatonin. 
The arrows depict the biosynthetic pathway. In physiologically relevant conditions, tryptophan is 
zwitterionic, and serotonin is in its amine salt form. NAS and melatonin will have no charged 
functional groups. 
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Another tryptophan derivative, the hormone melatonin, has been shown to interact non-
specifically with membrane lipids[71]. Along with tryptophan and serotonin, melatonin has been 
referred to as having "sedative" effects[49], [159], [160]. Such effects are a hallmark of many 
anesthetic agents that are able to interact with the bilayer, including certain antihistamines and 
alcohols[40]. Ethanol, for example, has been shown to be able to thin the membrane[160]. 
Melatonin's anti-oxidative effects against lipid peroxidation have also been reported 
extensively[161], and the ability to interact with the lipid may be directly involved in this 
function[136]. Such effects of melatonin support the notion that a common anesthetic-like 
mechanism of interaction may be involved[162]. In support of this view, one of our previous 
publications have reported that melatonin interacts with the bilayer mainly through hydrophobic 
interaction[118]. The lipid interaction data for NAS has not yet been reported. 
It was decided to investigate these four highly biologically relevant molecules, considering 
that they may all have non-specific membrane action. Tryptophan residues play an essential role 
in membrane proteins[153], and also its derived molecules serotonin, NAS, and melatonin may 
have anesthetic like mechanism of action[53], [118]. Also, because of the structural similarities, 
they were ideal for comparing the functional group specific effects on the interaction of the 
molecules to the membrane lipids.  
Further, tryptophan based indole derivatives are widely used as pharmacological agents in 
broad areas of medicinal chemistry as anticancer, antioxidant, antirheumatoidal, aldose reductase 
inhibitor, and anti-HIV agents[163]. The compounds are commonly suspected and in some cases 
known for their ability to interact with the membrane non-specifically with functional 
consequences. The interaction of these molecules with membrane lipids is suspected to increase 
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their availability within the membrane to interact with membrane bound proteins. It may also 
enhance their ability to interact with chemicals such as oxidative species and counter them with 
anti-oxidative properties, for which the indole-derived compounds are widely known[136], 
[163], [164] Reactive oxygen species are normally produced through many endogenous reactions 
including NADPH oxidase activation and oxidative phosphorylation[165]. Insight into how 
modifications to the tryptophan/indole backbone affects/modifies the membrane action of these 
compounds will broaden the understanding of the effects of these drugs and biomolecules. 
Although the membrane interaction of some of the tryptophan derived molecules have been 
reported, a biophysical structural study comparing the effects of these closely related molecules 
in the membrane lipid environment is highly limited.  
In this study, the effects of tryptophan, serotonin, NAS and melatonin on lipid biophysical 
properties were assessed using the Langmuir monolayer technique. There are a few studies that 
looked at the effects of non-monolayer forming water-soluble pharmacological molecules in the 
monolayer before[43], [129], [168]-[170], but studying non-monolayer forming biological 
molecules such as hormones and neurotransmitters has been limited. The present study addressed 
a need for an experimental assessment of structure based functional group specific effects of 
tryptophan and its derived biological molecules on the monolayer. 
2.5.2 Materials and Methods 
DPPC (≥99%), L-tryptophan (≥99.5%), serotonin hydrochloride (≥98%), N-acetyl-5-
hydroxytryptamine  (NAS,  ≥99%), and melatonin (≥98%) were purchased from Sigma-Aldrich 
in powder form and were used without further purification. The chemicals were directly 
dissolved in Millipore Water (Resistivity > 18.2 MΩ⋅cm) by agitation to yield the final solutions 
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used in the monolayer subphase. Chloroform (ACS grade, EMD Chemicals, USA) /methanol 
(HPLC grade, Caledon Laboratories, Canada) 4:1 solution was used as the DPPC monolayer 
spreading solvent.  
Lyophilized powdered DPPC was dissolved in chloroform:methanol 4:1 (v/v) solvent at 1.0 
mg/ml. 10 µl of the DPPC solution was deposited using a Hamilton syringe model #705 
(Hamilton Company, USA) on to a Langmuir-Blodgett trough (KSVNIMA, Finland) with a 
subphase volume of approximately 50 ml. The compression rate for the isotherms was 80 
cm2/min or 9.8 Å2/molecule × min. The subphase was kept at room temperature at 24 °C. The 
isotherms and the compressibility data were analyzed using an in-house developed script using 
Matlab. Each Pressure versus area isotherm presented represents an average of a minimum of 
three individual experiments, with the error bars in the figures calculated as ± 2 standard 
deviations (SD). Uncertainties presented in the following sections are SD’s unless otherwise 
specified.  Student's t-test (as previously specified on page 57) was performed to confirm 
statistically significant changes[126]. Statistically significant difference was considered for p 
values lower than 0.05, and the tests used were paired two sample t-tests performed using 
StatPlus:mac software version 5.8.2.0. (AnalystSoft INC. USA) 
The elastic compressibility modulus was calculated from the pressure versus area isotherm 
using equation (1).  Cs-1 represents the compression modulus, where A is area in the trough 
isotherm, π is the pressure.   
                               Cs-1 = −A(dπ/dA)                                                     (1)   
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In general, a lower Cs-1 value means an increase in the monolayer compressibility and vice 
versa.     
2.5.3 Results and Discussion 
DPPC monolayer pressure-area isotherms with tryptophan, serotonin, NAS, and melatonin in 
the subphase are shown in figure 30. The corresponding differences (change) in the area per 
molecule compared to control (ΔA) versus pressure (Π) are also shown. Briefly, all four of the 
tested molecules interacted with DPPC monolayers at certain pressures and concentrations. The 
concentrations tested here (0.1 to 10 mM) are physiologically relevant, as serotonin 
concentrations in the synaptic vesicles of serotonergic neurons may reach up to 270 mM, and the 
concentrations at the synaptic cleft may reach up to 25 mM[150]. Melatonin concentrations can 
reach high micromolar range[166] and millimolar range concentrations are routinely considered 
as pharmacologically relevant[53]. Tryptophan concentrations were also included in the 
physiological range considered by Sarangi et al[158].  
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Figure 30- DPPC Langmuir monolayer isotherms (left hand side) and the difference in area per 
molecule compared to control (right hand side). The error bars are showing ± 2SD. In each case, 
three curves were averaged together. Control is shown in black, serotonin in red, tryptophan in 
blue, NAS in green, and melatonin in cyan. (A) DPPC isotherms with 1.0 mM concentrations of 
serotonin (red), NAS (green), tryptophan (blue) in subphase (B) Difference in area per molecule 
compared to control derived from A. (C) 10.0 mM concentrations serotonin (red), NAS (green), 
tryptophan (blue) in subphase (D) Difference in area per molecule compared to control derived 
from C. (E) DPPC isotherms with 0.1 mM and 1.0 mM melatonin in subphase (F) Difference in 
area per molecule compared to control derived from E.  
 
Within figure 30A, only NAS showed significant change versus control, and it was only at the 
very low-pressure regions near the beginning of the isotherm specifically at the area of around 96 
Å2 (bottom right corner of the graph, p<0.05, Student's t-test). Though significant, the effect 
quickly diminished with increasing pressure (>10 mN/m). The result indicates that NAS was able 
to increase the area per molecule at low pressures where the monolayer is known to be in its 
liquid expanded phase. The region at the beginning of the isotherms is where the pressure is low 
and the area per molecule is large, with the lateral pressure of the lipid molecules at its minimum 
and the area per molecule at its maximum. Such conditions might favor incorporation of added 
molecules into the monolayer with minimal hindrance. The diminishing effects with increased 
pressure is most likely is due to the molecule (NAS) being squeezed out of the monolayer upon 
compression[43]. Molecules that primarily utilize the hydrophobic interaction when interacting 
with the lipids have been shown to display such patterns in monolayer isotherms[129], [167].  
Serotonin and tryptophan did not produce significant changes (p>0.05) at 1.0 mM 
concentration at any pressures (figure 30A,B), including at the bilayer equivalent pressure of 30 
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mN/m where effects of molecules in monolayers are often assessed. Although the bilayer 
equivalent pressure is the most commonly used parameter to relate monolayer effects to bilayers, 
the pressure value of 30 mN/m is still under debate[130]. Thus, in addition to the equivalent 
pressure, many groups also consider the bilayer equivalent molecular area. The commonly 
accepted experimentally determined value for DPPC molecule area in a bilayer is 64 Å2 [132]. 
When comparing values at the bilayer equivalent area, the three compounds at 1.0 mM also 
showed insignificant changes compared to control (figure 30A,B) matching the null results 
observed at the bilayer equivalent pressure of 30 mN/m. 
The peaks and the valleys observed around pressure 8 mN/m in figure 30B are due to having 
an offset in the LE to LE/LC phase transition points (the kinks preceding plateau regions found 
in the isotherms, figure 30A) between each of the isotherms and the control. The liquid expanded 
(LE) to liquid expanded/liquid condensed (LE/LC) transition normally occurs between pressures 
8-10 mN/m[88]. In figure 30B, only NAS showed a peak in the ΔA graph (as opposed to valleys 
with serotonin and tryptophan), which meant that the phase transition occurred at a higher 
pressure than the normal pressure with NAS, most likely due to having larger area per molecule 
compared to control. The result implies that NAS had a spreading effect. 
 The effects of the three molecules on the monolayers were clearly evident when the 
concentration was increased to 10.0 mM (figure 30C,D). In figure 30C, tryptophan, NAS, and 
serotonin all showed significant effects on the monolayer at the beginnings of the isotherms 
compared to control (p<0.05). At this higher concentration, the three compounds showed 
significantly different change in area relative to control (ΔA, figure 30D), and also between each 
other (p<0.05) at the beginning of the isotherms. Also, both low and high concentrations of 
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melatonin showed significantly different peak heights at the 8-10 mN/m region (figure 30F) 
again indicating a significant difference from control and from each other. Thus overall, the 
compounds with high concentrations all had a spreading effect on the monolayer. Relative to 
control, NAS and melatonin showed significant area change in both low and high concentrations, 
whereas tryptophan and serotonin showed significant changes only at the high concentration. 
Nevertheless, it is evident that the effects were not sustained with increased pressure, indicated 
by the fact that all of the curves converge with the control (likely due to molecules being 
squeezed out of the monolayer). Even NAS, which had the greatest effect in increasing the area 
per molecule at lower pressures (p<0.05, paired Student's t-test) compared to serotonin and 
tryptophan, also followed the same trend of losing its effects at higher pressures much like the 
others (figure 30D).  
In high concentration groups, at low-pressure regions (figure 30C, bottom right corner), 
serotonin's effects were significant compared to control (p<0.05), and they were not significantly 
different from the effects of tryptophan. Collectively, both serotonin and tryptophan showed 
significantly lower effects compared to NAS (p<0.05). Moving toward higher-pressure regions 
(within figure 30C, left side), at the bilayer equivalent pressure 30 mN/m, all molecules showed 
insignificant effects compared to control. Using molecular dynamics simulations, Peters et al. 
and Wood et al., showed that serotonin primarily interacts with the lipid headgroup through 
forming a salt-bridge[148], [151]. This implied that there would be a maximum saturation point 
for serotonin in relation to the number of binding sites available in the lipid molecules. Likewise, 
the similar values of ΔA from both the 1.0 mM and the 10.0mM serotonin indicates that a point 
of maximum influence had been reached at the lower concentration, implying that the 
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lipid/serotonin interaction involves a mechanism that results in a stoichiometric saturation. Thus 
the data supports the previously reported electro-static salt bridge driven interaction of serotonin. 
In a previous report, Peters et al. also determined the minimum distance between the lipid head 
groups and serotonin to be between 2 to 9 Å[148]. Our data suggests that at the commonly 
accepted bilayer equivalent pressure, serotonin increases the area per molecule by about 3 Å2.  
The bilayer equivalent area also marked a spot where NAS's effects were not significantly 
different from serotonin's effects (figure 30 C). This was in contrast to NAS having had 
significantly greater values at higher areas per molecule (>73 Å2/molecule) compared to 
serotonin. It may be possible to describe NAS as having experienced a quicker squeeze-out 
effect with increasing pressure compared to serotonin. The difference may have been due to the 
two molecules employing different interaction mechanisms. Considering that serotonin and 
tryptophan isotherms are within experimental uncertainty (except at the very beginning of the 
isotherm, figure 30C and D), and NAS is considered to display a quicker squeeze-out effect at 
higher molecular areas, it might be possible that the both serotonin and tryptophan employ 
similar interaction mechanism that differs from that of NAS. Since the squeeze-out effect seen 
with NAS is considered characteristic of molecules that employ hydroponic interactions[129], it 
might be possible that tryptophan and serotonin utilize a different lipid interaction mechanism, 
most likely involving electrostatic contributions when interacting with the lipids[151]. 
Nonetheless, at pressures greater than 15 mN/m, the effects of both tryptophan and serotonin 
have disappeared completely by displaying the squeeze-out effect as it did for NAS, which might 
mean that hydrophobic interactions are basically present in all three compounds. 
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Many previous reports have shown that melatonin is able to interact with membrane lipids[70], 
[118]. Of the four tested compounds, it is the most modified molecule furthest away from 
tryptophan within the brain biosynthetic pathway. It is also the most hydrophobic molecule 
tested with the lowest aqueous solubility. Unlike the other three molecules as shown in figure 
30C, it is not possible to attain and test melatonin at 10.0 mM concentration in aqueous solution. 
However, the effects of melatonin in monolayers were so strong that changes in the area per 
molecule that are insignificantly different could be observed with 10x lower concentrations 
compared to the other molecules. Melatonin isotherms at concentrations of 0.1 mM and 1.0 mM 
are shown in figure 30E.  
In low concentration groups, melatonin at 0.1 mM concentration showed an increase in 
pressure at a given area versus control at high areas (p<0.05), which was not significantly 
different from the results obtained for 1.0 mM concentration of NAS (figure 30A). When 
comparisons are made in the high concentration group (figure 30C vs figure 30E), 1.0 mM 
melatonin managed to increase the initial pressure of the monolayer that was not significantly 
different compared to the 10.0 mM concentration effects of serotonin and tryptophan. The initial 
isotherm pressure for NAS had the highest value both significantly above control and the rest of 
the molecules (p<0.05 vs control and also vs all three compounds). However, melatonin had 
similar effects at a10x lower concentration. 
At the bilayer equivalent area of 64 Å2, high concentration groups of all four of the tested 
molecules showed significant changes compared to control (p<0.05), and they were not 
significantly different from each other. Taking into account that melatonin's concentration was 
10x less than the rest, it may be suggested that the order of influence at the bilayer equivalent 
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area might have been Melatonin > Serotonin/ NAS / Tryptophan. Comparing the effects at the 
start of the isotherms, NAS had the most pronounced effect (p<0.05 against all other groups, 
paired Student's t-test). Even with NAS having the greatest result, taking into consideration the 
order of magnitude lower concentration of melatonin, it could still be considered that melatonin 
had the strongest influence at the start of the isotherms as well (Melatonin > NAS > Serotonin = 
Tryptophan). The comparisons roughly follow the biochemical modification pathway of 
tryptophan in reverse order (figure 29). It may be relevant to note that molecules might exert 
fewer local and more general effects when further modified away from tryptophan. Accordingly, 
serotonin with fewer modifications from tryptophan has more local effects as a neurotransmitter, 
as opposed to the highly modified melatonin, which has broad range of effects as a hormone. 
Nonetheless, at pressures >15 mN/m, (which includes the bilayer equivalent pressure) no 
significant difference vs control could be ascertained for any of the compounds. 
The overall shapes of the isotherms for all groups are similar in that the effects of the 
molecules are at their maximum in lower pressure regions, and the effects gradually diminish as 
the pressure increases. The rate of diminishing effects may be different for each compound, and 
the slower diminishing trend observed for serotonin compared to NAS may be attributable to its 
increased electrostatic interactions with the membrane lipids[151].  
Compressibility moduli for the four compounds (figure 31) were derived from the averaged 
isotherms (figure 30 A,C,E). Compressibility modulus (Cs-1) correlates directly with the bending 
modulus and the bulk modulus; it is a measure of the stiffness of the monolayer[87], [125]. A 
monolayer's ability to store mechanical energy as stress is reflective of its stiffness. Also as a 
second derivative of the surface free energy vs the area, it is expected to show discontinuities at 
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both first and second order transitions[168]. This is useful for confirming any shift in the phase 
transition point. In terms of comparing results, the effects at the bilayer equivalent pressure of 
30mN/m will again be considered. However, comparing the effects at the bilayer equivalent area 
(~64 Å2, which usually occurs at a pressure considerably lower than 30mN/m) will be difficult to 
consider, since the area measure is not present in the compressibility modulus data. Judging from 
the isotherms (figure 30A,C,E), at the bilayer equivalent area (~64 Å2) the isotherms tend to have 
pressure values between 11.5 mN/m to 15 mN/m. Thus these two pressure values might be 
useful as indirect estimates for the bilayer equivalent area. So compressibility results are 
compared, using paired Student's t-test, at three different pressures: at the bilayer equivalent 
pressure of 30 mN/m, and also at 11.5 mN/m and 15 mN/m, with the last two pressures 
approximately representing the bilayer equivalent area.
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Figure 31- Compressibility modulus Cs-1 (mN/m) versus pressure Π (mN/m), calculated from the 
isotherms (figure 30 A,C,E). (A) Tryptophan, (B) NAS, (C) Serotonin, (D) Melatonin. Black lines 
are controls, the lighter colors (sky blue for tryptophan, pink for serotonin, light green for NAS and 
light teal for melatonin) in each group denote low concentrations, the darker colors (dark blue for 
tryptophan, red for serotonin, dark green for NAS and dark teal for melatonin) denote higher 
concentrations used within each group. The high concentrations for the two charged molecules 
tryptophan (zwitterionic) and serotonin (cationic, amine salt) show a pattern of compressibility 
modulus change (flat almost liner increase over the pressure range) that is different compared to 
the pattern seen with uncharged NAS and melatonin (compressibility modulus follows the control 
curve shape overall). Each curve contains an average of n=3 trials, presented with ± 2SD. 
Individual isotherms (n=3 for each line) were converted to compressibility modulus and then the 
average and SD’s were determined with ± 2SD plotted. 
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The compressibility modulus results show that all of the tested molecules at the low 
concentration (0.1 mM for melatonin, 1.0 mM for the rest) remained within experimental 
uncertainty compared to control at pressures 11.5 mN/m, 15.0 mN/m, and 30.0 mN/m. 
However, high concentration samples showed significantly different values compared to 
control (p<0.05, paired Student's t-test) in at least one of the three tested pressures.   
Tryptophan at 10.0 mM showed lowered compressibility modulus at 30 mN/m (p<0.05, 
compared to control). The results imply that the monolayer is less stiff and thus became more 
fluid with the presence of tryptophan. The difference, however was not significant in the 
lower pressures tested (11.5 mN/m and 15.0 mN/m).  
Similar results are observed for serotonin as the similarities in the molecular structures 
may have resulted in comparable effects on the monolayer. With 10 mM concentration at 30 
mN/m, serotonin decreased (p<0.05) the compressibility modulus compared to control. The 
similar results for both tryptophan and serotonin is not surprising, as Wood et al.,[151] using 
molecular dynamics simulations, had shown that both tryptophan and serotonin are able to 
interact with POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) by salt-bridge, 
hydrogen bonds, and cation-π interactions, which are electrostatic interactions. They also 
noted that both these molecules were unable to permeate through the membrane hydrophobic 
core.  
Both serotonin and tryptophan did not change the compressibility at pressures below 30.0 
mN/m (no change compared to control at 15.0 mN/m or at 11.5 mN/m). The results 
contrasted with NAS and melatonin, as they showed significant difference relative to control 
at lower pressures but not at the higher 30mN/m pressure. NAS and melatonin yielded 
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significantly different compressibility modulus changes at a pressure of 11.5 mN/m 
compared to control (p<0.05, but not different compared to each other). A significant 
reduction in compressibility modulus with melatonin was also seen at 15 mN/m pressures 
(p<0.05). Neither NAS nor melatonin showed significant effects at 30.0 mN/m. The overall 
effects of NAS and melatonin can be said to be similar in that both the compounds decreased 
the stiffness of the monolayer and changed the monolayer to be in a more fluid (expanded 
state) only at low pressure ranges (<15mN/m for melatonin and <11.5 mN/m for NAS with 
no significant difference between the two). Again, melatonin results were with 10x lower 
concentration compared to NAS.  
The contrasting compressibilities shown by NAS and melatonin compared to tryptophan 
and serotonin are probably due to the differences in the lipid interaction mechanism. It may 
be important to note that both NAS and melatonin are known to cross the blood-brain barrier 
and bilayers[169], [170], whereas serotonin and tryptophan have not been shown to cross 
bilayers[151]. The findings suggest that melatonin and NAS are hydrophobically driven 
when interacting with membrane lipids, as non-charged molecules (NAS and melatonin) are 
able to pass through the hydrophobic core of the membrane, whereas tryptophan and 
serotonin with electrostatic interactions of their charged groups may not be able to cross the 
bilayer.  
In terms of differences within each pair, melatonin had effects that matched (no significant 
difference) that of NAS at 10x lower concentrations, and likewise, there was no significant 
difference between tryptophan and serotonin. However, it was reported previously that 
tryptophan may have a less strong of an interaction compared to serotonin with lipids, due to 
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its carboxylic acid group destabilizing the tryptophan-lipid interaction through preferential 
interaction with water[151]. 
In the compressibility modulus graphs (figure 31), there is a minimum point that occurs for 
each curve at between 6-12 mN/m pressures. This point denotes an LE to LE/LC phase 
transition[171] (figure 31, all panels). Both melatonin and NAS shifted the points to 
significantly higher pressures compared to control (p<0.05), but serotonin and tryptophan did 
not. The shift or the delay in the onset of the phase transition to a higher pressure may 
correspond with the relative hydrophobicity of the molecules, as less hydrophobic molecules 
tryptophan and serotonin, did not change the minimum points significantly. The results 
indicate that the hydrophobicity of the interacting substance might be an important factor in 
the molecular packing density and the LE to LE/LC transition.  
Melatonin, as the most hydrophobic molecule of the group, had the greatest effects in 
delaying the LE to LE/LC phase transition, concentration considering, as NAS had 
comparable (not significantly different) results but with 10x greater concentration than 
melatonin. The difference is remarkable considering that NAS and melatonin differ by only 
one functional group. NAS has a hydroxyl and melatonin has a methoxy group at the 5th 
position of the indole backbone (figure 29). This difference makes melatonin much more 
hydrophobic compared to NAS and also much more potent in affecting the monolayer. Our 
previous work on melatonin supports the hypothesis that hydrophobic interaction might be an 
important main driver of melatonin's interaction with DPPC and cholesterol[118]. Further, a 
different pattern of results seen with serotonin and tryptophan compared to NAS and 
melatonin also indicates that the interaction of tryptophan and serotonin with lipids might be 
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different than that of NAS and melatonin, most likely due to involving differences in 
electrostatic interactions. 
2.5.4 Conclusions  
The mode and the extent of interaction of the four related tryptophan derived bio molecules 
within the DPPC monolayer were measured using the Langmuir monolayer technique. It was 
determine that NAS and melatonin likely utilized hydrophobic interactions as the main driver 
in their incorporation within the monolayer, and melatonin's interaction was enhanced by an 
order of magnitude with the presence of a more hydrophobic methoxy functional group 
compared to the hydroxyl group on NAS. The interaction contrasted with that for tryptophan 
and serotonin. Melatonin and NAS both showed significant effects on compressibility 
modulus at low pressures, but insignificant effects at 30 mN/m compared to control. On the 
other hand, tryptophan and serotonin displayed insignificant effects at low pressures, but at a 
higher pressure (30 mN/m) they had significant effects compared to control. The difference 
observed might be attributable to electrostatic interactions of tryptophan (zwitterionic) and 
serotonin (amine salt). At the bilayer equivalent area, all four compounds had significant 
effects of increasing the area per molecule compared to control (p<0.05, paired Student's t-
test). The effects between the different molecules were insignificant, but since melatonin had 
10 times less concentration compared to the rest, it can be said that melatonin had the 
strongest effect comparatively. 
By characterizing the changes in the monolayer using the Langmuir monolayer technique, 
it was possible to qualitatively and quantitatively differentiate the interactions of the 
structurally related tryptophan and its derivatives with the phospholipids. Improvements were 
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made that increased the precision of isotherm measurements, and averaged isotherms with 
standard deviations were presented. The data presented here may add to the overall 
understanding of the non-specific interactions of these biologically pertinent molecules that 
may be playing a role in their diverse range of function. The methods and technique 
presented may also serve as a platform for characterizing non-specific membrane interactions 
of other biologically and pharmacologically relevant molecules. 
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Chapter 3                                                                                                   
Atomic Force Microscopy Study of Supported Bilayers  
3.1 Introduction 
It was important that the hypotheses of this thesis be tested using a bilayer membrane model, 
since it is a closer representative of the real plasma membrane, compare to the monolayer. In this 
chapter, results are outlined from AFM imaging combined with AFM force spectroscopy studies 
on supported phospholipid bilayer membranes that were created through the process of vesicle 
fusion. 
3.1.1 Atomic Force Microscopy (AFM)  
AFM is a member of a family of scanning probe microscopy (SPM) techniques that are 
capable of gathering surface topographical information at nanometer and even atomic 
resolutions. AFM is a mechanical scanning device utilizing a sharpened probe (a cantilever 
needle) that physically interacts with the surface and creates 3-dimensional data. As the 
cantilever moves along the surface and interacts with the surface, a laser beam detects the fine 
movement of the tip and the image of the surface is produced (figure 32). It is also highly 
versatile especially for life sciences since special preparation of samples is not required for 
scans, which can be performed in air or in liquid. 
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Figure 32- (Top) Cartoon of an AFM cantilever/tip and the sample, the movement of the cantilever 
is detected by the laser bean. (Bottom) Example illustration of a combined optical and AFM overlay 
sample images (100 x 100 µm, green square) of human epithelial cells. Optical microscopy picture 
(bottom left) shows two cells and subsequent AFM overlay imaging (in orange bottom center) 
reveals the 3-dimensional surface structure (bottom right). The AFM image in bottom center is an 
amplitude image, and the height scale for the 3-D AFM rendering (bottom right) is shown at the 
bottom left corner, height scale range 0.2-1.0 µm.  
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There are three imaging modes: contact mode, intermittent contact mode, and non-contact 
mode. The differences between the imaging modes can be explained by examining the atomic 
forces involved at the sample surface. Fundamental to the technique are the atomic forces present 
near the sample surface that are being detected by the tip, and the technique is thus named after 
them.  
As the tip approaches the surface of any given sample, various attractive and repulsive forces 
act on the tip. Some forces lead to the tip being attracted toward the surface of the sample, which 
causes the tip to bend down toward the sample, or the forces prevent or hold onto the tip from 
moving away from the surface. Examples of forces that can induce attraction include covalent 
and hydrogen bonds, capillary forces, and solvation forces. Repulsive forces occur due to 
electron wave overlap (Pauli exclusion principle) or ionic repulsion. There are long-range forces 
(up to 100 nm) comprised of electrostatic, magnetic, and Van der Waals forces involved as well 
that can be both attractive and/or repulsive[172], [173]. 
The effective role of the forces at the tip-sample interface, in practical summation, can be 
graphed in a force versus distance graph. When the tip is far away from the surface, the forces 
are not strong enough to affect the deflection of the cantilever (no interaction). However as the 
tip approaches the sample (tip-sample separation decreases) attractive forces can dominate, 
which pulls the tip toward the surface (downward slope in the force versus distance graph). 
When the tip becomes even closer to the surface, the contact regime is established, meaning 
expulsion forces push the tip away causing the cantilever to deflect upward (figure 33).  
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The three modes of imaging work in different force regimes. Contact and intermittent contact 
mode imaging operate at the repulsive region, where the tip is close enough to the sample that it 
is bent upward and is constantly being repelled by the sample. For the two modes, the operator 
manually selects the exact amount of force being exerted by the tip while scanning within the 
repulsive region. Non-contact mode will scan the surface while the tip is in the attractive region, 
which is further away from the surface than the contact/intermittent contact imaging modes. This 
mode is ideal for measuring long-range forces, rather than the short-range chemical forces 
experienced in the contact/intermittent contact regime (figure 33).     
In essence, AFM imaging consists of choosing a certain force threshold for the tip to be in and 
keeping the force experienced by the tip constant at or near the surface of the sample while 
performing a line-by-line raster scan of the surface. Some practical limitations in this approach 
of generating images are that the tip is most likely interacting laterally with the surface due to the 
nature of raster scanning involving sideway movement of the tip, which can lead to unwanted 
tip-sample interactions (much like drawing lines in the sand). Also, because the force threshold is 
set by the user/operator, the measured sample height could be over or underestimated, depending 
on the force exerted by the tip and the softness and flexibility of the sample material.   
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Figure 33- Force versus tip-sample distance graph, describing the summation of forces 
experienced by the tip at or near the sample surface. The force is high when the tip is closer to 
the surface (repulsive region). As the tip moves away from the surface (tip sample distance 
increase) the force decreases to a minimum and then attractive forces become dominant (at 
non-contact region). Moving the tip further away from the surface leads to very low to no 
detectable forces acting on the tip (no interaction).
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3.1.2 AFM Force Spectroscopy 
In force spectroscopy mode, the AFM tip is moved vertically down to the sample and then 
backed out. This generates a full range of force versus distance data (a force versus distance 
curve, or force curve for short) between the sample and the tip. By analyzing the forces 
(measured in piconewton scales) required to compress, breakthrough, and adhere to the sample, 
it is possible to determine various material properties of the sample. In order to calculate the 
force in the force vs distance curves (figure 34), the spring constant (K) of the cantilever is 
calculated using the thermal fluctuation method[174]. This step is also referred to as "force 
calibration".  
This mode is also advantageous compared to imaging, as imaging parameters restrict the tip to 
a specific limited force region within the tip-sample interaction range. This means that choosing 
a different parameter could result in different characterization of the same sample. The 
spectroscopy mode circumvents this problem by taking account of the full range of forces 
experienced by the tip at a single point of the sample. Instead of performing a raster scan, many 
force curves can be taken using a grid pattern, and analyzing the spectroscopy data over the grid 
area can be used to generate images as well as compute the material properties of the sample. 
The grid technique, also called 'force volume mode' is often used to measure the various material 
properties of a bilayer, such as elastic compressivity, rupture depth and breakthrough rupture 
force.
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Figure 34- Force spectroscopy vertical deflection (force) versus height (displacement) graph. Point 
A depicts the point of contact between the tip and the sample, point B denotes the maximum force 
exerted in indenting the sample, point C is after the tip had broken through the sample, point D is 
the point at which the tip is pressing on the substrate underneath the sample. FB denotes 
breakthrough force, which is indentation force required to compress the sample to cause rupture or 
failure. ZA-D is breakthrough depth, which is calculated as the distance from the tip sample contact 
point to the substrate.
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3.1.3 Vesicle Fusion 
Vesicle fusion describes the technique of forming model lipid bilayer membrane structures 
supported on a flat substrate, such as mica or glass. The vesicle fusion technique involves two 
steps. First, membrane phospholipid molecules are formed into lipid vesicles (hollow spherical 
bilayer self-assembly) in solution. This step is usually done through sonication or filtration. Then 
the solution containing the vesicles is deposited on a flat substrate such as mica, and the vesicles 
can rupture and form a uniform bilayer covering the surface. 
 
Figure 35- Schematic diagram of vesicle fusion process, reproduced from [175] presented with 
written permission. 
The conditions in which vesicle fusion occur can be manipulated to produce a stable supported 
vesicle layer, instead of a supported bilayer. Nonetheless, the process of vesicle fusion is a 
spontaneous uncontrolled event that is not yet fully characterized or understood precisely.  
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3.2 AFM Experiments to Assess Bilayers 
In order to study supported bilayers, several experiments were conducted. The first step was to 
assess supported bilayers by AFM imaging. 
3.2.1 Bilayer Imaging 
First, DPPC supported bilayers were made by following the protocols already employed in the 
lab. The traditional protocol, as outlined in previous literature, gave bilayers with varying 
degrees of defects, which are holes present in a patchy coverage of a bilayer. The bilayer making 
protocol was geared toward producing bilayers with defects (holes) that reveal not only the 
presence of the bilayer patches but also their thickness compared to the underlying substrate. 
Adding melatonin to the sample gave a very slight change in the bilayer thickness (< 0.5 nm), 
which was estimated from the cross sectional height measured from the AFM images. However, 
measuring the bilayer thickness using the cross sectional height measure was not reliable, 
especially for measuring such soft pliable samples. The operator sets the force exerted by the tip 
arbitrarily in generating AFM images, and the force also is often changed during imaging. The 
control bilayer thickness measured using AFM imaging and other comparable techniques are 
shown in Table 1. In the literature, thickness values for DPPC ranges from 4.8 to 10.0 nm, for 
DOPC 3.6 to 8.0 nm. The difference between the two different phases of lipids (fluid phase 
DOPC and gel phase DPPC mixed in the same sample) was reported to range from 0 to 2.0 nm. 
The variability in the control thickness values found in the literature confirmed the observed 
variability during the experiments (Table 1). The usually reported experimental variability was 
evident in the differences observed with and without melatonin (figure 36). The thickness values 
observed for the images shown in figure 36 were 6.24 ± 0.31nm for DPPC, and 6.67 ± 0.82 
  111 
SEM, n=10 for DPPC with melatonin (2.0 mM), so they were not significantly different. 
Although an increase in a different lipid bilayer (DMPC) thickness of around 0.5 nm with 
melatonin has been previously reported using AFM[70], it was not possible to measure such a 
small change in the thickness with melatonin with this method. We can place an estimated upper 
limit on the thickness change of 5.2 nm. The accuracy and precision of the controlled thickness 
measure needed to be improved in order to differentiate smaller changes in membrane thickness. 
Because of the force between the tip and the sample is rather arbitrarily set (force setpoint) and 
varied during imaging, and the height cross section measurements reflect that, it was decided that 
using a force spectroscopy method might be better suited for measuring changes in the bilayer 
thickness since it circumvents the use of force setpoint.   
 
 
Figure 36- DPPC bilayers with and without melatonin. Visual changes (changes in the size of 
defects, new domain formation, etc.) are not observed with melatonin added (2.0 mM). Changes 
may be present but they are not detected using AFM imaging. DPPC deposited in water at room 
temperature.  
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Table 1- Reported literature values for DPPC and DOPC bilayer thickness using different 
techniques. X-ray diffraction techniques are often compared to AFM results, however, the numbers 
represent the lipid thickness only without the hydration shell [200]-[202] 
First Author, 
year Lipid Method Thickness Thickness difference 
Leonenko 
2004[176] 
DPPC 
DOPC AFM 
DPPC 
5.5±0.2 
nm 
DOPC 
5.5±0.1nm 
0.0 nm 
Picas 2012[177] DPPC DOPC AFM 
DPPC 
5.3±0.4 
nm 
DOPC 
4.1±0.2 
nm 
1.2 nm 
Milheit 2002[178] DPPC DOPC AFM DPPC ~6.5 nm 0.97±0.14 nm 
Deleu 2013[179] DPPC DOPC AFM - 1.1±0.1 nm 
Seantier 
2008[180] 
DPPC 
DOPC AFM - 0.9 nm 
Geocondi 
2001[181] 
DPPC 
DOPC AFM - 1.21±0.03 nm (n=28) 
Geocondi 
2010[182] 
DPPC 
DOPC AFM 
DPPC 10 
nm 
DOPC 8 
nm 
2.0 nm 
Choucair 
2007[183] 
DPPC 
DOPC AFM - 1.4±0.3nm 
Mingeot-Leclercq 
2008[184] 
DPPC 
DOPC AFM - 1.1±0.1 nm 
Kirat 2010[185] DPPC AFM 5.5±0.1 nm - 
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Yarrow 
2011[186] DPPC AFM 5.2-5.4 nm - 
Rinia 2002[187] DPPC AFM ~6 nm - 
Mou 1996[188] DPPC AFM 5.6 nm - 
Keller 2005[189] DPPC AFM 5.0 nm - 
Wacklin 
2011[190] DPPC 
QCM/neutron 
reflectivity 4.8 nm - 
Dekkiche 
2010[191] DOPC AFM ~4.5 nm - 
Munford 
2005[192] DOPC AFM ~5 nm - 
Grant 2002[193] DOPC AFM 4.4 nm - 
Gallova 
2004[194] DOPC  
Small angle 
neutron scattering 
4.52±0.24 
nm - 
Drolle 2013[71] DPPC DOPC 
Small angle 
neutron scattering 
39.2 Å 
33.9 Å 5.3 Å 
Gandhavadi 
2002[195] DOPC x-ray diffraction 36.0 Å - 
Pan 2009[196] DOPC  x-ray diffraction 36.8 Å - 
Tristram- Nagle 
1998[197] DOPC x-ray diffraction 45.3 Å - 
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3.2.2 Force Spectroscopy Experiment 1 
To complement the results from AFM imaging and other methods, next we used atomic force 
spectroscopy to test its suitability to address physical properties of supported bilayers. Careful 
control force experiments on proper bilayer preparations are required to perform such 
experiments, and these have never been presented in the literature before. Such experiments are 
important for the future goal to address effect of melatonin on the bilayers. Bilayers with defects 
were created by vesicle fusion (as per the protocol utilized at the time being, also in the 
preceding AFM imaging section, that was only able to reliably produced them), and force 
spectroscopy was done on selected areas of bilayers.  
3.2.2.1 Experiment 1- Methods 
Flat intact bilayer islands away from defects (or holes) in the sample were selected for 
conducting force spectroscopy measurements (figure 37). Bilayer edges were avoided as guided 
by the literature[198] to avoid getting a lower force value and induce an overall greater 
variability in the results due to edge effects. A total of two bilayer samples were used- one for 
each of the two times of incubation, 1 hour and 24 hours. Each bilayer sample was prepared in 
pure water (control), imaged to select 10 different central locations on bilayer patches and force 
spectroscopy curves were gathered (100 curves from each spot, 10 spots, so a total of 1000 
curves). The number of raw curves gathered is denoted to as "N" numbers. Out of the N number 
of curves, only a proportion of the curves gave analyzable breakthrough events that are having 
the characteristic breakthrough discontinuities as reported in the literature (Fig 34). The number 
of useable curves collected is denoted as the "n" number.  
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From the n number of curves, breakthrough thickness, breakthrough force (BT-force or FB), 
and dissipation energy (ED) were observed and calculated. These values were determined using 
the manufacturer's AFM software (JPK Instruments, Germany). MAC II cantilevers (Agilent 
Technologies, USA) with spring constant k=2.4 N/m were used without further modification. 
Bilayer samples were in water. JPK Nanowizard II AFM was used. 
3.2.2.2 Experiment 1- Results 
Data from the experiment is presented in figure 37. There was no change in the BT-force 
between the 1 hour and the 24 hour sample, no significant changes in BT-force (FB), thickness 
(nm) and dissipation energy (ED) were observed. The n numbers used for the data were, for 1 
hour DPPC, n=10, and for 24 hour DPPC n=9. The N number for each of the groups was 
N=1000.  
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Figure 37- Force spectroscopy data of DPPC bilayer. Numbers are reported with ± SD, The top left 
image shows patches of DPPC bilayer where the tip was directed to break through (Ten different 
spots marked by black stars indicate how different central locations within the bilayer islands were 
chosen to collect the force curves. A sample force-distance curve (graph top right) shows the parts 
of the curve from where the values shown in the tables were obtained. The table values show 
changes after 1 and 24 hours incubation. The number of curves analyzed for 1 hour DPPC, n=10, 
24 hour DPPC n=9. Unmodified MAC II cantilevers were used on DPPC bilayer samples in water. 
The top right schematic shows how the thickness (nm) FB and ED values were obtained from the 
BT-force curve. Thickness was the measure of the width of the breakthrough part of the curve, FB 
was the BT-force, which was the height of the breakthrough transition of the curve. ED was the 
dissipation energy calculated using the area under the adhesion portion of the retract curve. 
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3.2.2.3 Experiment 1- Discussion 
No significant changes were observed with time (between 1 vs 24 hours of incubation) in 
terms of measurable bilayer properties (breakthrough thickness, breakthrough force and 
dissipation energy as shown by student's t test (95% confidence interval). The differences in 
values in each of the three parameters measured were 0.56±0.61 nm for thickness, 0.02±0.36 nN 
for BT-force (FB), and 1.41±1.12 J for dissipation energy (ED). The specific values for the three 
properties measured were obtained from the curves as shown in figure 37- thickness was 
measured as the width of the breakthrough curve on the force vs tip-sample separation graph 
(measured on the x-axis), force was measured as the height of the breakthrough as measured on 
the y-axis within the graph. Dissipation energy was the area of the adhesion curve on the retract 
portion of the curve.  
It might be important to consider that the results were obtained from a small fraction of the 
total number of force curves taken, and the analyzable n number of curves used were as slow as 
n=9 out of N=1000. The relatively small n numbers suggested that it was possible that the 
obtained results were from rare anomalous events only, rather than from events that are normally 
present most commonly during interaction between the tip and the sample. The low yield of 
forces is a well-known phenomenon [203], however, the result would need to be repeated 
extensively in order to obtain a greater number of the low proportion of n numbers to N. Because 
this may be difficult and time consuming, using another lipid model was considered. 
The reasons for having such low n numbers may have been that it was difficult to consistently 
choose intact bilayer areas for obtaining usable breakthrough forces by manually adjusting the 
tip positioning. This process of manually selecting specific areas within patches of bilayers has 
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been widely utilized in AFM bilayer force spectroscopy studies that were published before by 
Garcia-Manyes[198], [199] and Franz et al.[200]. However, there are limitations with this 
approach. In order to select the correct bilayer patch to conduct force spectroscopy, the sample 
must be imaged beforehand to capture its topography. The process of imaging the bilayer would 
shift the bilayer patch or the islands to adopt a different shape or be moved to a slightly different 
location. Choosing a precise location from which to collect the curves must be made under 
assumption that the imaged bilayer had not been altered too much from the process of imaging.  
3.2.2.4 Experiment 1- Conclusion   
Time of incubation (between 1 and 24 h) did not lead to statistically significant changes in the 
BT-force, thickness and dissipation energy. Due to low n numbers obtained in the experiment 1, 
it was decided that another type of lipid should be utilized for future experiments.  
3.2.3 Force Spectroscopy Experiment 2 
Another strategy to improve the usable force yield was to increase the bilayer coverage. First, 
having defect free bilayers would minimize the variability arising from tip interacting only with 
the substrate, as the bilayer would completely cover the entire surface. Secondly, it would 
minimize bilayer edge effects (the molecules are less confined and loosely associated), which 
can be different from the areas near the center of the bilayer patch. Lastly, a completely intact 
and uniform surface can better serve as a controlled surface on which to easily observe and 
discern the effects of different molecules of interest, such as the Aβ peptides, interacting with the 
bilayer surface.  
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The DPPC bilayer making protocol that was being utilized up to this point had been only 
effective in producing bilayers with defects. The procedures had been intentionally developed 
this way, as having defects in the bilayer is useful in verifying the presence of the bilayer and 
also convenient in measuring the cross sectional height, which roughly corresponds to the 
thickness of the bilayer. Although good for imaging, force spectroscopy experiments may now 
require defect free samples. 
Having a defect-free bilayer would normally have some downsides, as the image of it would 
just appear flat resembling that of the substrate (mica) with nothing on it. It is certainly very 
difficult to ascertain the presence of a bilayer on the sample if it is completely defect free. Also 
completely defect free bilayers are notoriously difficult to reproduce using vesicle fusion, 
especially using gel phase lipids, such as DPPC. Because it is difficult to produce intact bilayers 
with DPPC (figure 37 as well as 45 for examples of DPPC bilayers), it was decided that using 
another lipid bilayer system (DOPC) might be necessary to obtain defect-free bilayer samples.  
In addition to creating defect free bilayers with DOPC, a different AFM machine was tried, 
partly due to a scheduling conflict with other external experiments (had to go from JPK AFM to 
Agilent AFM). The logic behind the switch was that as long as the difference between control 
samples were measured using one system under same conditions, the results would be valid. 
Both of the AFM machines have been featured in several different previous force spectroscopy 
publications (not necessarily bilayer BT-force) that were done by other groups [201]–[203]. 
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3.2.3.1 Experiment 2- Background 
One of the most popular ways of addressing the difficulties with having completely featureless 
nature of defect-free bilayers is to produce samples with two or more lipid types mixed that 
would have different height contrast. As shown in table 1, DOPC and DPPC mixtures are used 
frequently in defect free bilayer studies. DOPC represents a "fluid" phase lipid, and DPPC 
represents a "gel" phase lipid[36]. In such mixed gel and fluid bilayers, the gel phase lipids form 
a protruding domain above the fluid phase DOPC (although some publications suggest that no 
difference should be seen between the bilayers of the two lipids, see table 1). There are several 
studies featuring protocols in producing a DOPC/DPPC bilayer mixture [184], [204](papers 
shown in table 1). The methods were followed as outlined in the papers to produce the mixed 
bilayer shown in figure 38. 
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Figure 38- AFM image of the DOPC and DPPC mixed (70:30) bilayer. The higher (yellow) domains 
are hypothesized to be composed of DPPC (cross sectional schematic is shown in bottom right). The 
dark brown background area in the image is assumed to be composed of DOPC. The cross sectional 
heights of the domains are shown in the top right. The 5 nm height domains correspond to DPPC 
regions, and 3 nm regions to DOPC (presumably). BT-forces were only taken from the dark brown 
background region, consisting of DOPC only. The presence of DPPC domains was intended only to 
aid in the verification of the intact, defect free underlying DOPC bilayer (Courtesy Dr. Attwood, 
presented with written permission, unpublished). 
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3.2.3.2 Experiment 2- Method 
The bilayer sample shown in figure 38 was used to conduct a force spectroscopy study, and the 
results are shown in table 2. A total of 2 trials have been conducted. The trials involved one tip 
and one sample and data from two different areas collected in sequence. T-tests were conducted 
to compare trials 1 versus 2. MAC II cantilevers (k=2.4) were used without any modification. 
Agilent 5500 AFM (Agilent Technologies, USA) was used. 
3.2.3.3 Experiment 2- Results 
The two control trials were significantly different (p<0.05 Student's t-test). The results showed 
that there is a significant difference in  BT-force and decreased in the ZA-D depths between 
different areas within the same sample.  
 
Table 2- BT-force data on the DOPC regions of the samples using various parameters 
 
The table shows raw data with SEM. Independent trials 1, 2 were conducted using one tip and one 
sample with forces measured for different sample regions without removing the tip from the 
solution. N= total number of force curves, n% the percentage of the total number of curves that 
were used to calculate the values, FB= Force breakthrough, Z denotes the distance between different 
points (subscript letters) assigned within the breakthrough event. Data from each group (same 
shade trials) were combined together in calculating the average values. MAC mode type II 
cantilevers with nominal spring constant k=2.4 N/m were used for all sets with no tip surface 
modification, in water. * Denotes p<0.05 Student's t-test for both between the individual trials. The 
ZA-B, ZB-C ZC-D, and ZA-D denote distance between different parts of the breakthrough curve, as 
shown previously in figure 34 (Courtesy Dr. Attwood, modified and presented with written 
permission, unpublished). 
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3.2.3.4 Experiment 2- Discussion 
When data within Table 2 is analyzed, trial 1 were significantly different from 2 (p<0.05 
Student's t-test). Control BT-forces form seemingly the same control bilayer sample gave 
different force and depth results just by conducting forces on different areas. The possible causes 
for the difference in forces were that the different areas actually contained different lipids, as the 
sample bilayer was a mixture of lipids 
The bilayer samples had topography that had been never reported in the literature before, as 
papers featuring DOPC/DPPC bilayers show defect free bilayers with two different domains, one 
lower and one higher[171], (table 1). In the literature, the height difference between the low fluid 
and high gel phase domains is almost unanimously agreed to be ~1 nm. The sample (figure 38) 
had 3 different domains with height differences of ~ 3-5 nm. It was proposed that the high 
domains were the results of multilayer (multiple bilayer) formations. Also, the seemingly 
anomalous high domains were completely avoided and force spectroscopy data was only 
collected on the lowest of the domains. The lowest domain was presumed to only contain DOPC 
(lowest and the thinnest bilayer domain), however, further evidence suggest this assumption may 
have been incorrect (figure 39).  
The problem here was that the thickness determined using BT-force curves (< 4.0 nm, table 2) 
did not correlate well with reported DOPC thickness measured using other methods (>5.0 nm) 
[199, 202]. It was possible that degradation of DOPC could be responsible for obtaining a 
reduced thickness with the BT-force results. For future experiments, it was decided that only 
fresh DOPC solution made on the same day would be used for conducting force experiments. 
Also, DOPC only lipid samples without any DPPC mixed in together would be used in future 
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experiments. Making such provisions did eventually produce AFM thickness results that 
correlated well with others in the literature [209]. 
3.2.3.5 Experiment 2- Conclusion 
A significant difference in BT-force and depth were observed in two different areas within a 
control bilayer sample. The mixed bilayer sample was questionable because they did not match 
any of the previously published data on mixed bilayers with the different domains [171], [184], 
[199]. It was possible that the results were due to having various domains and mixtures of lipids 
within the sampled areas. Thus a decision was made to make changes to both the bilayer protocol 
and BT-force protocols to reconfirm the result. 
3.2.4 Bilayer Protocol Redevelopment 
Redeveloping protocols began with reexamination of the DOPC/DPPC mixed bilayer 
protocols. It was discovered that there were two main misconceptions or knowledge gaps in the 
literature. First, there was a widely held dogmatic assumption that the DOPC and DPPC domain 
heights, as measured by the AFM image cross sectional measure, must differ by around 1 nm in 
mixed bilayers. Further, the assumption of ~1 nm height difference was based on the two lipids 
automatically phase separating and being sorted by their difference in chemistry (due to line 
tension)[205] upon deposition onto the substrate, even though they are intermixed within the 
vesicle solution. There are several indicators that suggest that this assumption may not be 
adequately substantiated in the literature. There are many other papers that suggest or report 
hybrid domains of mixed composition (a third mixed composition domain, rather than just two 
pure non mixed areas), the presence of which was dependent on sonication protocol and thermal 
history of the vesicle solution[183], [206]. Our own AFM experimental data gathered from 
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observing DOPC and DPPC bilayers mixing on mica also supported intermixing of the bilayer 
components, rather than phase separation of the mixtures (figure 39). The literature on mixed 
bilayer systems do not adequately mention or address the intermixing of the lipid components 
clearly with direct experimental evidence (it is simply inferred or assumed), and it needs to be 
further explained and tested to improve the reproducibility and credibility of the published data.  
Also, there were several misconceptions in the bilayer protocol literature. The first was that the 
presence of divalent cations is absolutely required for successful vesicle rupture and fusion[184]. 
The second was that careful thermal cycling of DPPC would not result in any extra domain 
formation within DPPC bilayers[204]. The following sections feature the published experimental 
data that definitively disproved these two prevailing misconceptions in producing supported 
bilayers. The results suggested, despite the wide availability of protocols and papers in existence, 
that there are still many unknowns in the mixed bilayer protocol and in the literature that 
discusses it. Because there were increased complexity in using and producing mixed bilayer 
compositions, it was decided that working with single component bilayers, although they are too 
simple to be significantly relevant biologically, might be best in obtaining reliable controlled 
results.
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Figure 39- Images showing how DPPC and DOPC molecules intermix and form domains. Scale bar 
1.0 µm. (A) DPPC bilayer with defects. (B) Same as image A but zoomed in. The image shows 
DPPC bilayers have a lower height domain, shown in darker brown color that span between the 
defects, which are shown as large darkest colored areas. (C) Image of the DPPC domains when 
DOPC is added to the sample. Instead of filling in the defects and staying separated, DOPC binds 
and mixes in with the existing DPPC bilayers and forms secondary domains. The height difference 
between the lower and higher domains is around ~1 nm, corresponding to the reported literature 
domain height difference between DOPC and DPPC. (D) Final mixed DOPC/DPPC bilayer after 2 
hours. The higher domain shape, size and density are all altered from the initial DPPC only state 
shown in A. Changes in the shapes and heights of the domains indicate that the two different lipids 
do not stay completely separated but that they are intermixing and forming complex intermediary 
steps in forming mixed composition bilayers.  The domain height difference is ~1.8nm, which is 
much greater than the usual value reported in the literature (≤ 1nm for DOPC-DPPC systems, table 
1, AFM measurements). 
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3.2.4.1 Producing Single Component DOPC Bilayers 
It was decided that using single composition bilayers might be better than using mixed 
compositions for BT forces due to the decreased complexity. Among single composition 
bilayers, using fluid phase bilayers, such as those made with DOPC to produce defect free 
bilayers for BT-force spectroscopy, had several advantages. First, it was less likely for DOPC 
than DPPC to form extra features on top of the bilayer, since DOPC forms a less ridged bilayer 
that is less likely to support and sustain an extra layer on top of itself (a double bilayer layering 
effect). Secondly, DOPC bilayers were more dynamic than DPPC in that the patches in the 
bilayer (small defects) would often close off and self seal over time (dynamic nature of 
supported bilayers is a well-established phenomenon)[175].  Figure 40 shows AFM topography 
images of DPPC and DOPC bilayers supported on mica and imaged in water. 
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Figure 40 - AFM images of DOPC bilayer patches illustrating the delicate, fluidic nature of DOPC. 
Sparsely covered sample of DOPC on mica (scan 1) was scanned successively over the same area. 
As can be seen, the tip drags the lipid together, forming successively larger patches, with the space 
between them growing. The effect is most obvious when the boundary between a previously 
scanned area and an untouched area is observed, such as at the corner. By using computer software 
to calculate and remove undulations arising from imperfections in the piezo movement in the plane 
of the raw image data (flattening the image), and using a custom Matlab code, the frequency versus 
z-height of pixels that belong to the mica area (dark brown) and also in bilayer areas (yellow) were 
assessed, and we are able to observe two distinct populations, representing the mica surface and the 
top surface of the bilayer (red Gaussian distributions, bottom right). By fitting two Gaussian 
distributions and then subtracting the difference between the peak heights, we find that the bilayer 
depth is 5 nm. The precision of this measurement is very high (standard error of the mean <0.02%), 
however the largest uncertainty in this measurement is due to the force setpoint. By scanning with a 
higher force, it is easy to compress the bilayer, measuring slightly less than the “true” depth. By 
scanning with a low force, it is possible that contributions from repulsive forces play a role, 
resulting in an overestimation of the height of the bilayer. It is thus probable that quantitative 
approach to depth measurement of soft bilayer systems can only be achieved by analyzing force 
distance curves (From [204], presented with written permission). 
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There were downsides to using DOPC. DOPC has unsaturated lipid tails, and the double bond 
is vulnerable to oxidative damage. DPPC with saturated tails are much more stable in air and 
also in water. Thus DOPC required greater care in storing and producing the vesicle solution, as 
well as after it was deposited into a supported bilayer. DOPC vesicle solutions were produced 
daily and this took extra time and also potentially increased variability in the results during 
repeated trials. Nonetheless, it was possible to optimize the protocol to produce defect free 
DOPC bilayers (figure 41). The details of the protocol are as follows. 
    
DOPC Bilayer Preparation 
Stock Solution Preparation: 
1. Open the ampule containing 25 mg DOPC in chloroform. 
2. Transfer the entire ampule directly to a 20 ml glass vial. Add an extra 1000 µl of chloroform 
to the ampule and wash out to the glass vial so as to remove all lipids. 
3. Evaporate the solvents under a stream of nitrogen until visibly dry (approximately 10–15 
min). 
4. Add 6 ml chloroform/methanol (2:1) and split into even aliquots to 6 small glass vials 
(capacity 4 ml each). Each stock vial therefore contains 4.17 mg DOPC. 
5. Top with nitrogen and store at −20°C. 
 
Liposome Preparation: 
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1. Transfer one of the 1000 µl stock aliquots to a clean 20 ml glass vial. Wash out the small 
vial with an extra 1600 µl chloroform/methanol (2:1) and add this to the 20 ml vial as well to 
make 2 mM and ensure no lipid is lost. 
2. Evaporate solvents with a continuous stream of nitrogen. After ~15 min all should be visibly 
dry. Continue for an extra 15 min to ensure all solvents are evaporated (30 min total). 
3. Bubble nitrogen gas through ~20 ml of Millipore water for ~15 min to remove the oxygen. 
4. Add de-oxygenated Millipore water to make 0.5 mg/ml. The lipid should quickly start to 
swell, separate from the glass vial and form an inhomogeneous suspension of cloudy material. 
Also add a stir bar and top the vial with nitrogen. 
5. Stir using magnetic stirrer for 30 min at 1100 rpm (the solution should appear homogeneous 
and milky). 
6. Place the solution at 4°C and allow to swell for 1 hour. 
7. Stir using magnetic stirrer at 1100 rpm for 30 min at room temperature. 
8. Place the vial in the middle of the sonicator where cavitation is greatest. The most powerful 
region of any bath sonicator can be found easily by placing a sheet of aluminium foil on the 
surface of the water and sonicating for ∼ 10 min, a large hole should appear at the region of most 
intense power. Sonicate for 30 min, during which there was a slight inadvertent heating of the 
water (start temperature is ~ 23°C, finish temperature is ~ 31°C. The solution should appear 
completely clear after sonication. If using higher concentrations of lipid, the solution may take 
longer to go to clarity. 
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9. Store the liposome solution at 4°C until needed. 
Vesicle Fusion: 
1. Remove the liposome solution from the fridge and stir at 1100 rpm for ~ 45 sec. 
2. Place 300 µl of cold solution directly into the AFM fluid cell containing freshly cleaved 
mica. 
3. Wait 15 min. 
4. Wash with 10 ml water through a syringe by slowly allowing the fluid cell to overflow so as 
to prevent sample de-wetting. 
Typically the above protocol will give a continuous bilayer of DOPC. However, slight 
decreases in the concentration (e.g., a little extra lipid lost during preparation of the liposome 
solution) may mean that a complete bilayer is not formed. In this case it was found that it is best 
to prepare several samples that have been incubated for slightly longer and shorter periods of 
time and image these using the AFM. By capturing the state of bilayer coverage at various points 
in time, it is then possible to be certain that for a given incubation time a complete bilayer was 
formed. In some cases, a complete bilayer may not form even for extended incubation times. In 
this case, another approach can be taken whereby a higher concentration of lipid (1 mg/ml) 
liposome solution is prepared. This solution can then be sequentially diluted to find the optimum 
concentration to form a complete bilayer. 
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Figure 41- Time series of DOPC bilayer formation. Four separate samples of DOPC bilayers on 
mica were prepared that were incubated for (A) 5 min (B) 10 min (C) 17 min and (D) 20 min. Below 
each image is an illustration of the state of the lipid coverage across the mica surface. The time 
series experiment is a good way of determining that a complete single bilayer covers the mica 
surface. Without doing the time series experiment, it is very difficult to distinguish a complete 
single bilayer from multilayer or even bare mica. In addition, when faced with a DOPC sample 
with partial patchy coverage, it is a simple task to prepare a new sample with a slightly increased 
incubation time that will result in continuous coverage. All images were taken in pure water at 
room temperature (From [204], presented with written permission). 
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Once a continuous DOPC bilayer is produced, it was useful to verify the presence of the 
bilayer through dewetting the sample. Supported bilayer structure is sustained by the balance 
between the hydrophobic bonding of the phospholipid acyl chains and hydrophilic expansion of 
the phospholipid head groups[87]. Drying the sample overwhelms the balance and leads to 
detachment of some of the bilayer from the substrate (forming defects). As illustrated in figure 
42, this technique is useful to verify the presence of the bilayer, however, it is a destructive 
process and should be performed sparingly. Also, increasing the volume or strength of the 
washing stream at the rinsing step of the bilayer preparation does not produce defects or have 
any other perceivable effects. Although transient aeration during such maneuvers may result in 
partial dewetting of the sample, which then would produce defects in the sample.
 
Figure 42- Illustration of the dewetting test used to confirm bilayer coverage. (A) A sample is 
prepared using DOPC liposomes. Apart from some protrusions the sample is defect-free, making a 
confirmation of the state of the sample (mica, single bilayer, multilayer) difficult (B) Sample 
instantaneously dewetted and then rehydrated. The holes confirm the presence of a single bilayer 
(C) After a short period the holes begin to close, demonstrating again the fluidic nature of DOPC. 
All images were taken in pure water at room temperature (From [204], presented with written 
permission). 
  134 
3.2.4.2 Producing Single Component DPPC bilayers 
The steps taken in producing DOPC bilayers was extended to produce DPPC bilayers. 
Producing defect free DPPC bilayers proved to be a much more difficult task, mainly due to the 
fact that DPPC is a gel phase lipid at room temperature. Only at above its melting transition 
temperature of 42°C, would it behave similarly to DOPC in terms of its deposition 
characteristics, and causing it to melt involved heating and cooling the sample (thermal 
fluctuation to turn into fluid phase then go back to solid or gel phase). The procedure induced 
fusion of the vesicles, however, differing degree of defects and domains appeared depending on 
the cooling rate (Figure 43). The domains and defects remained stable at room temperature for an 
extended period of time. Also, not heating enough and leaving it below its transition temperature 
yielded various incompletely fused structures (figure 44). 
The overall dilemma in creating a full coverage of defect free DPPC bilayer was that there 
must be a balance between adding heat to cause fusion of the vesicles and yet minimize 
temperature induced defect and domain formation from the heating. The key to creating a 
workable DPPC bilayer was in finding the optimal conditions at which the fusion of vesicles can 
be maximized while the domain and defect formation is minimized. Eliminating all features on 
DPPC bilayers was not achievable.   
135 
 
 
Figure 43- Effect of cooling rate on DPPC bilayers in water. All samples were prepared by 
incubation with DPPC liposome solution in water at 60 ◦C and incubation for 5 min followed by 
cooling to room temperature at (A) 5◦C/min (B) 1◦C/min (C) 0.5◦C/min. The region enclosed by the 
blue box has been enlarged and is shown below C. For this image of DPPC at room temperature, 
we see three different types of domains with the lower two being 1.1 nm and 0.6 nm below the 
upper most domain (From [204], presented with written permission). 
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Figure 44- Effect of mica temperature during deposition. All samples were prepared with a cooling 
rate of 5°C/min. Mica temperature during deposition was:(A) 60°C (B) 39°C (C) 37°C (D) 35°C (E) 
33°C (F) 30°C. Lower domains decrease dramatically as a proportion of total lipid coverage 
between 60°C and 39°C, after which a slow decrease is observed to 33°C. At 30°C we mostly 
observe unfused vesicles. Protrusions thought to be trapped vesicles are seen for all samples but 
dominate for temperatures below 60°C. Schematic (bottom) illustrates the various under-fused 
DPPC structures present in the images (From [204], presented with written permission).
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Some of the specific factors that were tested in creating a defect free DPPC supported bilayers 
included the sample heating rate, cooling rate, peak temperature, initial temperature, time of 
incubation, solution ionic strength, solution temperature, solution pH, and details in rinsing 
(temperature, harshness). The individual factors were tested one at a time for its effects on the 
final bilayer product. This step in the process was especially difficult and time consuming as the 
factors individually as well as in combination in various possible permutations had to be tested 
and confirmed for bilayer features and reproducibility. Countless different samples were created 
and imaged testing various combinations of conditions and factors. In the end, it was not possible 
to create a completely homogenous defect free supported bilayer of DPPC. The final product, 
with the best compromise between maximum amount of coverage and least amount of defects 
and domains, which was also unequivocally reproducible, is shown in figure 45. The final 
procedure used is as follows.  
150 µl of DPPC vesicle solution at 1 mg/ml concentration was added to the AFM liquid cell 
containing 150 µl of HEPES saline buffer (10 mM HEPES, 140 mM NaCl, pH 7.4) that was 
heated to 60°C. The sample was kept for 2 minutes at 60°C. With the heater on, the sample was 
rinsed to overflow with 10 ml of Milipore water (resistivity > 18.2 MΩ⋅cm, at room temperature) 
using a syringe. Remaining water in the liquid cell (contains a volume of ~1 ml) was flushed and 
replaced with the buffer using a micropipette with a total of 10 ml of the buffer by fluid 
replacement, pipetted in and out 1 ml at a time (x10 times). After the rinse, the sample (still at 
60°C) was cooled to 45°C at 1.0 Kelvin/min cooling rate, then from 45°C to room temperature 
the cooling rate used was reduced to 0.5 Kelvin/min
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Figure 45- DPPC bilayer with the best compromise between having the least amount of defects and 
domains with the largest area coverage. The sample still contains defects (darkest brown), domains 
(medium brown), as well as extra deposits of lipids on top (white blobs). The DPPC vesicle solution 
at room temperature (1.0 mg/ml) was deposited onto an AFM liquid sample holder at 60°C for 1 
minute, rinsed with a 10 ml of buffer with a syringe and cooled gradually from 60°C to 50°C at 1 
Kelvin/min, then 50°C to 35°C at 0.5 Kelvin/min. Cooling from 35°C to room temperature (24°C) 
was done with the AFM sample heater off. Both the vesicle solution and sample were in buffer 
(HEPES 10 mM, NaCl 150 mM, pH 7.4).
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3.2.5  Force Spectroscopy Experiment 3 - Force Spectroscopy on Supported DOPC 
Bilayers 
Refinements made in bilayer making protocols insured the production of mostly defect free 
bilayers that can be used for BT-force spectroscopy experiments (Figure 41 D). Now that 
producing completely homogenous bilayer samples was possible with DOPC, it was preferred 
over using DPPC bilayers (Figure 45). Several trials of BT-force experiments were conducted on 
DOPC bilayers. 
3.2.5.1 Experiment 3- Methods 
Control BT-force curves were collected using a grid of 256 squares in a 4.0 µm by 4.0 µm 
defect free bilayer area. A grid or a map was utilized to avoid bilayer recovery time dependence 
from taking multiple curves from the same spot. The collected 256 curves were analyzed for the 
BT-force, and breakthrough depth (BT-depth). The BT-force from the 256 curves formed a 
Gaussian distribution and the data was plotted on a force versus time graph as a single point 
presenting the mean force with the standard error of the mean (one data point in the graph 
represents the average and SEM from a map of 256 curves, distribution shown in figure 46.  
A total of three different trials were conducted. Each trial involved using a single tip and one 
separately prepared bilayer sample. In each trial, a series of force maps (for an example for a 
data from just one force map, see figure 46) were collected in one of the samples over a course of 
100 minutes. Unmodified gold (NPG) cantilevers with spring constant k= 0.06 N/m were used 
with JPK Nanowizard II AFM (JPK Instruments, Germany). 
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3.2.5.2 Experiment 3- Results 
The results are shown in figure 47. Control BT-force values were different from the three 
independent trials depending on the particular tip of the same type being used. The absolute force 
value per a given tip differed. The absolute force values were trial A 2.44 ±0.5 nN, trial B 1.98 
±0.5 nN and trial C 4.10 ±0.2 nN. Two sample t-tests with unequal variances were performed in 
between each of the trials, trials A vs B gave p= 0.02, and A vs C gave p=1.6x10-6. B vs C gave 
p= 1.5 x10-10 (all p<0.05, see figure 47 also table 3). Thickness number are not presented in 
figure, but for trial A it was 8.27 ±4.8 nm, trial B 7.99 ±6.2 nm and trial B 7.47 ±2.3 nm. No 
significant differences were observed for the thickness in between the trials (p>0.05 for all trials) 
The variations in forces within a map (distributions shown in figure 46, represents error within 
each data point shown in figure 47) were overall smaller compared to shifts in the average values 
(difference between data points) that varied over time (figure 47). BT-force values for control, 
even though they were relatively stable over time, always changed from tip to tip and also even 
within a tip when used on a different occasion; the same tip could give a different, but stable, 
BT-forces on a different day on a different DOPC bilayer sample. Also the trials shown in figure 
47 C showed a much higher force compared to the other trials but overall for reasons unknown. 
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Figure 46- Example BT-force and the values estimated from the curves (top image). 256 of these 
curves are collected in a grid pattern and the values from the curves are plotted on graphs as 
Gaussian distributions. The mean values of each distribution is depicted as a single point in a force 
vs time graphs, such as the one shown in figure 47, or a single point in depth vs time graph (not 
shown). (A) Force distribution (B) the ZA-B depth (C) ZB-D depth (D) ZA-D depth. DOPC bilayer was 
prepared in water using the procedures outlined in section 3.2.4.1. The cantilever used was an 
unmodified NPG lever with spring constant around 0.06 N/m. Only control sample measures are 
presented. For distribution, non-linear least squares fitting algorithm (Levenberg-Marquardt) was 
used that was implemented in Matlab software (From [204], presented with written permission).  
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Figure 47- Force versus time graphs of breakthrough (rupture) force spectroscopy results with 
control DOPC from three different trials A, B, and C. Each trial utilized one tip and one sample 
(separately prepared control bilayer sample per each trial). Unmodified NPG- gold-coated leavers 
(k=0.06 N/m) were used for these trials. Each data point represents an average ± SEM of 256 curves 
from a force map, conducted in water at room temperature. 
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3.2.5.3 Experiment 3- Discussion 
The change in rupture force was noticeable between each data point over the time course of the 
experiments, in all three trials (figures 47). The absolute BT-forces for control varied from 1.9 to 
4.1 nN even though the same types of tip and sample were used. The differences in the data 
points within each trial indicate that there is a time dependent change in force that exists with 
this technique, and this result also corresponds with the results obtained in force experiment 2. 
Another issue observed is the force change that is tip dependent, even though the tips used were 
from the one box of tips of the same manufactured type (they were all NPG levers from the same 
box).  It was plausible that all of the tips could be undergoing a time dependent change from 
repeated use over time throughout the trials, such that the forces would vary depending on the 
changes in the tip shape or the structure over time. 
Some factors that might be involved that created the tip-to-tip variation in BT-forces could be 
that different tips (of the same type) may have different radii curvatures due to manufacturing 
variations, and also there could be a slight variations in the location of the AFM laser spot that is 
on the tip could create the difference in the force values. It is also possible that the silicon 
cantilever material of the tips could have varying minute physical defects, which may have 
caused different force values.  
3.2.5.4 Experiment 3- Conclusion 
Control forces taken using three different but same type of tips gave different force values. The 
force values also fluctuated over time within one tip and one sample. The results correspond with 
the results of experiment 2, in that they both indicate time dependent change occurs with BT-
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depending on the various experimental factors, but how the specific factors had affected the 
forces remains unknown. 
3.2.6 Summary of Force Spectroscopy Results  
A total of three experiments have been conducted to measure breakthrough force on bilayers 
using force spectroscopy. Table 3 is a summary comparison of all of the experiments. Procedural 
variations exist between the experiments to study different factors involved in control BT-forces. 
Significant differences in forces were measured in exp. 2 and 3 that depended on the particular 
tip used and the experiment time. Bilayer incubation time however, which was tested in exp. 1, 
was not a factor that changed the BT-forces, as the resulting differences in exp.1 for thickness, 
BT-force and dissipation energy were all statistically insignificant.  
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Table 3- Summary Comparison of Force Spectroscopy Data Set Results 
Force Data 
Set 
Exp. 1  
(Figure 37) 
Exp. 2  
(Table 2) 
Exp.3  
(Figure 47) 
Tested Factor 
Effects of bilayer 
incubation time on 
forces 
Effects of different 
areas of the sample 
on forces 
Using different tips (of 
the same type) on forces, 
and time dependence of 
forces  
Experimental 
Protocol 
• One tip used for 
two control 
samples, samples 
incubated for 1 
and 24 hours 
• One tip used with 
one control sample 
• Two trials per 
sample collected - 
two different areas 
on the sample 
without removing 
the tip 
• One tip used with one 
control sample 
• Force measured over 
time 
• Repeated with three 
different (same type) 
tips	  
Outcome 
Varying time did 
not lead to changes 
in BT-forces 
(p=0.32) 
Different areas gave 
different BT-forces 
BT-forces changed over 
time/ Different tips gave 
different BT-forces.  
 
 
The factors that created the differences in forces have been identified, but how exactly they 
created the changes in forces are unclear. It is also possible that there could be other unidentified 
factors involved other than the two currently identified that are able to cause changes in forces. 
Further experiments are needed to increase the understanding of the different factors involved in 
technique, in terms of how they change the observed BT-forces in supported bilayers. As a future 
suggestion, conducting additional experiments based on exp.3 but with various different tip types 
and lipids may be ideal to confirm results.  
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3.2.7 Concluding Remarks for AFM Force Experiments 
Technical improvements were made throughout the section including creating defect free 
bilayers and successfully reproducing analyzable breakthrough force data in control bilayers. 
Incubation time, tip variation and sample areas have been successfully identified as factors that 
can produce variability in results, which maybe useful information for future experiments.  
Due to the highly time consuming nature of these experiments, more work is planned in the 
future to study the effect on melatonin by BT-forces methods in a separate project by another 
student. The developed protocols and control experiments presented in the current work will 
provide a valuable foundation for future work.  
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3.3 Imaging Amyloid-β (Aβ) Accumulation on Bilayers 
Many previous publications have utilized AFM imaging to study accumulation of Aβ on 
supported bilayers[83], [183], [207]–[212]. The amounts of Aβ present on bilayers as well as its 
effect on its physical integrity were of great interest since they may be relevant to the cell 
toxicity of Aβ. Many previous papers had studied the effects of Aβ (1-40) on various different 
composition bilayers including DPPC, DOPC and brain lipid extract bilayers[209], [210], [213], 
[214]. A number of recent papers had investigated Aβ (1-42) [83], [183], [207], [209], [212], 
which is known to be much more toxic than the 1-40 fragment, and thus is of greater interest in 
the AD pathophysiology compared to the 1-40. One of the reasons for the previous studies using 
the 1-40 fragment over the 1-42, even though known to be less toxic, would be that the 1-40 
fragment made very drastically observable changes to the bilayer surface topography compared 
to that observed with 1-42[207]. The results are counterintuitive as increased damage to the 
bilayer is often assumed to correlate with increased overall toxicity. However, this correlation 
may not be true, at least in studies using AFM, because the more toxic 1-42 fragment has been 
shown to cause minimal to very low bilayer topographical disturbance [183], [207]. However, 
cell and animal studies have repeatedly confirmed that the 1-42 fragment should be the most 
toxic compared to the other fragments[8], [21], [215].  
Nevertheless, AFM bilayer studies featuring the 1-42 fragment showed that it is capable of 
accumulating on various bilayers and also capable of inducing low levels of detectable damage 
to the bilayer surface[207]. Furthermore, it showed preferential accumulation on gel phase DPPC 
bilayer domains over the fluid phase DOPC [183]. This result was also interesting, since the 
average cell membrane, with all of its multiple of components, is known to be in fluid phase at 
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physiological conditions. It has been shown that cholesterol enriched domains (that have 
somewhat similar physical properties to gel phase domains but also have a distinct electrostatic 
nature) induce preferential binding of Aβ[212]. Another AFM study testing Aβ (1-42) on brain 
extract enriched with cholesterol reported increased disturbance and binding compared to 
samples without added cholesterol [207]. 
It was decided that for assessing melatonin's effects, AFM imaging of two different bilayer 
types would be performed to characterize Aβ (1-42) accumulation and bilayer surface structure 
disturbance (damaging effects). The first type used was brain extract membrane. Studying the Aβ 
effect on supported bilayers made up of brain lipid extract was advantageous due to its biological 
relevance. The composition of the bilayer would be very close to the physiological membranes 
found in brain neural tissue. Also the majority of the available data in the literature was on brain 
extract, meaning that comparisons and verifications could be made in interpreting our results. 
The second bilayer choice was DPPC. Work by Choucair et al., studying the Aβ (1-42) peptide 
with AFM showed that Aβ preferentially accumulates on DPPC domains versus DOPC in a 
mixed bilayer system[183]. Thus, choosing to utilize DPPC in the study essentially guaranteed 
the observation of accumulation of the Aβ, which was advantageous for several reasons. First, 
the gel phase lipid, as mentioned above, is often utilized as a raft model component since its 
physical properties resemble that of cholesterol enriched bilayers. Using DPPC gel phase bilayer 
platform as a surrogate for cholesterol lipid raft model made sense due to the relative simplicity 
of producing it and also its closeness to the raft membrane model. Secondly, knowing that DPPC 
promotes accumulation of Aβ made it an appropriate choice as a control starting point to test 
against effects of melatonin. The hypothesis being tested is that melatonin would probably 
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decrease the accumulation of Aβ on the bilayer by fluidizing the gel or the lipid raft phase (Lo 
phase) bilayers.  
3.3.1 Materials and Methods 
Brain extract bilayer (porcine) in chloroform was purchased from Avanti Polar Lipids (AL, 
USA). The same procedures used for preparing DOPC bilayers were used in preparing brain 
extract bilayers (shown in section 3.2.4.1), since both brain extract lipids and DOPC are in fluid 
phase at room temperature. DPPC was purchased from Sigma-Aldrich in powder form and the 
procedure for forming supported bilayers is outlines in section 3.2.4.2. Melatonin was purchased 
from Sigma and was used without further purification. Melatonin was directly dissolved in the 
buffer to 2.0 mM. 
Aβ (1-42) NaOH was purchased from rPeptide (GA, USA) in lyophilized powder form and 
used without further purification. 500 µg of Aβ in NaOH is brought to room temperature to avoid 
condensation[216] and dissolved in 0.01M NaOH to 1mg/ml concentration[217]. The peptide is 
sonicated for 1 minute in a bath sonicator to disassociate larger aggregates[218]. 69.5 µl of the 
solution is aliquoted into 14 different Eppendorf vials and snap frozen in dry ice, then kept at -
20°C[210]. Before experiments, a vial containing the frozen solution is thawed at room 
temperature and added to the AFM liquid cell to the final concentration of 5- 15 µM. The Aβ 
preparation yielded very small monomeric to very low oligomeric (most likely dimer or trimers) 
species according to size, as verified by AFM image cross sections, consistently for up to 15 
days (figure 48).  
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Several different AFM cantilevers were utilized for liquid imaging. MAC mode type II 
cantilevers (silicon tip) with the nominal spring constant of 2.4 N/m (Agilent Technologies, 
USA), DNP-S cantilevers (silicon nitride) with spring constant 0.02 N/m (Bruker, USA), SNL 
levers with spring constant 0.02 N/m (sharpened silicon, Bruker, USA), and NPG levers (Gold 
coated, Bruker, USA) with spring constant of 0.02 N/m were utilized. The gold-coated levers 
were also chemically modified with PEG, using the tip modification procedure outlined in 
appendix A. 
Experimental procedure included creating an appropriate bilayer and imaging the surface first 
as control. After a minimum of three different areas has been imaged, then Aβ or Aβ+melatonin 
was added to the bilayer. The sample was left to incubate at room temperature (24°C) and rinsed 
at varying predetermined times to stop the aggregation progress and imaged to assess membrane 
damage. Time dependent in situ imaging trials were also conducted, however, for those 
experiments the presence of Aβ in solution (from not being able to rinse away) made the imaging 
highly difficult due to frequent contamination of the tip (see page 152, figure 49). All bilayer 
samples were imaged at room temperature in buffer (HEPES 10 mM, NaCl 150mM, pH 7.4). 
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Figure 48- Aβ preparation thawed and deposited on mica, imaged in air. Left image shows samples 
from day 1 and right image shows samples from day 15. Overall, the size and shape of the 
aggregate is preserved and no fibirillar or larger aggregates have developed between the two 
samples. 5 µl of the amyloid solution was deposited on mica, left for 5 minutes, rinsed with 100 µl of 
water, and dried with a stream of nitrogen, sample imaged in air at room temperature with NCH-
50 cantilever with nominal k= 42 N/m imaged using intermittent contact mode.
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3.3.2 Results and Discussion 
3.3.2.1 Brain Extract Bilayer and Aβ 
Brain extract bilayers were created and Aβ (1-42) was added in three different concentrations 
(5, 10, 15 µM). The samples were incubated and imaged at several different times (immediate 
after the addition of Aβ, 2, 6, and 24 hours, the results are shown in figure 49). 
 
Figure 49- Aβ (1-42) on brain extract bilayers in 3 different concentrations. Images taken after 24 
hours. All images are 30 µM by 30 µM in size. Aβ is shown as white blobs. The trails or tails behind 
the aggregates are created by the tip moving across the image horizontally in a line-by-line scan 
(scanning fast left and right moving slowly one line at a time from bottom to top), which results in 
graduate upward push or line by line nudging of the aggregates upward, every time a horizontal 
line scan is performed. The moving aggregates always have tails that are perpendicular to the fast 
scan direction, and parallel to the slow scan direction. Sample imaged using intermittent contact 
mode in buffer (HEPES 10 mM, NaCl 150mM, pH 7.4). NPG levers (Gold coated, Bruker, USA) 
with the spring constant of 0.02 N/m were utilized. The gold-coated levers were also chemically 
modified with PEG thiols. 
 
Overall, concentration dependent effects on the accumulation of Aβ on the bilayer surface 
were not obvious, even at shorter times of incubations. The main difference between the 
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concentrations is that the final sizes of the aggregates are greater in the higher concentration 
samples compared to the lower concentration ones (figure 49). Surface coverage was 
comparable. Further precise quantitative assessment of the samples was highly challenging, as 
Aβ seemed to not be strongly bound to the bilayer. Imaging the samples caused the aggregates 
(white blobs) to shift across the images and drag trails behind them as they were being moved in 
the direction of the imaging tip. The mobile aggregates are shown in figures 50 and 51.
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Figure 50- Sequential images of 10 µM Aβ on brain extract bilayer taken from the same area. After 
repeated scans, Aβ is completely removed from the brain extract bilayer through scanning. Image 
sizes 8 µM2, incubation time 24 hours. Sample imaged using intermittent contact mode in buffer 
(HEPES 10 mM, NaCl 150mM, pH 7.4). Vertical height scales are shown to the right of each image. 
NPG levers (Gold coated, Bruker, USA) with the spring constant of 0.02 N/m were utilized. The 
gold-coated levers were also chemically modified with PEG thiols. 
 
Figure 51- Even at the highest concentration of Aβ tested (18 µM) incubated for 48 hours (longest 
incubation time tested), the aggregates are still mobile and can be swept clean from the bilayer 
surface through scanning. Sequential images from left to right, image size 8 µM2. Sample imaged 
using intermittent contact mode in buffer (HEPES 10 mM, NaCl 150mM, pH 7.4). Vertical height 
scales are shown to the right of each image. NPG levers (Gold coated, Bruker, USA) with the spring 
constant of 0.02 N/m were utilized. The gold-coated levers were also chemically modified with PEG 
thiols.
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After numerous trials (figure 50 and 51), the results indicated that Aβ does not strongly bind to 
the brain extract and that scanning the surface would change the surface coverage of them 
depending on the number of scans performed over the area and also depending on the setpoint 
(force applied) by the tip while scanning (figures 49-51). Adding melatonin to the system to try 
to ascertain any measurable changes caused by it was unsuccessful, because with melatonin, the 
Aβ blobs also displayed similar shifting characteristics that made it impossible to statistically 
measure the surface coverage amount accurately. Also, the highly mobile aggregates on the 
surface (figure 52) changed shape and measureable height during a scan, making it impossible to 
estimate the accumulated aggregate size. The bilayer also appeared clean and damage free after 
being cleared of all aggregates from repeated scans, much like the control samples. 
 
Figure 52- 5 µM Aβ added to brain extract bilayer in 2.0 mM melatonin solution. The left streaks 
on the aggregates are due to their being pushed by the tip (moved the aggregates upward from 
bottom to top). The over results resembles that of the control and no discernable changes could be 
observed or measured due to having easily movable aggregates; the very first scanned image of the 
area is shown.  Sample imaged using intermittent contact mode in buffer (HEPES 10 mM, NaCl 
150mM, pH 7.4). NPG levers (Gold coated, Bruker, USA) with the spring constant of 0.02 N/m were 
utilized. The gold-coated levers were also chemically modified with PEG thiols.
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Further continuation and conducting repeat trials in the same system seem futile, since it was 
unclear if there were any obvious differences produced with melatonin. Even if there were 
changes in the accumulation with melatonin, it was not possible to precisely quantify the 
difference.  
A decision was made to utilize DPPC bilayers instead of the brain extract, since Aβ had been 
shown to preferentially and measurably bind to DPPC bilayers[183], [210], more strongly than to 
brain extract and the studies were done using the same method (AFM). Also, the brain extract 
samples were highly prone to degradation and biological contamination and it was extremely 
difficult to maintain the integrity of the sample for longer than 24 hours (In many trials, defect 
and extra contaminations would spontaneously appear over time, figure 53). DPPC bilayers were 
much more stable overtime and did not show perceivable changes in the control topography 
within the time periods tested. 
 
Figure 53- Control brain extract bilayer at 1 hr (left) and after 24 hours (right). Even after insuring 
meticulous control of the incubation conditions, brain extract bilayers showed spontaneous changes 
in their topography, making them less suitable for the time dependent Aβ accumulation studies. 
Samples imaged using intermittent contact mode in buffer (HEPES 10 mM, NaCl 150mM, pH 7.4), 
NPG levers (Gold coated, Bruker, USA) with the spring constant of 0.02 N/m were utilized. The 
gold-coated levers were also chemically modified with PEG thiols.
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3.3.2.2 DPPC Bilayer and Aβ 
DPPC bilayers were created with the protocol outlined in section 3.2.4.2. As expected, Aβ was 
more strongly bound to DPPC compared to the brain extract as it took more scans to rid of all 
aggregates from the surface compared to the brain extract samples. However, unlike the fluid 
brain extract that can form a completely flat defect free bilayer, DPPC coverage could not be as 
ideal due to its deposition characteristics discussed in section 3.2.4.2. Defects in the DPPC 
bilayer acted as nucleation sites for Aβ to preferentially bind and aggregate on, compared to the 
flat top surface of the bilayer as well as the lower flat domain areas (figure 54).
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Figure 54- (A) Image of a control DPPC bilayer with extended intact bilayer areas but also 
containing defects (black areas) as well as lower domains (darker brown). (B) Image contains Aβ at 
12 µM incubated for 6 hours. There is a definite preference for Aβ (white blobs) to accumulate and 
cover the areas with defects compared to the flat bilayer regions. (C) Same sample as B but in a 
different area. The amount of amyloid accumulation per image depends on the location within the 
sample where the image is taken, due to varying sizes of areas with defects. (D) Zoomed image of 
the same sample (3.4 µm2) shows that amyloid aggregates are preferentially located around bilayer 
defects, as opposed to the top surface of the bilayer (lower domains in darker brown and high 
domains in light brown). Only the darkest black areas (defects or holes in the bilayer) are covered 
by the amyloid aggregates. Samples imaged using intermittent contact mode in buffer (HEPES 10 
mM, NaCl 150mM, pH 7.4), NPG levers (Gold coated, Bruker, USA) with the spring constant of 
0.02 N/m were utilized. The gold-coated levers were also chemically modified with PEG thiols. 
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There were several challenges in quantifying the accumulation of Aβ on the bilayers. Adding 
more amyloid would result in high surface coverage that led to frequent tip contamination. Tip 
contamination results in image artifacts (determined by presence of exactly repeating shapes, 
evidence of tip sticking and dragging the sample as is evident as streaks or white lines, or tails 
around features in the direction of the tip), false extra features in the images as well as 
misrepresenting the sizes and shapes of the actual features. Tip contamination was reduced 
through the use of modified gold levers with the tips covered in PEG-thiol groups (Appendix A), 
which is one of the most inert coatings known for the use in AFM. Having low concentrations of 
Aβ could drastically reduce tip contamination, however, this approach also reduced the number 
of aggregates that could be analyzed. The final concentration of Aβ was chosen at 12 µM, which 
gave optimum accumulation of the aggregates, and were imaged with modified gold levers to 
yield images without artifacts.  
Even when the difficulties in imaging were overcome, there were other issues. First, the 
amounts of Aβ added and present on the surfaces between samples could not be kept constant, as 
the volume of liquid in the AFM liquid cell could not be determined precisely. This was due to 
the fact that submerging the scanner into the sample to obtain the image of the sample before the 
addition of amyloid would displace the liquid volume inside the AFM liquid cell and also 
varying amounts of evaporation would occur during imaging (it takes about 20 minutes per 
image). Even if the exact amount of Aβ being added and the volume of buffer in the AFM 
sample cell could be known, addition of Aβ to the bilayer surface could not be controlled to 
ensure even coverage or application, since the amyloid solution had to be added drop by drop 
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using a micropipette. Thus, depending on the area covered and also on the concentration 
variability, differing amounts of Aβ were added to sample surfaces unevenly.  
In figure 55, DPPC samples with 1, 6 and 24 hours incubation with Aβ are shown. The first 
hour sample shows the least amount of Aβ (left image), but the 6 hours sample (middle image) 
seems to show more Aβ bound around the bilayer defects compared to the longer incubated 24 
hour sample (right image). The 24 hours sample shows more Aβ on the flat intact surfaces of the 
bilayer compared to the 6 hour sample, but around the defect areas, the amount of Aβ still 
appears to be less than that of the 6 hour sample.  
Possible explanations for such a result could be that such patterns are accurate, or more likely 
it is due to these images being taken from three independent samples. In order to obtain 
sufficiently low uncertainty, every parameter from the volume of the buffer in the liquid cell to 
the amount of Aβ being added, and the homogeneity of the added mixture must be as equal as 
possible. All these factors must be precisely controlled for multiple samples, in order to produce 
samples that contain the same amount of Aβ that can be cross-compared.  
The results shown in figure 55 represent the best-effort standardized samples with equal 
treatments. Due to experimental uncertainty that could not be controlled further (random errors 
in the volume of liquid inside the cell, uniformity in adding the concentrated Aβ solution), the 
samples still showed some variability. In addition, the DPPC surface had unevenly distributed 
defects and domains that led to uneven distribution of Aβ. Another issue with images was that 
the tip was moving the aggregates around (figure 56). Also, all samples needed to be made 
independently, as samples needed to be rinsed before being imaged, otherwise the tip 
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contamination would be too great to generate images with minimum amount of artifacts (no 
matter what tip we used, including PEG thiol coated tips that are known to be the least attractive 
with peptides, image artifacts due to intermittent contamination of the tip was, though 
minimized, still unavoidable. Image artifacts are shown as straight white thin lines in the image). 
In essence, it was not possible to determine, with any confidence, if a sample had more or less 
accumulation of Aβ aggregates as a function of incubation time, because Aβ was added across 
the sample unevenly, different samples had variable areas of bilayer defects to which Aβ had an 
affinity, and the scanning action of the technique used to image the number of deposits moved 
the aggregates  
 
 
Figure 55- (A) DPPC bilayers with Aβ at 12 µM, incubated for 1 hour, (B) 6 hours and (C) 24 hours. 
The 6 hour sample B shows the greatest amount of Aβ accumulation in the areas with defects, but 
the 24 hour sample C shows more Aβ aggregates on the flat defect free areas. Images taken using 
intermittent contact mode with NPG (gold coated) levers modified with PEG thiols, imaged at room 
temperature in buffer (HEPES 10 mM, NaCl 150mM, pH 7.4), from three independent samples. 
 
Quantifying the differences in the samples is complicated by the fact that even though Aβ 
binds more strongly to DPPC compared to the brain extract, the aggregates are still not stably 
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affixed to the bilayer. Figure 56 shows a sample that has been incubated with Aβ for 2 hours. 
The two images are of the same spot except the image on the right has a clean square area in the 
middle of the image. The cleaned area is created by repeated scans, and an image of a larger final 
area that includes the original area is shown. With Aβ on DPPC, it is possible to image the 
accumulation of Aβ on the surface to a reasonable degree. However, as seen in the figure, even 
the slightest increase in the force between the tip and the sample will result in clearing the 
aggregates and or result in underestimation of the sizes or heights of the aggregates (decreasing 
force would result in the opposite).  
 
Figure 56- DPPC with Aβ incubated for 2 hours. Left image shows the first scan of the area, and 
right image shows the same area but after a small scan was performed in the middle (one pass using 
the same force). Scanning the sample clears the surface of the aggregates gradually in every single 
pass. Image parameters were kept constant throughout (large image area 8 µm2). Even the very 
first pass of the region reduces the amount of aggregates present. Images taken with NPG (gold 
coated) levers modified with PEG thiols, at room temperature in buffer (HEPES 10 mM, NaCl 
150mM, pH 7.4) using intermittent contact mode. 
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In addition, further complicating the matter is the presence of the aggregates in the defect areas 
where there are holes and breaks in the bilayer. It is quite obvious that Aβ prefers to accumulate 
in and around these areas (figure 54). However, because the holes extending below the top plane 
of the bilayer mask the size of the aggregates, it was not possible to reliably compare the vertical 
height of the aggregates in these areas, where the majority of the aggregates were located 
(figures 54 and 55, white blobs in image). 
 Nevertheless, it was still possible that adding melatonin would yield such drastic differences in 
the Aβ accumulation that the results may stand out beyond these various factors that caused 
variability. When samples with melatonin were imaged, the level of Aβ accumulation in different 
melatonin samples was not consistent. Results from one of the trials are shown in figure 57, and 
there were more Aβ present in the 2 hour sample compared to the 6 or 24 hour samples. 
Inconsistencies in the accumulation of Aβ were similar to those in control samples. Also, it 
appeared that with melatonin, there were increased surface coverage and larger aggregate sizes 
present compared to control. However, the differences in the surface accumulation of Aβ 
between the two groups were difficult to ascertain from the images, because scanning altered the 
surface features (figure 58) also in control and melatonin samples. It made the quantifiable 
information present on the images (the number of features, height of the features, width and 
lengths of the features, etc.) variable. Also, the feature sizes and surface coverage were 
constantly shifting from one scan to the next.  
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Figure 57- Top images are control DPPC bilayers with Aβ incubated for (A) 2 hours, (B) 6 hours 
and (C) 24 hours. Bottom row samples incubated with 2.0 mM melatonin for (D) 2 hours, (E) 6 
hours and (F) 24 hours. (All images size 8 µm2). The difference in the accumulation of Aβ could not 
be measured reliably due to factors discussed in the text. Images taken with NPG (gold-coated) 
levers modified with PEG thiols, imaged at room temperature in buffer (HEPES 10 mM, NaCl 
150mM, pH 7.4) using intermittent contact mode. 
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Figure 58- DPPC bilayer with Aβ incubated for 2 hours with 2.0 mM melatonin. The two images 
are identical, except the image on the right has been scanned in the center repeatedly. It was 
evident that every single pass of the area removed some aggregates until the area became 
completely clear, meaning that even the very first scan of the sample might be removing aggregates 
from the surface. Scanning parameters were kept constant but multiples images were taken on one 
spot until the aggregates were moved. Imaged using intermittent contact mode, at room 
temperature in buffer (HEPES 10 mM, NaCl 150mM, pH 7.4), taken with NPG (gold-coated) levers 
modified with PEG thiols, image size 8 µm2. 
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Repeated trials with and without melatonin resulted in samples that displayed highly varied 
images among all samples, in terms of bilayer surface features as well as amounts of defects and 
domains (figure 59). Having reliable quantification of Aβ accumulation in melatonin samples 
would be highly unlikely due to shifting aggregates and non-uniform surface 
distribution/coverage that also changed depending on scanning frequency and parameters.  
 
Figure 59- Three different trials of 1 hour incubation without melatonin (top row) and with 
melatonin (bottom row). (A1) Control from trial 1, (A2) control from trial 2 and (A3) control from 
trial 3. (B1) sample from trial 1 incubated with melatonin, (B2) sample from trial 2 with melatonin, 
(B3) sample from trial 3 with melatonin (All images are 8 µm2). The order of experiments was A1, 
B1, A2, B2, A3, and B3. Six independent samples imaged with NPG (gold-coated) levers modified 
with PEG thiols, imaged at room temperature in buffer (HEPES 10 mM, NaCl 150mM, pH 7.4) 
using intermittent contact mode.   
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3.3.3 Summary and Conclusion 
Assessment of Aβ accumulation on brain extract and DPPC bilayers was conducted. Brain 
extract bilayer samples showed accumulation of round amorphous Aβ aggregates on the surface, 
however the aggregates were loosely bound and highly mobile. Repeatedly scanning the sample 
resulted in clearing of the aggregates and revealed intact, and to the best of knowledge, damage 
free brain extract bilayer. The results were comparable with previous studies where only a very 
small limited amount of defects were observed with Aβ (1-42) on brain extract bilayers[207]. 
Aβ accumulation on DPPC showed smaller aggregates compared to the ones observed on brain 
extract. They were amorphous and round in shape similar to the ones found on the brain extract, 
and they were bound to the bilayer more strongly. However, repeated scanning of an area also 
caused clearing of the aggregates that revealed the DPPC bilayer underneath that was also 
observably damage free. Samples were highly diverse in terms of the bilayer topography (bilayer 
defects and domains), which were favored by Aβ. Accumulation also depended on scanning 
parameters and frequency, which is impossible to keep constant between different samples but 
only possible within a sample to a very limited degree (most often parameters had to be changed 
multiple times during a single scan of an image). With all of the factors combined, it is 
concluded that the very slight differences observed qualitatively in melatonin samples compared 
to control might be the result of uncertainties or variations in the samples and assessment, rather 
than due to the presence or absence of melatonin.  
In conclusion, the imaging experiments were inconclusive due to having non-uniform bilayer 
samples and also due to unstable aggregates that are moved by the tip. However, an amyloid 
oligomer incubation procedure was successfully developed.
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Chapter 4 
Collaborative Works 
4.1 Introduction 
Collaborative work has been performed to obtain complementary data in support of the 
hypotheses presented in this thesis as well as to make contributions in other closely related 
research projects. Many different methods have been utilized including fluorescence microscopy 
(FM), and cell viability testing of cell cultures (mouse hippocampal cells, retinal ganglion cells). 
In silico molecular dynamics simulations data were also utilized to support and discuss of the 
findings presented in the previous chapters. Some of the collaborative work presented here has 
been published in peer-reviewed journals, and many are currently being prepared for 
submissions to various peer-reviewed journals. The published data are presented with written 
permission (see Statement of Contributions).   
 169 
4.2 Investigating Aβ Deposits on Human Retina 
Characterization Aβ deposits in human retina was performed using FM and AFM. The work 
was conducted as part of a project in Dr. Campbell's group. The main motivation of the project 
was to utilize and modify the biophysical techniques used in the main part of the study to 
identify and characterize deposits of Aβ present in human retinas. The importance of the goal lies 
in the fact that the retina is a neural tissue that is considered to be a direct extension of the brain 
with parallel characteristics and features. Thus, it was possible that the neuro-pathophysiological 
featured found in the brains of AD patients may also be present in the retina. The retina is high 
accessible for direct assessment using ophthalmological methods, compared to the brain. 
Examining the retina for signs of AD could effectively serve as a disease diagnostic and 
assessment strategy. 
FM combined with AFM was used to identify and characterize Aβ deposits in human retinas. 
Briefly, epifluorescence microscopy utilizes fluorophores, which are chemical compounds that 
are able to absorb the energy of photons at a specific wavelength of light and release the energy 
back with a different lower energy, longer wavelength of light. The released light or emitted light 
has a specific color (wavelength). The spectral differences (wavelength and frequency 
difference) between the absorbed (excitation light) and emitted lights are specific for a given 
fluorophore and are also specific to the configuration and the surrounding environment of the 
fluorophore. For instance, a fluorophore named thioflavin can undergo a detectable spectral shift 
when bound to Aβ aggregates. By attaching fluorophores to the molecules or structures of 
interest, it is possible to identify, track, and characterize them through fluorescence visualization. 
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As a preliminary step, Aβ is deposited on to a flat clean substrate (specially cleaned glass 
using aqua regia) and imaged using the FM-AFM combination (figure 60). The technique, 
although not novel, was new to the lab and was specifically setup and tested for this purpose. 
The results demonstrated the capabilities of the setup in detecting and characterizing Aβ 
aggregates in the retina using the thioflavin T fluorophore (Sigma-Aldrich). Aβ (1-42) NaOH 
purchased from rPeptide (GA, USA) was used without further purification. Aβ was incubated in 
buffer (10 mM HEPES saline 150 mM NaCl, pH 7.4) for 24 hours, thioflavin T solution in 
ethanol (5%) was added to Aβ and Aβ was deposited on to glass, dried and imaged in air (figure 
61). Preliminary control experiments were prepared and conducted solely by the author. Human 
retina experiments were conducted in collaboration (see Statement of Contributions).  
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Figure 60- Testing the combined FM (grey scale) and AFM (yellow-brown) imaging of Aβ 
aggregates in different resolutions deposited on glass. The FM and AFM images can be overlaid on 
top of each other as shown in top right with the 100 µm2 images. Imaged using intermittent contact 
mode in air using NCH probes with nominal spring constant of 42 N/m.
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Figure 61- Images of post-mortem human retinas. (A) AFM topography image of the inner limiting 
membrane within the human retina harvested from a control subject. No large deposits are found, 
and also shows tube like tracks of the underlying nerve fiber layer (stratum opticum). (B) AFM 
phase image of the same spot as image A indicates the uniform material property of the inner 
limiting membrane covering the nerve fiber layer. (C) Grey scale fluorescence imaging of the inner 
limiting membrane within the retina harvested from an AD patient. Sample is fluorescently labeled 
with thioflavin S for Aβ, and large deposits of labeled aggregates are present, scale bar 10 µm (D) 
AFM topography image of the corresponding fluorescent spot shown in C. Amyloid deposits 
correspond with the fluorescent staining and are similar to amyloid deposits on glass. AFM imaging 
was performed in air using intermittent contact mode using NCH levers with nominal spring 
constant of 42 N/m. 
A B 
C D 
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4.3 Cell Viability Testing with Aβ and Melatonin 
The capability of melatonin in preventing and reducing Aβ toxicity is central to this thesis. 
Although there are quite a few papers that have provided evidence for the cell protection of 
melatonin against Aβ, this fact is still gaining acceptance and is not yet universally accepted. The 
results of these experiments provided experimental support for melatonin's ability to protect the 
cells from Aβ toxicity. Showing melatonin's cell protection was important in justifying the 
foundational reasons for the overall project. Also extended experiments using cyclodextrin 
(cholesterol harvesting molecule) were performed to give relevant biological insight at the 
cellular level, and the results were used to determine the direction of other parallel experiments 
conducted within the thesis.  
Assessing the physical properties of Aβ aggregates are critical for controlling their 
toxicity[21]. It is challenging to precisely control and reproduce specifically aggregated species 
of Aβ for use in cell viability tests. Among many different Aβ incubation protocols, three 
different approaches were chosen and performed. The aggregates were imaged using AFM to 
ascertain the effects of the different incubation protocols. The variations in the protocol ranged 
from pretreatment with DMSO, separation with centrifugation, and no treatment. The results are 
shown in figure 62.
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Figure 62- Representative images of three different Aβ aggregate samples incubated in cell culture 
media. (A) Predissolved Aβ in DMSO, incubated in cell culture media. Image size is 5 µm2 (B) Aβ 
aggregates from a centrifuged supernatant, transferred and incubated in cell culture media. Image 
size is 1.2 µm2 (C) no pretreatment Aβ aggregates incubated in media. Image size is 5 µm2. Sample 
preparation for AFM imaging entailed incubating Aβ with various pretreatments in cell culture 
media, depositing 25 µl of the solution on to freshly cleaved mica, wait 5 minutes, rinsed with 50 µl 
of water three times, then dried with nitrogen. Images taken in intermittent contact mode using 
NCH levers with spring constant k ~ 42 N/m. 
Overall, the different pretreatments yielded comparably shaped Aβ aggregates. Samples with 
no pretreatment or DMSO pretreatment of Aβ showed 4-5nm aggregates. The samples that were 
centrifuged showed much smaller, amorphous layer of particles (presumably monomers or very 
low number oligomers). Control samples without amyloid showed small 1-2nm aggregates, as 
well as large 10-40 nm blobs. The DMSO and centrifuged control samples both showed <40 nm 
large features. The control samples also showed a thin layer of compounds, presumably of media 
additives (HyClone media), as a layer 0.5-1 nm thick lining the substrate. These extra features 
present in control samples were excluded from consideration when assessing amyloid samples. 
The results from this work helped to finalize the protocols used in amyloid cell viability studies. 
The results from the cell studies are presented in Appendix B.  
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4.4 Dynamic Light Scattering (DLS) 
DLS experiments were aimed at characterizing the unilamellar vesicle solutions being used for 
depositing supported bilayer samples. For obtaining repeatable results in producing supported 
bilayer samples, it was crucial that the quality of the vesicle solution, containing unilamellar 
vesicles made through bath sonication, be of consistent quality. The usual method of quality 
control for the vesicle solutions (end point determination of the finished product at the end of the 
sonication cycle) was to inspect it with the naked eye and determine the clarity and the 
transparency of the solution. However, for obvious reasons, the quality of the dispersion could 
not be precisely controlled and determined this way. 
Using dynamic light scattering, particle (vesicle) size and its distribution were measured for 
six different DPPC vesicle solutions each prepared in slightly different ways. The variables for 
the solutions included the length of time of sonication, temperature during sonication, 
concentration and overall volume. 
The results of the experiment are shown in figure 63. The sensitivity of the measurement was 
too low (± 10 nm) to characterize and differentiate the vesicle solutions in terms of the size 
distribution of the vesicles they contain, which had average diameters around 74 nm. The 
uncertainties in the measurements were greater than the differences between the sample 
solutions, and it was not possible to determine the precise differences between the sample 
solutions. So relying on the DLS measurements as quality control for the solutions each time 
they were produced seemed unfeasible. A decision was made to rigorously setup detailed 
solution making procedures and meticulously execute the steps every time, in order to maintain 
the solution quality constant each and every time. The intent of conducting DLS experiment was 
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also to characterize the effects of time on the solution during long-term storage. The solutions 
often became cloudy over time and also change in their deposition characteristics as well as in 
the produced bilayer quality. If shelf life of solutions (the length of time in which the distribution 
of vesicles in solution remains unchanged) could be adequately determined, then a working 
solution that produces good supported bilayer samples could be reliably kept and reused 
overtime. The detection sensitivity of the DLS machine, however, was not high enough to 
determine the subtle differences in the various solutions that were differently aged. Since shelf 
life could not be determined, the only way to ensure consistent solution quality was to produce 
them fresh in exactly the same way every time, and use it within a set time (usually within 24 
hours).  
 
Figure 63- DLS measurements of DPPC vesicle solutions, showing size distribution by intensity for 
six unilamellar vesicle different solutions. The z average (intensity-weighted average) diameters for 
the trials were between 73.4- 78.4 nm with standard errors of the mean of ± 10 nm.   
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4.5 Other Contributions- Molecular Dynamics Simulations 
This section features collaborative work on molecular dynamics (MD) simulations. Specific 
contributions made in this section are outlined in detail in the "Statement of Contributions" 
section at the beginning of the thesis (Pages iii-v). 
MD simulations were conducted and the results clarified the location of melatonin in respect to 
the phospholipids in a membrane model environment. It also characterized the interaction of 
melatonin as mainly hydrophobicity driven, rather than electrostatic. Comparisons to how 
cholesterol and phospholipids interact with each other in contrast to melatonin were also made 
using this technique. The data showed that at 12% concentration, melatonin is able to have a 
countering influence compared to 20% cholesterol in a lipid monolayer [71], [118]. In section 
2.3.3, figures 22B and 23, the monolayer experiment results showed that 20% concentration of 
cholesterol in the monolayer had condensing effects that was countered by 1.0 mM melatonin in 
the subphase. However, with the experimental monolayer technique, it is not possible to 
determine the concentration of melatonin directly inside the monolayer rather than just in the 
subphase, so it is difficult to make a direct quantitative comparison with the simulations data. 
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Chapter 5                                                                                          
Summary and Conclusions 
 
5.1 Summary 
Increasing evidence suggests that Aβ interaction with the cell membrane may be an important 
factor in AD. The hormone melatonin had been shown to have protective effects in AD, which 
may involve its ability to interact and change the lipid membrane structural properties. The 
primary goal of the research was to characterize the membrane effects of melatonin on binding 
and accumulation of Aβ. 
Langmuir monolayers were employed as the first membrane model, as the technique and the 
model were advantageous in measuring the area per molecule and changes in the lateral 
expansion and contraction of membrane lipid molecules (membrane surface area). After a period 
of successful method refinement, the effects of melatonin, cholesterol, and Aβ were measured in 
DPPC monolayers. The results showed that melatonin may be able to interact with membrane 
lipids in a way that is countering the effects of cholesterol. Effects of Aβ binding in monolayers 
were also measured, however, the results showed high variability and dependence on 
experimental conditions. An extended study using the method involving other melatonin related 
biological molecules, tryptophan, NAS, and serotonin, showed that the tested related molecules 
were capable of interacting with the membrane monolayer at physiologically relevant 
concentrations, and differences in the interactions could be successfully measured and 
characterized using the technique.  
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The next phase of the project involved creating supported lipid bilayers to conduct BT-forces. 
The supported bilayer membrane model platform served as a close analogue resembling the real 
cell plasma membrane in terms of its basic physicochemical configuration. Even through 
extensive data exists in the literature on supported bilayers, the methods and procedures outlined 
produced variable results in planned experiments. A great deal of effort and time was spent in 
devising protocols for producing supported bilayers in a consistent and reproducible manner. 
Once the bilayer making protocols were successfully established, AFM BT-force spectroscopy 
was conducted to characterize various structural parameters of bilayers. Protocols were 
developed to successfully conduct force versus time experiments on defect free bilayer samples. 
Experiments showed that control BT-force values may fluctuate depending on various factors, 
and repeated experiments will be needed with varying tip types and lipid mixtures. Due to the 
time consuming nature of these experiments, more work is planned to study the effect on 
melatonin with BT-force spectroscopy in a separate future project. The developed protocols and 
control experiments presented in the current work provide a valuable foundation for the future 
work. 
In order to obtain additional supplementary data for the project, many other techniques have 
also been utilized in collaboration with other research groups. MD simulations were utilized to 
gather complementary data that could further the understanding of melatonin’s interaction with 
membrane phospholipids at the atomic and molecular scales. DLS was utilized to supplement 
and improve the supported bilayer sample making protocols. Also, in order to extend the 
relevance of the project to the cellular level, complementary cell studies through conducting cell 
viability assays were performed. In support of the assumptions made in the hypothesis of the 
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project, the results of the cell studies verified and confirmed the effects of melatonin and Aβ on 
various cell types.  
Collaborative work involving studying the human retina for characterizing and identifying Aβ 
deposits was also conducted. The retina study served as a pioneering platform for developing a 
potential AD diagnostic strategy by studying the retinal tissue as a brain tissue surrogate. Setting 
up and developing protocols for using FM-AFM combination approach was an important first 
step in collecting the first set of preliminary data for the project.  
5.2 Conclusion 
The project had an ambitious goal of characterizing melatonin's effects on the structure and 
properties of model lipid membrane and membrane interaction with Aβ in relation to its toxicity.  
The monolayer experiments showed that melatonin is able to interact with phospholipids in ways 
that oppose cholesterol, and also it is able to directly interact with cholesterol in a membrane 
model environment. Additional experiments also showed that melatonin and its related biological 
precursor molecules, tryptophan, NAS and serotonin (p<0.05 paired t-test against control at 
bilayer equivalent area) are able to directly interact with membrane phospholipids and alter the 
physical properties of the membrane model assemblies. The results indicated and characterized 
the capacity of these small molecules to directly affect the membrane, which is a less commonly 
recognized factor in cellular and molecular biology.  The results supported further appreciation 
of the existence of direct membrane action of molecules.  
Membrane actions of melatonin on Aβ binding and incorporation was investigated but could 
not be quantified due to experimental uncertainties. Verification of melatonin's molecular effects 
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on bilayer membranes and any direct consequence of such effects on Aβ toxicity and other 
related cellular processes will need further investigation. However, during the process of 
investigation, various methodological improvements were made in monolayer isotherm 
experiments, in the protocol for making supported bilayers and in conducting control BT-force 
spectroscopy, which provided a foundation for future experiments. 
Collaborative work involved both emerging and traditional methods in conducting biological 
research. It utilized traditional biological techniques to study effects of melatonin in cell cultures 
and developed new protocols for studying amyloid-β in real human tissues. The work broadened 
the scope of the thesis, and I was able to experience and learn the different methods in the field. 
The studies helped advance the research field by inventing new approaches and protocols to 
investigate biologically motivated problems. 
In conclusion, this project contributed to the field of membrane nanobiophysics through 
verifying and characterizing the effects of small biological molecules in model membranes, and 
also by improving and refining the various techniques utilized. The results and the technical 
improvements made in this work will foster future work that will help with further development 
of the field.  
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MDPI  journals  than  those  of  traditional,  subscription-­based  and  printed  journals  are  [4].
Links  and  Notes
1.   Open  access  citation  impact  advantage:  http://en.wikipedia.org/wiki/Open_access#Authors_and_researchers .  For  example,  a  standard  research
paper  "Shutalev,  A.D.;;  Kishko,  E.A.;;  Sivova,  N.V.;;  Kuznetsov,  A.Y.  Molecules  1998,  3,  100-­106"  has  been  cited  51  times,  the  highest  number  among
all  the  papers  published  so  far  by  the  same  author.
2.   Lin,  S.-­K.  Editorial:  Non-­Open  Access  and  Its  Adverse  Impact  on  Molecules.  Molecules  2007,  12,  1436-­1437  (PDF  format  16  K,  HTML  format).
3.   Recently  a  research  paper  of  30  pages  has  been  published:  Molecules  2008,  13(5),  1081-­1110.
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Appendix A Tip Modification 
AFM Tip Modification Procedure 
1. NPG gold coated cantilevers were purchased from Bruker AFM Probes (CA, USA) 
2. Transfer a cantilever into 20 ml glass scintillation vials with 2.0 ml ethanol 
3. Incubate for 10 minutes at room temperature 
4. Transfer the cantilever into another 20 ml glass scintillation vial with 2.0 ml water 
(Millipore, >18.2 MΩcm) 
5. Incubate for 10 minutes 
6. Take the tip out of the vial, place it onto a freshly cleaved mica and place it inside the 
UV ozone clear for 60 minutes 
7. After 60 minutes, put the tip in a 20 ml glass scintillation vial that contains 2 ml of 
ethanol and 1 mg/ml of the desired thiol compound, which were either 11-mercapto-1-
undecanol (Sigma-Aldrich), or HS-(CH2)11-EG6-OH (Prochemia, Poland) 
8. Leave the cantilever in thiol/ ethanol solution for 24 hours at room temperature, protect 
the vial and cantilever from light by wrapping the glass vial with aluminum foil. 
9. After 24 hours of incubation, rinse the tip by dipping it into a 20 ml glass vial 
containing 2 ml of ethanol 
10. Wait 2 minutes 
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11. Transfer and rinse the cantilever by dipping it into 2.0 ml of water in a 20 ml glass 
scintillation vial  
12. Wait 2 minutes 
13. The tip is now ready to be used for AFM force experiments, keep the cantilever under 
water or buffer as much as possible and only use it for one set of force experiments. 
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Appendix B Cell Viability Study 
The results from the hippocampal neuronal cultures were not conclusive (data not shown). The 
tested Aβ aggregate production protocol in section 4.3 was used on SH-SY5Y cells. The results 
showed that the Aβ was most toxic at between 2-5 µM concentrations (figure E-1). Testing Aβ 
toxicity on RGC-5 celled showed that 50 µM melatonin treatment significantly reduced cell 
death caused by 2 µM Aβ treatment, as measured via the MTT reduction assay (figure E-2). 
Extended experiments involving methyl-β-cyclodextrin (BCD or CD) in various combinations 
with melatonin were also performed to study the effects of cholesterol reduction in melatonin's 
effects (figure E-3). Melatonin showed positive effects against Aβ, however, BCD showed 
inherent toxicity that is further exacerbated by the presence of melatonin. Also the results were 
not statistically significant versus Aβ only, which negated any potential protective effects from 
CD or CD and melatonin together.  
 
  242 
 
Figure E-1 - Aβ toxicity in SH-SY5Y cells. (0.5-1 x 105/ml) were treated with 10 nM to 10 µM Aβ (1-
42) for 24 hours and the cell viability was measured using the MTT assay. Data presented are the 
mean with standard error of the mean of 2 independent experiment with each condition repeated in 
triplicate per experiment. The maximum toxicity of the Aβ preparation used for the experiment 
occurred at concentrations between 2.5 to 5 µM of Aβ. (Data and figure credit: L. Liu)
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Figure E-2 - Melatonin is neuroprotective against Aβ in RGC-5 cells. The cells were treated with 
vehicle (V), 50 µM melatonin, 2 µM Aβ (1-42), or both melatonin and Aβ. After a 24 hour 
incubation, the remaining cell # was measured suing the MMT assay. Data presented are the mean 
with the standard error of the mean of 3 independent experiments with each condition repeated in 
triplicate per experiment. *p < 0.01, Abeta vs vehicle, #p <0.05 Abeta vs mealtonin+Abeta, one-way 
ANOVA, Bonferroni post-test. (Data and figure credit: M. Vasefi)
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Figure E-3 - Melatonin is neuroprotective against Aβ in RGC-5 cells. The cells were treated 
with vehicle (V), 50 µM melatonin, 2 µM Aβ (1-42), or both melatonin and Aβ. After a 24 hour 
incubation, the remaining cell # was measured suing the MMT assay. Data presented are the 
mean with the standard error of the mean of 3 independent experiments with each condition 
repeated in triplicate per experiment.  Labeled values p < 0.05. 95 % CI for (V vs Ab) 0.2021 to 
0.7422, (V vs Ab+M) 0.06962 to 0.5260, (V vs Ab+CD) 0.1120 to 0.5684, (V vs Ab+M+CD) 
0.1368 to 0.5932, (V vs M+CD) 0.1696 to 0.6260, (M vsAb+CD) 0.02518 to 0.4816, (M vsAb+CD) 
0.04998 to 0.5064, (M vsAb+CD) 0.08272 to 0.5391, (Ab vs M) -0.6554 to -0.1153. One way 
ANOVA, Bonferroni post-test. (Data and figure credit: M. Vasefi) 
